Akademik Bilgiler



ERDEM GÖKER
PROFESÖR
Tıp Fakültesi
Dahili Tıp Bilimleri Bölümü
İç Hastalıkları Ana Bilim Dalı
İletişim Bilgileri- E-posta: erdem.goker@ege.edu.tr
- Telefon: 3747321, İş telefonu/Fax
- Telefon: 3434343-4401-30, İş Telefonu
Eğitim Bilgileri- Lisans: Hacettepe Üniversitesi Tıp Fakültesi, Türkiye, 1985
- Yüksek Lisans: Ege Üniversitesi Tıp Fakültesi, Türkiye, 1992
- Doktora: Memorial Sloan Kettering Cancer Center, New York, A.B.D., 1995
- Yardımcı Doçentlik: Ege Üniversitesi Tıp Fakültesi, Medikal Onkoloji, Türkiye, 1995
- Doçentlik: Ege Üniversitesi Tıp Fakültesi, Medikal Onkoloji, Türkiye, 1995

İdari ve Akademik Görevleri (4 adet)- EÜ Kanserle Savaş Araştırma ve Uygulama Merkezi Yönetim Kurulu Üyesi, 1999-
- EÜTF Yayın Komisyonu Üyesi, 1998-
- E.Ü İlaç Araştırma-Geliştirme ve Farmakokinetik Araştırmalar Merkezi Müdür Yardımcısı, 1998-
- Ege Üniversitesi Tıp Fakültesi Fakülte Kurulu Üyesi, 1997-2000
Uzmanlık Alanları- Onkoloji (1011210)
- İç Hastalıkları (1070601)
İndekslerce Taranan Dergilerdeki Yayınları (60 adet)- 2010, Ozkok S, Demirci S, Yalman D, Zeytunlu M, Nart D, Yuzer Y, Coker A, Goker E.Postoperative gemcitabine alone and concurrent with radiation therapy in locally advanced pancreatic carcinoma.Tumori. 2010 Jul-Aug:96(4):560-7.
- 2010, Makay O, Kazimi M, Aydin U, Nart D, Yilmaz F, Zeytunlu M, Goker E, Coker A.Fat replacement of the malignant pancreatic tissue after neoadjuvant therapy.Int J Clin Oncol. 2010 Feb:15(1):88-92. Epub 2010 Jan 21.
- 2009, Makay O, Gurcu B, Sanli UA, Zekioglu O, Oktay A, Goker E, Kapkac M.Complete response after chemotherapy in metastatic involvement of the orbita in breast cancer.Breast J. 2009 Jul-Aug:15(4):418-9. Epub 2009 May 12.
- 2009, Yesilbalkan OU, Karadakovan A, Göker E.The effectiveness of nursing education as an intervention to decrease fatigue in Turkish patients receiving chemotherapy.Oncol Nurs Forum. 2009 Jul:36(4):E215-22.
- 2009,Curran D, Pozzo C, Zaluski J, Dank M, Barone C, Valvere V, Yalcin S, Peschel C, Wenczl M, Goker E, Bugat R.Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trial.Qual Life Res. 2009 Sep:18(7):853-61. Epub 2009 Jul 1.
- 2008, Kucukzeybek Y, Gorumlu G, Karaca B, Erten C, Cengiz E, Kemal Gul M, Karabulut B, Uslu R, Sanli UA, Goker E.Docetaxel and platinum combination chemotherapy in locally advanced or metastatic head and neck cancer.J BUON. 2008 Apr-Jun:13(2):199-203.
- 2008, Sanli UA, Uslu R, Karabulut B, Sezgin C, Selvi N, Aydin HH, Saydam G, Goker E, Omay SB.Alterations in the activity and expression of serine/threonine protein phosphatases during all trans retinoic acid-induced apoptosis in breast cancer cells. Oncol Rep. 2003 Nov-Dec:10(6):2083-8.
- 2008, Dank M, Zaluski J, Barone C, Valvere V, Yalcin S, Peschel C, Wenczl M, Goker E, Cisar L, Wang K, Bugat R.Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction.Ann Oncol. 2008 Aug:19(8):1450-7. Epub 2008 Jun 16.
- 2007, Sezgin C, Gokmen E, Esassolak M, Ozdemir N, Goker E.Risk factors for central nervous system metastasis in patients with metastatic breast cancer.Med Oncol. 2007:24(2):155-61.
- 2007, Karasulu HY, Karabulut B, Göker E, Güneri T, Gabor F.Controlled release of methotrexate from w/o microemulsion and its in vitro antitumor activity.Drug Deliv. 2007 Apr:14(4):225-33.
- 2007, Sezgin C, Kurt E, Evrensel T, Ozdemir N, Manavoglu O, Goker E.Efficacy of lower dose capecitabine in patients with metastatic breast cancer and factors influencing therapeutic response and outcome.South Med J. 2007 Jan:100(1):27-32.
- 2007, Sezgin C, Gokmen E, Esassolak M, Ozdemir N, Goker E.Risk factors for central nervous system metastasis in patients with metastatic breast cancer.Med Oncol. 2007:24(2):155-61.
- 2006, Sanli UA, Karabulut B, Uslu R, Korkut M, Goker E. Single-agent irinotecan for recurrent/metastatic colorectal cancer: a retrospective analysis. Med Princ Pract. 15(4):288-92, 2006.
- 2006, N. Askar, T. Cırpan, E. Toprak, B. Karabulut, N. Selvı, M.C. Terek, R. Uslu, U.A. Sanlı & E. Goker. Arsenic trioxide exposure to ovarian carcinoma cells leads to decreased level of topoisomerase II and cytotoxicity. International Journal of Gynecological Cancer Online Early, 2006.
- 2006, Sezgin C, Karabulut B, Uslu R, Sanli UA, Goksel G, Yuzer Y, Goker E.Gemcitabine treatment in patients with inoperable locally advanced/metastatic pancreatic cancer and prognostic factors.Scand J Gastroenterol. 2005 Dec:40(12):1486-92.
- 2005, Karabulut B, Sezgin C, Terek MC, et al. Topotecan in platinum-resistant epithelial ovarian cancer. CHEMOTHERAPY 51 (6): 347-351 2005
- 2005, Ozkok S, Yalman D, Goker E, et al. Docetaxel concomitant with radiotherapy in patients with nonsmall cell lung cancer unresponsive to platinum-based induction chemotherapy. LUNG CANCER 49: S381-S381 Suppl. 2 JUL 2005
- 2005, Dank M, Zaluski J, Barone C, et al. Randomized phase 3 trial of irinotecan (CPT-11)+5FU/folinic acid (FA) vs CDDP+5FU in 1(st)-line advanced gastric cancer patients. JOURNAL OF CLINICAL ONCOLOGY 23 (16): 308S-308S Part 1 Suppl. S JUN 1 2005
- 2005, Akay S, Karasu Z, Akyildiz M, et al. Successful treatment of liver transplant-associated Kaposi's sarcoma with long-term vincristine. TRANSPLANTATION PROCEEDINGS 37 (5): 2188-2189 JUN 2005
- 2005, Bolukbas Y, Karabulut B, Yalman D, et al.Radiosensitizer effect of octreotide on du 145 prostate carcinoma cells. EUROPEAN JOURNAL OF ENDOCRINOLOGY 152: Suppl. 1 FEB 2005
- 2005, Kurt E, Sezgin C, Evrensel T, et al.Therapy, outcome and analysis of c-kit expression in patients with extrapulmonary small cell carcinoma. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE 59 (5): 537-543 MAY 2005
- 2005, Sezgin C, Karabulut B, Uslu R, et al. Potential predictive factors for response to weekly paclitaxel treatment in patients with metastatic breast cancer. JOURNAL OF CHEMOTHERAPY 17 (1): 96-103 FEB 2005
- 2005, Uslu R, Sanli UA, Dikmen Y, et al.Predictive value of serum interleukin-8 levels in ovarian cancer patients treated with paclitaxel-containing regimens. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER 15 (2): 240-245 MAR-APR 2005
- 2005, Adakan S, Yoldemir T, Tavmergen E, Goker E, Killi R. Predictivity of uterine artery, arcuate artery, and intraovarian artery Doppler indices measured on the day of human chorionic gonadotropin injection on pregnancy outcomes. Fertil Steril. 2005 Aug:84(2):529-32.
- 2005, Akay S, Karasu Z, Akyildiz M, Tokat Y, Goker E.Successful treatment of liver transplant-associated Kaposi's sarcoma with long-term vincristine.Transplant Proc. 2005 Jun:37(5):2188-9.
- 2004, Sezgin VC, Sanli UA, Karabulut B, et al.Capecitabine (X) monotherapy in patients (pts) with pretreated metastatic breast cancer (MBC): Is response correlated to cerbB-2 expression? JOURNAL OF CLINICAL ONCOLOGY 22 (14): 66S-66S 760 Suppl. S JUL 15 2004
- 2004, Karasulu HY, Karabulut B, Kantarci G, et al.Preparation of arsenic trioxide-loaded microemulsion and its enhanced cytotoxicity on MCF-7 breast carcinoma cell line DRUG DELIVERY 11 (6): 345-350 NOV-DEC 2004
- 2004, Goker E, Sanli UA, Yuzer Y, et al.Bioembolisation for unresectable hepatocellular carcinoma: Preliminary results of a translational research study. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH 23 (3): 403-409 SEP 2004
- 2003, Sanli UA, Uslu R, Karabulut B, et al.Alterations in the activity and expression of serine/threonine protein phosphatases during all trans retinoic acid-induced apoptosis in breast cancer cells. ONCOLOGY REPORTS 10 (6): 2083-2088 NOV-DEC 2003
- 2003, Cengiz C, Akarca US, Goker E, et al.Detection of mutant p53 in hepatocellular cancer from turkey and its correlation with clinicopathologic parameters. DIGESTIVE DISEASES AND SCIENCES 48 (5): 865-869 MAY 2003
- 2002, Sanli UA, Uslu R, Karabulut B, et al.Which dosing scheme is suitable for the taxanes? An in vitro model ARCHIVES OF PHARMACAL RESEARCH 25 (4): 550-555 AUG 2002
- 2002, Ozsaran Z, Anacak Y, Esassolak M, Goker E, Yalman D, Haydaroglu A, Oztop F.Primary osteosarcoma of the sphenoid bone with multiple recurrences: a case report and review of the literature.J BUON. 2002 Jan-Mar:7(1):71-4.
- 2001, Omay SB, Saydam G, Sahin F, et al. The cytotoxic effect of chalcons on myeloid leukemia cell lines. BLOOD 98 (11): 4417 Part 2 NOV 16 2001
- 2000, Uslu R, Sanli UA, Sezgin C, et al. Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines. CLINICAL CANCER RESEARCH 6 (12): 4957-4964 DEC 2000
- 1999, Uslu R, Sezgin C, Karabulut B, Sanli UA, Tobu M, Saydam G, Buyukkececi F, Omay SB, Goker E. Arsenic trioxide-mediated cytotoxicity in prostate and ovarian carcinoma lines. CLINICAL CANCER RESEARCH 5: 271 , Suppl. S NOV 1999.
- 1999, Uslu R, Ozsaran A, Sanli UA, Dikmen Y, Goker ENT, Goker E.The effect of Taxol treatment on serum interleukin-8 (IL-8) levels in patients with ovarian carcinoma. CLINICAL CANCER RESEARCH 5: 394 , Suppl. S NOV 1999.
- 1999, Goker E, Aykan NF, Serdengecti S, Gunel N, Alakavuklar M, Icli F, Yucel I, Uskent N, Arpaci F, Firat D. Oral uracil/tegafur (UFT) plus leucovorin (LV) in patients with metastatic colorectal cancer (CRC). EUROPEAN JOURNAL OF CANCER 35: 247 , Suppl. 4 SEP 1999.
- 1999, Mogulkoc N, Goker E, Atasever A, Veral A, Ozkok S, Bishop PW. Endobronchial metastasis from osteosarcoma of bone CHEST 116: (6) 1811-1814 DEC 1999.
- 1997, Gorlick R, Göker E, Trippett T, Steinherz P, Elisseyeff Y, Mazumdar M, Flintoff WF, Bertino JR: Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression. Blood 89:1013-1018, 1997
- 1997, Waltham MC, Lin S, Li WW, Göker E, gritsman H, Tong WP, Bertino JR: Capillary electrophoresis of methotrexate polyglutamates and its application in evaluation of g-glutamyl hydrolase activity. J Chromatography B 689:387-392, 1997
- 1996, Gorlick R and Göker E, Trippett T, Waltham M, Banerjee D, Bertino JR: Mechanisms of intrinsic and acquired resistance to methotrexate in acute leukemia. New England J of Medicine 335:1041-1048, 1996
- 1996, Bertino JR, Goker E, Gorlick R, Li WW, Banerjee D: Resistance mechanisms to methotrexate in tumors. Stem Cells 14:5-9, 1996
- 1995, Göker E, Waltham M, Kheradpour A, Trippett T, Mazumdar M, Elisseyeff Y, Schnieder B, Steinherz P, Tan C, Berman E, Bertino JR: Amplification of the dihydrofolate reductase gene is a mechanism of acquired resistance to methotrexate in patiens with acute lymphoblastic leukemia and is correlated with p53 gene mutations. Blood 86:677-684, 1995
- 1995, Lacerda JF, Göker E, Kheradpour A, Dennig D, Elisseyeff Y, Jagiello C, O'Reilly R, Bertino JR: Selective treatment of SCID mice bearing methotrexate transport resistant human acute lymphoblastic leukemia tumors with trimetrexate and leucovorin protection. Blood 85:2675-2679, 1995
- 1995, Göker E, Kheradpour A, Waltham M, Banerjee D, Tong WP, Elisseyeff Y, Bertino JR: Acute monocytic leukemia: a myeloid leukemia subset that may be sensitive to methotrexate. Leukemia 9:274-276, 1995
- 1995, Kheradpour A, Berman E, Göker E, Lin JT, Tong WP, Bertino JR: A phase II study of continuous infusion of trimetrexate in patients with refractory acute leukemia. Cancer Invest 13:36-40, 1995
- 1995, Banerjee D, Abalı EE, Waltham M, Schnieders B, Hochhauserd D, Li WW, Fan J, Gorlick R, Göker E and Bertino JR: Molecular mechanisms of resistance to antifolates, a review. Acta Biochimica Polonica 42:4, 1995
- 1994, Lenz HJ, Danenberg K, Schnieders B, Göker E, Peters GJ, Garrow T, Shane B, Bertino JR, Danenberg PV: Quantitative analysis of folylpolyglutamates synthetase gene expression in tumor tissues by the polymerase chain reaction: marked variation of expression among leukemia patients. Oncology Res 6:329-335, 1994
- 1994, Tan CTC, Wollner N, Trippett T, Göker E, Tong WPY, Kheradpour A, Meyers AP, VanSykle KM, Guarino L, Elisseyeff Y, Bertino JR: Pharmacologic guided trial of sequential methotrexate and thioguanine in children with advanced malignancies. J Clin Oncology 12:1955-1962, 1994
- 1994, Koch OM, Volkenandt M, Göker E, Buer J, Probst M, banerjee D, Danenberg PV, Bertino JR: Molecular detection and characterization of clonal cell populations in acute lymphocytic leukemia by analysis of conformational polymorphisms of cRNA molecules of rearranged T-cell receptor g and immunoglobulin heavy chain genes. Leukemia 8:946-952, 1994
- 1994, Conti JA, Kemeny N, Seiter K, Göker E, Tong W, Andre K, Ragusa K, Bertino JR: Trial of sequential trimetrexate, fluorouracil, and high dose leucovorin in previously treated patients with gastrointestinal carcinoma. J Clin Oncology 12:695-700, 1994
- 1993, Göker E, Lin JT, Trippett T, Elisseyeff Y, Tong WP, Niedzwiecki D, Tan C, Steinherz P, Schweitzer BI, Bertino JR: Decreased polyglutamylation of methotrexate in acute lymphoblastic leukemia blasts in adults compared to children with this disease. Leukemia 7:1000-1004, 1993
- 1993, Bertino JR, Göker E: Drug resistance in acute leukemia. Leukemia&Lymphoma 11:37-41, 1993
- 1993, Kheradpour A, Goker E, Elisseyeff Y, Sullivan M, Bertino JR: The establishment of preB acute lymphoblastic leukemia cell line from a patient clinically resistant to methotrexate with DHFR gene amplification and a p53 mutation. Blood 82:541a, 1993
- 1993, Goker E, Kheradpour A, Trippett T, Waltham M, Elisseyeff Y, Schnieders B and Bertino JR: Dihydrofolate reductase gene amplification in acute lymphoblastic leukemia blasts resistant to methotrexate is associated with mutations in the p53 gene. Blood 82:38a, 1993
- 1992, Bertino JR, Li WW, Lin J, Trippett T, Göker E, Schweitzer B, Banerjee D: Enzymes of the thymidylate cycle as targets for chemotherapeutic agents. Mount Sinai J Med 59:391-395, 1992
- 1992, Trippett T, Schlemmer S, Elisseyeff Y, Göker E, Wachter M, Steinherz P, Tan C, Berman E, Wright JE, Rosowsky A, Schweitzer b, Bertino JR: Defective transport as a mechanism of acquired resistance to methotrexate in patients with acute lymphocytic leukemia. Blood 80:1158-1162, 1992
- 1991, Koch OM, Volkenandt M, Goker E, Banerjee D, Bertino JR: A strategy for direct sequence analysis of junctional DNA sequences of T-cell receptor gamma and immunoglobulin heavy chain rearrengements. Blood 78:(10) Suppl.1, 1991
- 1991, Koch OM, Volkenandt M, Goker E, Banerjee D, Danenberg K, Danenberg P, Bertino JR: Analysis of T-cell receptor gamma junctional DNA sequences by PCR and cRNA conformational polymorphisms (cRNA SSCP) in acute lymphocytic leukemia. Blood 78:(10) Suppl.1,1991
- 1991, Trippett T, Schlemmer S, Elisseyeff Y, Goker E, Wachter M, Steiherz P, Tan C, Berman E, Wright JE, Rosowski A, Schweitzer B, and Bertino JR: Defective transport as a mechanism of acquired resistance to methotrexate in patients with acute lymphocytic leukemia. Blood 78:(10) Suppl.1,1991

İndekslerce Taranmayan Dergilerdeki Yayınları (13 adet)- Kazimi M, Uguz A, Yakan S, et al.Isolated Late Recurrence of Renal Cell Carcinoma in the Inferior Vena Cava .UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI.Volume: 20 Issue: 2 Pages: 115-118 Published: JUN 2010
- Şanlı UA, Uslu R, Göker E: Nukleozid Analogları. Hematoloji-Onkoloji Güncel Derleme Dergisi 1:122-135, 1999
- Kapkaç M, Kılıç M, İçöz G, Ersin S, Göker E, Akyıldız M: Günümüzde Hodgkin Hastalığında Evreleme Laparotomisinin Yeri. Türk Hematoloji-Onkoloji Dergisi 8:73-76, 1998
- Göker E, Özdemir E: Tümör Belirteçleri. Spektrum Derlemeler sf. 19-27, ed. Kaya Emerk, Açılım Yayıncılık , İzmir, 1997
- 1996, Resistance mechanisms to methotrexate in tumors
- Çağırgan S, Büyükkeçeci F, Karaca M, Özer A, Göker E. Kronik idiyopatik trombositopenik purpurada klinik sonuçlarımız. Ege Tıp Dergisi 32: 449-50, 1993.
- Büyükkeçeci F, Özkılıç H, Karaca M, Özer A, Çağırgan S, Göker E, Dilber S. Ferritin metobolism in platalets. Medical J Ege University 2: 37-8, 1992.
- Göker E, Atalay M, Duman Y, Yilmaz C, Kabalak T and Tuzun M. Acute effects of human growth hormone on tissue perfusion. Acta Paediatr Scand, 377: 173, 1991.
- Önder MR, Nalbantgil İ, Kılıççıoğlu B, Göker E. Akut sol kalp yetmezliğine yol açan Salmonella myokarditi. Ege Tıp Dergisi 29: 202-4, 1990
-  The acute effects of human growth factor on the dynamics of thyroid hormones in normal subjects. Göker E, Yılmaz C, KAbalak T, Tuzun M, Hamulu FS, Özmen B. Acta Paediatr Scand, 372: 153, 1990.
- Ertürk Ü, Çağırgan S, Göker E, Sarıca T. Multipl pulmoner embolizm gösteren intrakardiak kist hidatik. Türk Kardiaol Dern Arş 17: 201-2, 1989.
- Karaca M, Büyükkeçeci F, Özer A, Göker E. Paroksismal gece hemoglobinürisi, sürvi ve komplikasyonları. Ege Üniv Tıp Fak Dergisi 28: 1843-50, 1989.
- Önder MR, Nalbantgil İ, Kılıçcıoğlu B, Göker E. Angiotensin konverting enzim inhibitörüne bağlı öksürük. Ege Üniv Tıp Fak Der 29: 2903-6, 1989.

Uluslararası Toplantılarda Sunulan Bildirileri (9 adet)- Arsenic trioxide-mediated cytotoxicity in prostate and ovarian carcinoma linUslu R, Sezgin C, Karabulut B, Sanli UA, Tobu M, Saydam G, Buyukkececi F, Omay SB, Goker E.es. CLINICAL CANCER RESEARCH 5: 271 , Suppl. S NOV 1999.
- The effect of Taxol treatment on serum interleukln-8 (IL-8) levels in patients with ovarian carcinomaUslu R, Ozsaran A, Sanli UA, Dikmen Y, Goker ENT, Goker E.. CLINICAL CANCER RESEARCH 5: 394 , Suppl. S NOV 1999.
- Oral uracil/tegafur (UFT) plus leucovorin (LV) in patients with metastatic colorectal cancer (CRC).Goker E, Aykan NF, Serdengecti S, Gunel N, Alakavuklar M, Icli F, Yucel I, Uskent N, Arpaci F, Firat D. EUROPEAN JOURNAL OF CANCER 35: 247 , Suppl. 4 SEP 1999.
- Gorlick R, Göker E, Trippett T, Elisseyeff Y, Bertino JR: Decreased reduced folate carrier expression is observed in human leukemic blasts with defective methotrexate transport. PAACR 1996
- Tong WP, Lin S, Li WW, Waltham M, Goker E and Bertino JR: Capillary electrophoresis of methotrexate polyglutamates and its application in evaluation of folylpolyglutamate hydrolase activity. PAACR 35:304, 1994
- Izzo J, Zielenski Z, Goker E, Chang YM, Jhanwar J, Bertino JR: The effect of fluoropyrimidines and new folate thymidilate synthase inhibitors on four newly established colon carcinoma cell lines. PAACR 35:449, 1994
- Conti JA, Kemeny N, Goker E, Tong W, Colofiore J, Andre M, Ragusa K, Bertino JR: A phase I trial of sequential trimetrexate (TMTX), fluorouracil (FU) and high-dose leucovorin (LV) in previously treated patients with gastrointestinal carcinoma. . PASCO 12:194, 1993
- Lenz HJ, Schnieders B, Danenberg K, Goker E, Shane B, Bertino JR and Danenberg PV: A polymerase chain reaction (PCR) assay for folylpolyglutamate synthetase (FPGS) gene expression: marked variation in human leukemia blast samples. PAACR 34:504, 1993
- Tan C, Trippett T, Tong W, Van Syckle K, Goker E, Wollner N, and Bertino JR: A pharmacologic guided trial of sequential methotrexate (MTX) and 6-Thioguanine (TG). PAACR 33:209,1992

Ulusal Toplantılarda Sunulan Bildirileri (20 adet)- V. Canfeza Sezgin, Rüçhan Uslu, Ulus A. Şanlı, Bülent Karabulut, Erdem Göker. Nüks/metastatik kolorektal kanserli hastalarda ikinci hat tedavi: İrinotecan (CPT 11). XIII. Ulusal Kanser Kongresi, 27-Nisan-1 Mayıs 1999, Antalya. Bildiri Özetleri Kitabı, S85, sayfa 22 (sözel bildiri).
- Çağ Çal, Rüçhan Uslu, U. Ali Şanlı, Ceyhun Özyurt, Gürhan Günaydın, S. Bedii Omay, Erdem Göker. İlaca rezistan prostat kanseri hücre hatlarında doksazosin ve kemoterapötik ajanların sinerjistik sitotoksisiteleri. XIII. Ulusal Kanser Kongresi, 27-Nisan-1 Mayıs 1999, Antalya. Bildiri Özetleri Kitabı, S9, sayfa 3 (sözel bildiri).
- Aydın Özsaran, U. Ali Şanlı, Yımaz Dikmen, Rüçhan Uslu, Coşan Terek, Erdem Göker. Paclitaxel/Cisplatin kombine kemoterapi rejimine refrakter veya bu tedavi sonrasında nüks olan over kanserli hastalarda "salvage" kemoterapisi yararlı mı?. XIII. Ulusal Kanser Kongresi, 27-Nisan-1 Mayıs 1999, Antalya. Bildiri Özetleri Kitabı, S41, sayfa 11 (sözel bildiri).
- Ulus A. Şanlı, Rüçhan Uslu, V. Canfeza Sezgin, Bülent Karabulut, Erdem Göker. Osteosarkomda neoadjuvant/adjuvant yüksek doz methotraxate içeren çok ajanlı kemoterapinin etkinliği. XIII. Ulusal Kanser Kongresi, 27-Nisan-1 Mayıs 1999, Antalya. Bildiri Özetleri Kitabı, S61, sayfa 16 (sözel bildiri).
- Bülent Karabulut, Ulus A. Şanlı, Rüçhan Uslu, V. Canfeza Sezgin, Yıldıray Yüzer, A. Şükrü Menteş, Erdem Göker. Bioembolizasyon: Labaratuvardan kliniğe hepatosellüler karsinom (HCC) için yeni bir sağaltım modeli. XIII. Ulusal Kanser Kongresi, 27-Nisan-1 Mayıs 1999, Antalya. Bildiri Özetleri Kitabı, S81, sayfa 21 (sözel bildiri).
- 23. Ulus A. Şanlı, Rüçhan Uslu, Bülent Karabulut, V. Canfeza Sezgin, Erdem Göker. Metastatik meme kanseri olgularında ilk hat olarak kullanılan docetaxel/adriamycin kombinasyonu. XIII. Ulusal Kanser Kongresi, 27-Nisan-1 Mayıs 1999, Antalya. Bildiri Özetleri Kitabı, P73, sayfa 45.
- Ulus A. Şanlı, Rüçhan Uslu, V. Canfeza Sezgin, Bülent Karabulut, Erdem Göker. Antrasikline dirençli metastatik meme kanseri olan hastalarda tek ajan olarak docetaxel'in etkinliği. XIII. Ulusal Kanser Kongresi, 27-Nisan-1 Mayıs 1999, Antalya. Bildiri Özetleri Kitabı, P74, sayfa 45.
- Rüçhan Uslu, Ulus A. Şanlı, Bülent Karabulut, V. Canfeza Sezgin, Erdem Göker. Önceki Faz I çalışmalarda belirlenen maksimum tolere edilebilir doz (MTD) günümüz destek tedavileri ile yeniden değerlendirilmeli mi ?: ifosfamide deneyimi. XIII. Ulusal Kanser Kongresi, 27-Nisan-1 Mayıs 1999, Antalya. Bildiri Özetleri Kitabı, P242, sayfa 86.
- V. Canfeza Sezgin, Rüçhan Uslu, Ulus A. Şanlı, Bülent Karabulut, Erdem Göker. Pankreas kanserinde tek ajan Gemcitabine (GEM) sağlatımı. XIII. Ulusal Kanser Kongresi, 27-Nisan-1 Mayıs 1999, Antalya. Bildiri Özetleri Kitabı, P259, sayfa 91.
- 27. Rüçhan Uslu, Cem Cengiz, U. Ali Şanlı, Funda Yılmaz, Gül Yüce, S. Bedii Omay, Erdem Göker. Türkiye'de hepatosellüler karsinom (HCC) olgularında p53 tümör baskılayıcı gen mutasyonu karsinogenezde ne kadar etkili? Doğuda mıyız, batıda mı?. XIII. Ulusal Kanser Kongresi, 27-Nisan-1 Mayıs 1999, Antalya. Bildiri Özetleri Kitabı, P267, sayfa 93.
- Bülent Karabulut, Ulus A. Şanlı, Rüçhan Uslu, V. Canfeza Sezgin, Erdem Göker. Evre III Malign Melanomada postoperatif adjuvant interferon a2b (IFN): Hangi doz en iyisi ? Ulusal Kanser Kongresi, 27-Nisan-1 Mayıs 1999, Antalya. Bildiri Özetleri Kitabı, P309, sayfa 103.
- 30. Erdem Göker , Rüçhan Uslu, Aydın Özsaran, Ulus A. Şanlı, Yılmaz Dikmen, Ender Terzioğlu, Nuran Alan, Ege N. Tavmergen Göker. Over kanserli hastalarda taxol tedavisinin serum interlökin-8 (il-8) düzeyleri üzerine etkisi. Türk-Alman Jinekoloji Kongresi Antalya, 1999.
- R. Uslu, U. Şanlı, G. Aşçı, C. Sezgin, M. Aytimur, S. Sanal, E. Göker. Sarkomlarda mega doz ifosfamid: Toksisite çalışması. 2. Türk ortopedik onkoloji kongresi, 22-24 Nisan 1998, Ankara. Özet Bildiri Kitapçığı sayfa 91.
- U. A. Şanlı, R. Uslu, B. Ç. Bilkay, S. Sanlı, E. Göker. Osteosarkomlu olgularda kemoterapi sonuçlarımız. 2. Türk ortopedik onkoloji kongresi, 22-24 Nisan 1998, Ankara. Özet Bildiri Kitapçığı, sayfa 92.
- Göker E: Akut Lenfoblastik Lösemilerde Methotrexate Direnci. Eğitim Kitabı. 25. Ulusal hematoloji Kongresi , İstanbul 1997
- Göker E, Bertino JR. Akut lenfositer lösemide methotraxate rezistansı. X. Ulusal Kanser Kongresi, İstanbul 1993.
- Göker E, Büyükkeçeci F, Karaca M, Özer A, Çağırgan S. Kronik Myelositer lösemili olgularımızda sürvi. 21. Türk Ulusal Hematoloji Kongresi, İstanbul, 1989.
- Veznedaroğlu B, Atabay G, Yeğinboy S, Sin A, Göker E, Başçı A. Periton dializinde solunum fonksiyonları. 6. Ulusal Böbrek Hastalıkları ve Transplantasyon Kongresi, Antalya 1989.
- Çağırgan S, Büyükkeçeci F, Karaca M, Özer a, Göker E. Kronik idiyopatik trombositopenik purpurada klinik tedavi ve sonuçlarımız. 21 Türk Ulusal Hematoloji Kongresi, İstanbul 1989.
- Büyükkeçeci F, Karaca M, Özer A, Göker E, Çağırgan S. Plazmaferezle ilgili bir ön çalışma. 21 Türk Ulusal Hematoloji Kongresi, İstanbul 1989.

İndeksli Yayınlarını Kaynak Gösteren Yayınlar (813 adet)- 2011, Banka S, Blom HJ, Walter J, et al. Identification and Characterization of an Inborn Error of Metabolism Caused by Dihydrofolate Reductase Deficiency AMERICAN JOURNAL OF HUMAN GENETICS 88 2 216-225 FEB 11 2011
- 2011, Szczepanek J, Styczynski J, Haus O, et al. Relapse of Acute Lymphoblastic Leukemia in Children in the Context of Microarray Analyses ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS 59 1 61-68 FEB 2011
- 2011, Bertino JR, Waud WR, Parker WB, et al. Targeting tumors that lack methylthioadenosine phosphorylase (MTAP) activity Current strategies CANCER BIOLOGY & THERAPY 11 7 627-632 APR 1 2011
- 2011, Kang H, Kauh J. Chemotherapy in the Treatment of Metastatic Gastric Cancer: Is There a Global Standard? CURRENT TREATMENT OPTIONS IN ONCOLOGY Volume: 12 Issue: 1 Pages: 96-106 Published: MAR 2011
- 2011, Mariette C, Piessen G, Briez N, et al. Oesophagogastric junction adenocarcinoma: which therapeutic approach? LANCET ONCOLOGY Volume: 12 Issue: 3 Pages: 296-305 Published: MAR 2011
- 2011, Takiuchi H. Irinotecan is inactive as a first-line treatment, but plays an important part in gastric cancer treatment GASTRIC CANCER Volume: 14 Issue: 1 Pages: 1-3 Published: MAR 2011
- 2011, Narahara H, Iishi H, Imamura H, et al. Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002) GASTRIC CANCER Volume: 14 Issue: 1 Pages: 72-80 Published: MAR 2011
- 2011, Sun WJ, Metz JM, Gallagher M, et al. Two phase I studies of concurrent radiation therapy with continuous-infusion 5-fluorouracil plus epirubicin, and either cisplatin or irinotecan for locally advanced upper gastrointestinal adenocarcinomas CANCER CHEMOTHERAPY AND PHARMACOLOGY Volume: 67 Issue: 3 Pages: 621-627 Published: MAR 2011
- 2011, Dalla Chiesa M, Tomasello G, Buti S, et al. Sequential chemotherapy with dose-dense docetaxel, cisplatin, folinic acid and 5-fluorouracil (TCF-dd) followed by combination of oxaliplatin, folinic acid, 5-fluorouracil and irinotecan (COFFI) in metastatic gastric cancer: results of a phase II trial CANCER CHEMOTHERAPY AND PHARMACOLOGY Volume: 67 Issue: 1 Pages: 41-48 Published: JAN 2011
- 2011, Chitapanarux I, Lorvidhaya V, Tharavichitkul E, et al.A phase II study of docetaxel and carboplatin with concurrent radiation therapy for locally advanced head and neck cancer AURIS NASUS LARYNX Volume: 38 Issue: 1 Pages: 108-113 Published: FEB 2011
- 2011, Rivera F, Galan M, Tabernero J, et al. Phase II trial of induction irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for unresectable, locally advanced gastric and oesophageal-gastric junction adenocarcinoma CANCER CHEMOTHERAPY AND PHARMACOLOGY Volume: 67 Issue: 1 Pages: 75-82 Published: JAN 2011
- 2011, Ning Y, Manegold PC, Hong YK, et al. Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models INTERNATIONAL JOURNAL OF CANCER Volume: 128 Issue: 9 Pages: 2038-2049 Published: MAY 1 2011
- 2011, Chauhan HPS, Bhatiya S, Bakshi A, et al. SYNTHESIS, SPECTROSCOPIC, STRUCTURAL CHARACTERIZATION, AND ANTIMICROBIAL STUDIES OF 1,3-DITHIA-2-ARSACYCLOPENTANE DERIVATIVES WITH OXYGEN AND SULFUR DONOR LIGANDS PHOSPHORUS SULFUR AND SILICON AND THE RELATED ELEMENTS Volume: 186 Issue: 3 Pages: 511-519 Published: 2011
- 2010, Okines AFC, Cunningham D.Trastuzumab in gastric cancer.EUROPEAN JOURNAL OF CANCER 46(11):1949-1959, JUL 2010
- 2010, Gubanski M, Johnsson A, Fernebro E, et al.Randomized phase II study of sequential docetaxel and irinotecan with 5-fluorouracil/folinic acid (leucovorin) in patients with advanced gastric cancer: the GATAC trial.GASTRIC CANCER 13:(3) 155-161, 2010.
- 2010, Lyros O, Mueller A, Heidel F, et al.Analysis of anti-proliferative and chemosensitizing effects of sunitinib on human esophagogastric cancer cells: synergistic interaction with vandetanib via inhibition of multi-receptor tyrosine kinase pathways. INTERNATIONAL JOURNAL OF CANCER 127(5):1197-1208,SEP 1 2010
- 2010, Power DG, Kelsen DP, Shah MA.Advanced gastric cancer - Slow but steady progress.CANCER TREATMENT REVIEWS 36(5):384-392,AUG 2010
- 2010, Lordick F, Grenacher L, Rocken C, et al.Diagnosis and treatment of gastric cancer.DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT 135(34-35):1671-1682, AUG 2010
- 2010, Mezhir JJ, Pillarisetty VG, Shah MA, et al.Randomized Clinical Trials in Gastric Cancer.SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA 19(1):81-+,JAN 2010
- 2010, Barnett SA, Rizk NP.Randomized Clinical Trials in Esophageal Carcinoma.SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA 19(1):59-+,JAN 2010
- 2010, Lacueva J, Gallego J, Diaz-Gonzalez JA.Updating controversies on the multidisciplinary management of gastric cancer.CLINICAL & TRANSLATIONAL ONCOLOGY 12(10):677-685,OCT 2010
- 2010, Rao S, Starling N, Cunningham D, et al.Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study.ANNALS OF ONCOLOGY 21(11):2213-2219,2010.
- 2010, Wang DL, Gu DY, Huang HY, et al.Irinotecan-involved regimens for advanced gastric cancer: A pooled-analysis of clinical trials.WORLD JOURNAL OF GASTROENTEROLOGY 16:(46) 5889-5894, 2010.
- 2010, Sato Y, Takayama T, Sagawa T, et al.Phase II study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer.CANCER CHEMOTHERAPY AND PHARMACOLOGY 66(4):721-728,SEP 2010
- 2010, Moon YW, Rha SY, Jeung HC, et al.Outcomes of multiple salvage chemotherapy for advanced gastric cancer: implications for clinical practice and trial design.CANCER CHEMOTHERAPY AND PHARMACOLOGY 66(4):797-805 SEP 2010
- 2010, Ajani JA, Barthel JS, Bekaii-Saab T, et al.Gastric Cancer Clinical Practice Guidelines in Oncology (TM). JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK 8(4):378-409 APR 2010
- 2010, Shah MA, Kelsen DP. Gastric Cancer: A Primer on the Epidemiology and Biology of the Disease and an Overview of the Medical Management of Advanced Disease. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK 8(4):437-447 APR 2010
- 2010, Okines A, Verheij M, Allum W, et al.Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. ANNALS OF ONCOLOGY 21 Pages: v50-v54 Supplement: Suppl. 5 MAY 2010
- 2010, Loupakis F, Masi G, Fornaro L, et al.Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma. CANCER CHEMOTHERAPY AND PHARMACOLOGY 66(3): 559-566 AUG 2010
- 2010, Kim BG, Oh SY, Kwon HC, et al.A Phase II Study of Irinotecan With Biweekly, Low Dose Leucovorin and Bolus and Continuous Infusion 5-Fluorouracil (Modified FOLFIRI) as First Line Therapy For Patients With Recurrent or Metastatic Gastric Cancer. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS 33(3): 246-250 JUN 2010
- 2010, Al-Batran SE, Ajani JA.Impact of Chemotherapy on Quality of Life in Patients With Metastatic Esophagogastric Cancer. CANCER 116(11):2511-2518 JUN 1 2010
- 2010, Luo HY, Xu RH, Wang F, et al.Phase II Trial of XELOX as First-Line Treatment for Patients with Advanced Gastric Cancer. CHEMOTHERAPY 56(2):94-100 2010
- 2010, Hohler T, Ruschoff J, Ridwelski K, et al.HER2 Testing and Targeted Therapy in Advanced Gastric Cancer ONKOLOGIE Volume: 33 Pages: 26-30 Supplement: Suppl. 4 APR 2010
- 2010, Farhat FS, Kattan J, Ghos.Role of capecitabine and irinotecan combination therapy in advanced or metastatic gastric cancer. EXPERT REVIEW OF ANTICANCER THERAPY 10(4): 541-548 APR 2010
- 2010, Hurmuzlu M, Monge OR, Smaaland R, et al.High-dose definitive concomitant chemoradiotherapy in non-metastatic locally advanced esophageal cancer: toxicity and outcome.DISEASES OF THE ESOPHAGUS 23(3): 244-252 2010
- 2010, Doi T, Muro K, Boku N, et al.Multicenter Phase II Study of Everolimus in Patients With Previously Treated Metastatic Gastric Cancer. JOURNAL OF CLINICAL ONCOLOGY 28(11): 1904-1910 APR 10 2010
- 2010, Wagner AD, Unverzagt S, Grothe W, et al.Chemotherapy for advanced gastric cancer. COCHRANE DATABASE OF SYSTEMATIC REVIEWS Issue: 3 Article Number: CD004064, 2010
- 2010, Yang KC, Chao Y, Luo JC, et al.The Unusual Presentation of Gastric Adenocarcinoma as a Testicular Mass: A Favorable Response to Docetaxel and Cisplatin Plus Oral Tegafur/Uracil and Leucovorin.JOURNAL OF THE CHINESE MEDICAL ASSOCIATION 73(2): 88-92 FEB 2010
- 2010, Lordick F, Luber B, Lorenzen S, et al.Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). BRITISH JOURNAL OF CANCER 102(3): 500-505 FEB 2 2010
- 2010, Berglund A, Bystrom P, Johansson B, et al.An explorative randomised phase II study of sequential chemotherapy in advanced upper gastrointestinal cancer. MEDICAL ONCOLOGY 27(1): 65-72 2010
- 2010, Park SR, Kook MC, Choi IJ, et al.Predictive factors for the efficacy of cetuximab plus chemotherapy as salvage therapy in metastatic gastric cancer patients. CANCER CHEMOTHERAPY AND PHARMACOLOGY 65(3): 579-587 FEB 2010
- 2010, Moehler M, Kanzler S, Geissler M, et al.A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction.ANNALS OF ONCOLOGY 21(1): 71-77 JAN 2010.
- 2010, Gril B, Evans L, Palmieri D, et al. Translational research in brain metastasis is identifying molecular pathways that may lead to the development of new therapeutic strategies. EUROPEAN JOURNAL OF CANCER 46(7) Special Issue: Sp. Iss. SI Pages: 1204-1210 MAY 2010
- 2010, Dhankhar R, Vyas SP, Jain AK, et al. Advances in Novel Drug Delivery Strategies for Breast Cancer Therapy. ARTIFICIAL CELLS BLOOD SUBSTITUTES AND BIOTECHNOLOGY 38(5) Pages: 230-249 OCT 2010
- 2010, Kaufmann M, Maass N, Costa SD, et al. First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: Results of the MONICA trial . EUROPEAN JOURNAL OF CANCER 46(18) Pages: 3184-3191 DEC 2010
- 2010, Zielinski C, Gralow J, Martin M. Optimising the dose of capecitabine in metastatic breast cancer: confused, clarified or confirmed?. ANNALS OF ONCOLOGY 21(11) Pages: 2145-2152 NOV 2010
- 2010, Naughton M. Evolution of Capecitabine Dosing in Breast Cancer . CLINICAL BREAST CANCER 10(2) Pages: 130-135 APR 2010
- 2010, Richards NG, Rittenhouse DW, Freydin B, et al. HuR Status is a Powerful Marker for Prognosis and Response to Gemcitabine-Based Chemotherapy for Resected Pancreatic Ductal Adenocarcinoma Patients . ANNALS OF SURGERY 252(3) Pages: 499-506 SEP 2010
- 2010, Strother RM, Gregory KM, Pastakia SD, et al. Retrospective Analysis of the Efficacy of Gemcitabine for Previously Treated AIDS-Associated Kaposi's Sarcoma in Western Kenya ONCOLOGY 78 1 5-11 2010
- 2010, Park JH, Park KJ, Roh YH, et al. Primary Extrapulmonary Small Cell Carcinoma of the Appendix - A Case Report - KOREAN JOURNAL OF PATHOLOGY 44 1 101-105 2010
- 2010, Sezgin C, Gokmen E, Kapkac M, et al. p53 Protein Accumulation and Presence of Visceral Metastasis Are Independent Prognostic Factors for Survival in Patients with Metastatic Inflammatory Breast Carcinoma MEDICAL PRINCIPLES AND PRACTICE 20 2 159-164 2010
- 2010, Sharma B, Singh S, Varney ML, et al. Targeting CXCR1/CXCR2 receptor antagonism in malignant melanoma EXPERT OPINION ON THERAPEUTIC TARGETS 14 4 435-442 APR 2010
- 2010, Dhankhar R, Vyas SP, Jain AK, et al. Advances in Novel Drug Delivery Strategies for Breast Cancer Therapy ARTIFICIAL CELLS BLOOD SUBSTITUTES AND BIOTECHNOLOGY 38 5 230-249 OCT 2010
- 2010, Smith DM, Patel S, Raffoul F, et al. Arsenic trioxide induces a beclin-1-independent autophagic pathway via modulation of SnoN/SkiL expression in ovarian carcinoma cells CELL DEATH AND DIFFERENTIATION 17 12 1867-1881 DEC 2010
- 2010, Chen MJ, Yang PY, Ye YZ, et al. Arsenic Trioxide Induces Apoptosis in Uveal Melanoma Cells Through the Mitochondrial Pathway AMERICAN JOURNAL OF CHINESE MEDICINE 38 6 1131-1142 2010
- 2010, Zhong F, Zhang SN, Shao CK, et al. Arsenic Trioxide Inhibits Cholangiocarcinoma Cell Growth and induces Apoptosis PATHOLOGY & ONCOLOGY RESEARCH 16 3 413-420 SEP 2010
- 2010, Ren TT, Guo W, Peng CL, et al. Arsenic trioxide inhibits osteosarcoma cell invasiveness via MAPK signaling pathway. CANCER BIOLOGY & THERAPY Volume: 10 Issue: 3 Article Number: 12349 Published: AUG 1 2010
- 2010, Ren TT, Guo W, Peng CL, et al. Arsenic trioxide inhibits osteosarcoma cell invasiveness via MAPK signaling pathway. CANCER BIOLOGY & THERAPY Volume: 10 Issue: 3 Article Number: 12349 Published: AUG 1 2010
- 2010, Han YH, Moon HJ, You BR, et al. Effects of arsenic trioxide on cell death, reactive oxygen species and glutathione levels in different cell types. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE Volume: 25 Issue: 1 Pages: 121-128 Published: JAN 2010
- 2010, Gao M, Dong W, Hu MR, et al.GADD45 alpha Mediates Arsenite-Induced Cell Apoptotic Effect in Human Hepatoma Cells Via JNKs/AP-1-Dependent Pathway. JOURNAL OF CELLULAR BIOCHEMISTRY Volume: 109 Issue: 6 Pages: 1264-1273 Published: APR 15 2010
- 2010, Salazar AM, Miller HL, McNeely SC, et al.Suppression of p53 and p21(CIP1/WAF1) Reduces Arsenite-Induced Aneuploidy CHEMICAL RESEARCH IN TOXICOLOGY Volume: 23 Issue: 2 Pages: 357-364 Published: FEB 2010
- 2010, Mazboudi O, Abboud MR, Muwakkit S, et al. Endobronchial metastasis of osteosarcoma presenting as position-dependent and variable airway obstruction of the trachea THORAX 65 1 92-92 JAN 2010
- 2010, Uchiyama H, Sowa Y, Wakada M, et al. Cyclin-dependent kinase inhibitor SU9516 enhances sensitivity to methotrexate in human T-cell leukemia Jurkat cells CANCER SCIENCE 101 3 728-734 MAR 2010
- 2010, Ajani JA, Wang XM, Izzo JG, et al. Molecular Biomarkers Correlate with Disease-Free Survival in Patients with Anal Canal Carcinoma Treated with Chemoradiation DIGESTIVE DISEASES AND SCIENCES 55 4 1098-1105 APR 2010
- 2010, Askari BS, Krajinovic M Dihydrofolate Reductase Gene Variations in Susceptibility to Disease and Treatment Outcomes CURRENT GENOMICS 11 8 578-583 DEC 2010
- 2010, Mondello C, Smirnova A, Giulotto E. Gene amplification, radiation sensitivity and DNA double-strand breaks MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH Volume: 704 Issue: 1-3 Special Issue: Sp. Iss. SI Pages: 29-37 Published: APR-JUN 2010
- 2010, Stefanko E, Wrobel T. Mechanisms of Resistance to Cancer Chemotherapy ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE Volume: 19 Issue: 1 Pages: 5-12 Published: 2010
- 2010, Affleck JG, Nowickyj SM, Walker VK. Selection for methotrexate resistance in mammalian cells bearing a Drosophila dihydrofolate reductase transgene CELL BIOLOGY AND TOXICOLOGY Volume: 26 Issue: 2 Pages: 117-126 Published: APR 2010
- 2010, Uchiyama H, Sowa Y, Wakada M, et al. Cyclin-dependent kinase inhibitor SU9516 enhances sensitivity to methotrexate in human T-cell leukemia Jurkat cells CANCER SCIENCE Volume: 101 Issue: 3 Pages: 728-734 Published: MAR 2010
- 2010, de Beaumais TA, Dervieux T, Fakhoury M, et al. The impact of high-dose methotrexate on intracellular 6-mercaptopurine disposition during interval therapy of childhood acute lymphoblastic leukemia CANCER CHEMOTHERAPY AND PHARMACOLOGY 66 4 653-658 SEP 2010
- 2009, He RB, Chen JQ.Pre-operative Chemotherapy for Gastric Cancer. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH 37(5): 1259-1266 SEP-OCT 2009
- 2009, Boku N, Yamamoto S, Fukuda H, et al.Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.LANCET ONCOLOGY 10(11): 1063-1069 NOV 2009
- 2009, Pinto C, Di Fabio F, Barone C, et al.Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study). BRITISH JOURNAL OF CANCER 101(8): 1261-1268 OCT 13 2009
- 2009, Wagner AD, Wedding U. Advances in the Pharmacological Treatment of Gastro-Oesophageal Cancer. DRUGS & AGING 26(8): 627-646 2009
- 2009, Rivera F, Carrato A, Gravalos C, et al.Recommendations on current approach to gastric cancer. CLINICAL & TRANSLATIONAL ONCOLOGY 11(8): 518-525 AUG 2009
- 2009, Rivera F, Carrato A, Gravalos C, et al.Recommendations on current approach to gastric cancer. CLINICAL & TRANSLATIONAL ONCOLOGY 11(8): 518-525 AUG 2009
- 2009, Gold HT, Hall MJ, Blinder V, et al.Cost Effectiveness of Pharmacogenetic Testing for Uridine Diphosphate Glucuronosyltransferase 1A1 Before Irinotecan Administration for Metastatic Colorectal Cancer. CANCER 115(17):3858-3867 SEP 1 2009
- 2009, Comella P, Lorusso V, Maiorino L, et al.Oxaliplatin, irinotecan, and fluorouracil/folinic acid in advanced gastric cancer: a multicenter phase II trial of the Southern Italy Cooperative Oncology Group. CANCER CHEMOTHERAPY AND PHARMACOLOGY 64(5):893-899 OCT 2009
- 2009, Curran D, Pozzo C, Zaluski J, et al.Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trial. QUALITY OF LIFE RESEARCH 18(7): 853-861 SEP 2009
- 2009, Catalano V, Labianca R, Beretta GD, et al.Gastric cancer. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY 71(2): 127-164 AUG 2009
- 2009, El-Sayyad HI, Ismail MF, Shalaby FM, et al.Histopathological effects of cisplatin, doxorubicin and 5-flurouracil (5-FU) on the liver of male albino rats. INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES 5(5): 466-473 2009
- 2009, Chau I, Ashley S, Cunningham D. Validation of the Royal Marsden Hospital Prognostic Index in Advanced Esophagogastric Cancer Using Individual Patient Data From the REAL 2 Study. JOURNAL OF CLINICAL ONCOLOGY 27(19): E3-E4 JUL 1 2009
- 2009, Burtness B, Gibson M, Egleston B, et al.Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer. ANNALS OF ONCOLOGY 20(7): 1242-1248 JUL 2009
- 2009, Celio L, Sternberg CN, Labianca R, et al.Pemetrexed in combination with oxaliplatin as a first-line therapy for advanced gastric cancer: a multi-institutional phase II study. ANNALS OF ONCOLOGY 20(6): 1062-1067 JUN 2009
- 2009, Jackson C, Cunningham D, Oliveira J. Gastric cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. ANNALS OF ONCOLOGY 20: 34-36 Supplement: Suppl. 4 MAY 2009
- 2009, Chau I, Norman AR, Cunningham D, et al.The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma-025EFindividual patient data from 1775 patients in four randomised controlled trials.ANNALS OF ONCOLOGY 20(5): 885-891 MAY 2009
- 2009, Wolff K, Wein A, Reulbach U, et al.Weekly high-dose 5-fluorouracil as a 24-h infusion and sodium folinic acid (AIO regimen) plus irinotecan in patients with locally advanced nonresectable and metastatic adenocarcinoma or squamous cell carcinoma of the oesophagus: a phase II trial. ANTI-CANCER DRUGS 20(3): 165-173 MAR 2009
- 2009, Maeda H, Miyajima N, Kano S, et al.Ubiquitin-Conjugating Enzyme UBE2Q2 Suppresses Cell Proliferation and Is Down-Regulated in Recurrent Head and Neck Cancer. MOLECULAR CANCER RESEARCH 7(9): 1553-1562 SEP 2009
- 2009, Hwang TL, Fang CL, Chen CH, et al. Permeation Enhancer-Containing Water-In-Oil Nanoemulsions as Carriers for Intravesical Cisplatin Delivery. PHARMACEUTICAL RESEARCH 26(10) Pages: 2314-2323 Published: OCT 2009
- 2009, Azeem A, Rizwan M, Ahmad FJ, et al. Components Screening and Influence of Surfactant and Cosurfactant on Nanoemulsion Formation. CURRENT NANOSCIENCE 5(2) Pages: 220-226 MAY 2009
- 2009, Azeem A, Rizwan M, Ahmad FJ, et al. Nanoemulsion Components Screening and Selection: a Technical Note. AAPS PHARMSCITECH 10(1) Pages: 69-76 MAR 2009
- 2009, Karasulu HY, Kantarci G, Karaca B, et al. Determining the Cytotoxicity of Methotrexate-Loaded Microemulsion on Human Breast, Ovarian, and Prostate Carcinoma Cell Lines: A New Modality for an Old Drug. DRUG DEVELOPMENT RESEARCH 70(1) Pages: 49-56 FEB 2009
- 2009, Siedentopf F, Gohler T, Hesse T, et al. Capecitabine in the Routine Treatment of Advanced Breast Cancer: Results from a Non-Interventional Observational Study in 876 Patients . ONKOLOGIE 32(11) Pages: 631-636 2009
- 2009, Tsavaris N, Kavantzas N, Tsigritis K, et al.Evaluation of DNA ploidy in relation with established prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis . BMC CANCER 9 Article Number: 264 JUL 31 2009
- 2009, Pine JK, Fusai KG, Young R, et al. Serum C-reactive protein concentration and the prognosis of ductal adenocarcinoma of the head of pancreas . EJSO 35(6) Pages: 605-610 JUN 2009
- 2009, Vergote I, Finkler N, del Campo J, et al. Phase 3 randomised study of canfosfamide (Telcyta (R), TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer EUROPEAN JOURNAL OF CANCER 45(13) 2324-2332 SEP 2009
- 2009, Brell JM, Krishnamurthi SS, Javle M, et al. A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinoma. CANCER CHEMOTHERAPY AND PHARMACOLOGY 63 (5) Pages: 851-857 APR 2009
- 2009, Menges M, Hoehler T. Current strategies in systemic treatment of gastric cancer and cancer of the gastroesophageal junction . JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY 135(1) Pages: 29-38 JAN 2009
- 2009, Hojo T, Kinoshita T, Shien T, et al. Primary small cell carcinoma of the breast BREAST CANCER 16 1 68-71 JAN 2009
- 2009, Cicin I, Usta U, Karagol H, et al. Extrapulmonary small cell carcinoma localized in lymph nodes: Is it a different clinical entity? ACTA ONCOLOGICA 48 3 354-360 2009
- 2009, Schilder RJ, Pathak HB, Lokshin AE, et al. Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash GYNECOLOGIC ONCOLOGY 113 1 21-27 APR 2009
- 2009, Kim HJ, Shin JH, Kim TH, et al. Efficacy of Transarterial Embolization. with Arsenic Trioxide Oil Emulsion in a Rabbit VX2 Liver Tumor Model JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY 20 10 1365-1370 OCT 2009
- 2009, Izdebska M, Grzanka A, Ostrowski M, et al.Effect of arsenic trioxide (Trisenox) on actin organization in K-562 erythroleukemia cells. FOLIA HISTOCHEMICA ET CYTOBIOLOGICA Volume: 47 Issue: 3 Pages: 453-459 Published: 2009
- 2009, Wirtitsch M, Roth E, Bachleitner-Hofmann T, et al. omega-3 and omega-6 Polyunsaturated Fatty Acids Enhance Arsenic Trioxide Efficacy in Arsenic Trioxide-Resistant Leukemic and Solid Tumor Cells. ONCOLOGY RESEARCH Volume: 18 Issue: 2-3 Pages: 83-94 Published: 2009
- 2009, Sanchez Y, Calle C, de Blas E, et al. Modulation of arsenic trioxide-induced apoptosis by genistein and functionally related agents in U937 human leukaemia cells. Regulation by ROS and mitogen-activated protein kinases. CHEMICO-BIOLOGICAL INTERACTIONS Volume: 182 Issue: 1 Pages: 37-44 Published: NOV 10 2009
- 2009, Wang JZ, Loh KP, Wang Z, et al. Fluorescent Nanogel of Arsenic Sulfide Nanoclusters. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION Volume: 48 Issue: 34 Pages: 6282-6285 Published: 2009
- 2009, Izdebska M, Grzanka D, Gackowska L, et al. The influence of Trisenox on actin organization in HL-60 cells. CENTRAL EUROPEAN JOURNAL OF BIOLOGY Volume: 4 Issue: 3 Pages: 351-361 Published: SEP 2009
- 2009, Duan Q, Komissarova E, Dai W. Arsenic trioxide suppresses paclitaxel-induced mitotic arrest. CELL PROLIFERATION Volume: 42 Issue: 3 Pages: 404-411 Published: JUN 2009
- 2009, Wang W, Adachi M, Zhang R, et al.A Novel Combination Therapy With Arsenic Trioxide and Parthenolide Against Pancreatic Cancer Cells. PANCREAS Volume: 38 Issue: 4 Pages: E114-E123 Published: MAY 2009
- 2009, Franco R, Sanchez-Olea R, Reyes-Reyes EM, et al.Environmental toxicity, oxidative stress and apoptosis: Menage a Trois. MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS Volume: 674 Issue: 1-2 Special Issue: Sp. Iss. SI Pages: 3-22 Published: MAR 31 2009
- 2009, Gunes DA, Florea AM, Splettstoesser F, et al.Co-application of arsenic trioxide (As2O3) and cisplatin (CDDP) on human SY-5Y neuroblastoma cells has differential effects on the intracellular calcium concentration ([Ca2+](i)) and cytotoxicity. NEUROTOXICOLOGY Volume: 30 Issue: 2 Pages: 194-202 Published: MAR 2009
- 2009, Doyle D. Notoriety to respectability: a short history of arsenic prior to its present day use in haematology. BRITISH JOURNAL OF HAEMATOLOGY Volume: 145 Issue: 3 Pages: 309-317 Published: MAY 2009
- 2009, Wang Y, An RH, Dong XS, et al.Protein Kinase C Is Involved in Arsenic Trioxide-Induced Apoptosis and Inhibition of Proliferation in Human Bladder Cancer Cells. UROLOGIA INTERNATIONALIS Volume: 82 Issue: 2 Pages: 214-221 Published: 2009
- 2009, Karasulu HY, Kantarci G, Karaca B, et al.Determining the Cytotoxicity of Methotrexate-Loaded Microemulsion on Human Breast, Ovarian, and Prostate Carcinoma Cell Lines: A New Modality for an Old Drug. DRUG DEVELOPMENT RESEARCH Volume: 70 Issue: 1 Pages: 49-56 Published: FEB 2009
- 2009, Dogruel F, Leman J. 'Conduct' and 'Counter-conduct' on the Southern Border of Turkey: Multicultural Antakya MIDDLE EASTERN STUDIES 45 4 593-610 2009
- 2009, Ozyurek E oThe Light of the Alevi Fire Was Lit in Germany and then Spread to Turkeyo: A Transnational Debate on the Boundaries of Islam TURKISH STUDIES 10 2 233-253 2009
- 2009, Nakao M, Oguri T, Maeno K, et al. Endobronchial Metastasis from Primary Papillary Serous Carcinoma of the Peritoneum INTERNAL MEDICINE 48 13 1165-1168 2009
- 2009, Nerkar AG, Ghone SA, Sareen A, et al. In Silico Screening of Pyridine Derivatives as Potential DHFR Inhibitors for Anticancer Activity ASIAN JOURNAL OF CHEMISTRY 21 9 6975-6980 DEC 2009
- 2009, Nerkar AG, Ghone SA, Thaker AK In Silico Screening and ADME Predictions of Some Quinazolinones as Potential Dihydrofolate Reductase Inhibitors for Anticancer Activity ASIAN JOURNAL OF CHEMISTRY 21 7 5363-5372 AUG-SEP 2009
- 2009, Kaasgaard T, Andresen TL, Jensen SS, et al. Liposomes containing alkylated methotrexate analogues for phospholipase A(2) mediated tumor targeted drug delivery CHEMISTRY AND PHYSICS OF LIPIDS Volume: 157 Issue: 2 Pages: 94-103 Published: FEB 2009
- 2009, Prasad P, Vasquez H, Das C, et al. Histone acetylation resulting in resistance to methotrexate in choroid plexus cells JOURNAL OF NEURO-ONCOLOGY Volume: 91 Issue: 3 Pages: 279-286 Published: FEB 2009
- 2009, Baffa R, Fassan M, Volinia S, et al. MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets JOURNAL OF PATHOLOGY 219 2 214-221 OCT 2009
- 2009, Al-Shakfa F, Dulucq S, Brukner I, et al. DNA Variants in Region for Noncoding Interfering Transcript of Dihydrofolate Reductase Gene and Outcome in Childhood Acute Lymphoblastic Leukemia CLINICAL CANCER RESEARCH Volume: 15 Issue: 22 Pages: 6931-6938 Published: NOV 15 2009
- 2009, Marverti G, Ligabue A, Paglietti G, et al. Collateral sensitivity to novel thymidylate synthase inhibitors correlates with folate cycle enzymes impairment in cisplatin-resistant human ovarian cancer cells EUROPEAN JOURNAL OF PHARMACOLOGY Volume: 615 Issue: 1-3 Pages: 17-26 Published: AUG 1 2009
- 2009, Volpato JP, Pelletier JN. Mutational 'hot-spots' in mammalian, bacterial and protozoal dihydrofolate reductases associated with antifolate resistance: Sequence and structural comparison DRUG RESISTANCE UPDATES Volume: 12 Issue: 1-2 Pages: 28-41 Published: FEB-APR 2009
- 2009, Tanaka H, Yao MC. Palindromic gene amplification - an evolutionarily conserved role for DNA inverted repeats in the genome NATURE REVIEWS CANCER Volume: 9 Issue: 3 Pages: 215-224 Published: MAR 2009
- 2009, Bertino JR Cancer research: from folate antagonism to molecular targets BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY 22 4 577-582 DEC 2009
- 2009, Corsello SM, Roti G, Ross KN, et al. Identification of AML1-ETO modulators by chemical genomics BLOOD 113 24 6193-6205 JUN 11 2009
- 2009, Kusmierek K, Chwatko G, Glowacki R, et al. Determination of endogenous thiols and thiol drugs in urine by HPLC with ultraviolet detection JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES 877 28 3300-3308 OCT 15 2009
- 2009, Jia YF, Zheng Y, Ma XL, et al. The Enhancement of drug sensitivity of human AFP-producing gastric carcinoma cell line FU97 to arsenic trioxide Using AFP as targeting siRNA 2009 3RD INTERNATIONAL CONFERENCE ON BIOINFORMATICS AND BIOMEDICAL ENGINEERING, VOLS 1-11 Pages: 623-626 Published: 2009
- 2008, Pieters A, Laurent S, Dero I, et al.The role of oral fluoropyrimidines in the treatment of advanced gastric cancer. ACTA GASTRO-ENTEROLOGICA BELGICA 71(4): 361-366 OCT-DEC 2008
- 2008, Karasulu HY. Microemulsions as novel drug carriers: the formation, stability, applications and toxicity. EXPERT OPINION ON DRUG DELIVERY 5(1) Pages: 119-135 JAN 2008
- 2008, Zhang QY, Kang XM, Yang BF, et al. Antiangiogenic Effect of Capecitabine Combined with Ginsenoside Rg3 on Breast Cancer in Mice . CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS 23(5) Pages: 647-653 OCT 2008
- 2008, Nakai Y, Isayama H, Kawabe T, et al. Efficacy and Safety of Metallic Stents in Patients With Unresectable Pancreatic Cancer Receiving Gemcitabine . PANCREAS 37(4) Pages: 405-410 NOV 2008
- 2008, Bartosch-Harlid A, Andersson B, Aho U, et al. Artificial neural networks in pancreatic disease . BRITISH JOURNAL OF SURGERY 95(7) Pages: 817-826 JUL 2008
- 2008, Wang P, Meng ZQ, Chen Z, et al. Survival rate of pancreatic cancer in elderly patients . HEPATO-GASTROENTEROLOGY 55(82-83) Pages: 681-686 MAR-APR 2008
- 2008, Katz MHG, Hwang R, Fleming JB, et al. Tumor-node-metastasis staging of pancreatic adenocarcinoma . CA-A CANCER JOURNAL FOR CLINICIANS 58(2) Pages: 111-125 MAR-APR 2008 .
- 2008, Park JK, Yoon YB, Kim YT, et al. Survival and prognostic factors of unresectable pancreatic cancer . JOURNAL OF CLINICAL GASTROENTEROLOGY 42(1) Pages: 86-91 JAN 2008
- 2008, Isik B, Yilmaz S, Kirimlioglu V, et al. Kaposi's sarcoma after liver transplantation from a donor with a history of ventriculoperitoneal shunt and craniotomy for primary central nervous system lymphoma: Report of a case SURGERY TODAY 38 1 90-94 JAN 2008
- 2008, Saydam BK, Goksel G, Korkmaz E, et al. Comparison of inflammatory breast cancer and noninflammatory breast cancer in Western Turkey MEDICAL PRINCIPLES AND PRACTICE 17 6 475-480 2008
- 2008, Coley HM. Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. CANCER TREATMENT REVIEWS 34(4): 378-390 JUN 2008
- 2008, Tang SC. Predictive markers of tubulin-targeting agents in breast cancer. CLINICAL BREAST CANCER Volume: 8 Pages: S79-S84 Supplement: Suppl. 2 Published: MAR 2008
- 2008, Wilson C, Scullin P, Worthington J, et al. Dexamethasone potentiates the antiangiogenic activity of docetaxel in castration-resistant prostate cancer BRITISH JOURNAL OF CANCER 99 12 2054-2064 DEC 9 2008
- 2008, Wilson C, Purcell C, Seaton A, et al.Chemotherapy-Induced CXC-Chemokine/CXC-Chemokine Receptor Signaling in Metastatic Prostate Cancer Cells Confers Resistance to Oxaliplatin through Potentiation of Nuclear Factor-kappa B Transcription and Evasion of Apoptosis. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 327(3): 746-759 DEC 2008
- 2008, Wilson C, Wilson T, Johnston PG, et al. Interleukin-8 signaling attenuates TRAIL- and chemotherapy-induced apoptosis through transcriptional regulation of c-FLIP in prostate cancer cells. MOLECULAR CANCER THERAPEUTICS 7(9): 2649-2661 SEP 2008
- 2008, Merritt WM, Lin YG, Spannuth WA, et al. Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. JOURNAL OF THE NATIONAL CANCER INSTITUTE 100(5): 359-372 MAR 5 2008
- 2008, Karasulu HY Microemulsions as novel drug carriers: the formation, stability, applications and toxicity EXPERT OPINION ON DRUG DELIVERY 5 1 119-135 JAN 2008
- 2008, Jian OY, Xu XH, Chen JH, et al. Involvement of Protein Phosphatase 2A in Arsenic Trioxide-Induced Differentiation and Apoptosis of NB4 Cells METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY 30 6 411-419 JUL-AUG 2008
- 2008, Izdebska M, Grzanka A, Szczepanski MA, et al.Selected mechanisms of the therapeutic effect of arsenic trioxide in cancer treatment. POSTEPY HIGIENY I MEDYCYNY DOSWIADCZALNEJ Volume: 62 Pages: 463-467 Published: 2008
- 2008, Bae-Jump VL, Zhou CX, Boggess JF, et al.Arsenic Trioxide (As2O3) Inhibits Expression of Estrogen Receptor-alpha Through Regulation of the Mitogen-activated Protein Kinase (MAPK) Pathway in Endometrial Cancer Cells. REPRODUCTIVE SCIENCES Volume: 15 Issue: 10 Pages: 1011-1017 Published: DEC 2008
- 2008, Cui X, Kobayashi Y, Akashi M, et al.Metabolism and the Paradoxical Effects of Arsenic: Carcinogenesis and Anticancer. CURRENT MEDICINAL CHEMISTRY Volume: 15 Issue: 22 Pages: 2293-2304 Published: SEP 2008
- 2008, Diaz Z, Mann KK, Marcoux S, et al. A novel arsenical has antitumor activity toward As2O3-resistant and MRP1/ABCC1-overexpressing cell lines. LEUKEMIA Volume: 22 Issue: 10 Pages: 1853-1863 Published: OCT 2008
- 2008, Han YH, Kim SZ, Kim SH, et al.Arsenic trioxide inhibits the growth of Calu-6 cells via inducing a G2 arrest of the cell cycle and apoptosis accompanied with the depletion of GSH. CANCER LETTERS Volume: 270 Issue: 1 Pages: 40-55 Published: OCT 18 2008
- 2008, Bowling BD, Doudican N, Manga P, et al.Inhibition of mitochondrial protein translation sensitizes melanoma cells to arsenic trioxide cytotoxicity via a reactive oxygen species dependent mechanism. CANCER CHEMOTHERAPY AND PHARMACOLOGY Volume: 63 Issue: 1 Pages: 37-43 Published: DEC 2008
- 2008, Kang YH, Lee SJ. Role of p38 MAPK and JNK in enhanced cervical cancer cell killing by the combination of arsenic trioxide and ionizing radiation. ONCOLOGY REPORTS Volume: 20 Issue: 3 Pages: 637-643 Published: SEP 2008
- 2008, Han YH, Kim SZ, Kim SH, et al. Induction of apoptosis in arsenic trioxide-treated lung cancer A549 cells by buthionine sulfoximine. MOLECULES AND CELLS Volume: 26 Issue: 2 Pages: 158-164 Published: AUG 31 2008
- 2008, Kang YH, Lee SJ. The role of p38 MAPK and JNK in arsenic trioxide-induced mitochondrial cell death in human cervical cancer cells. JOURNAL OF CELLULAR PHYSIOLOGY Volume: 217 Issue: 1 Pages: 23-33 Published: OCT 2008
- 2008, Park JH, Kim EJ, Jang HY, et al. Combination treatment with arsenic trioxide and sulindac enhances apoptotic cell death in lung cancer cells via activation of oxidative stress and mitogen-activated protein kinases. ONCOLOGY REPORTS Volume: 20 Issue: 2 Pages: 379-384 Published: AUG 2008
- 2008, Han YH, Kim SZ, Kim SH, et al. Suppression of arsenic trioxide-induced apoptosis in HeLa cells by N-acetylcysteine. MOLECULES AND CELLS Volume: 26 Issue: 1 Pages: 18-25 Published: JUL 31 2008
- 2008, Zhao SG, Zhang J, Zhang X, et al. Arsenic trioxide induces different gene expression profiles of genes related to growth and apoptosis in glioma cells dependent on the p53 status. MOLECULAR BIOLOGY REPORTS Volume: 35 Issue: 3 Pages: 421-429 Published: SEP 2008
- 2008, Wei YY, Liu D, Ge YQ, et al. Down-regulation of beta 1,4GalT V at protein level contributes to arsenic trioxide-induced glioma cell apoptosis. CANCER LETTERS Volume: 267 Issue: 1 Pages: 96-105 Published: AUG 18 2008
- 2008, Han YH, Kim SZ, Kim SH, et al. Enhancement of arsenic trioxide-induced apoptosis in HeLa cells by diethyldithiocarbamate or buthionine sulfoximine. INTERNATIONAL JOURNAL OF ONCOLOGY Volume: 33 Issue: 1 Pages: 205-213 Published: JUL 2008
- 2008, Zhao SG, Xu Z, Zhang J, et al. Intravenous administration of arsenic trioxide encapsulated in liposomes inhibits the growth of C6 gliomas in rat brains. JOURNAL OF CHEMOTHERAPY Volume: 20 Issue: 2 Pages: 253-262 Published: APR 2008
- 2008, Han YH, Kim SH, Kim SZ, et al. Apoptosis in arsenic trioxide-treated Calu-6 lung cells is correlated with the depletion of GSH levels rather than the changes of ROS levels. JOURNAL OF CELLULAR BIOCHEMISTRY Volume: 104 Issue: 3 Pages: 862-878 Published: JUN 1 2008
- 2008, Copley L, van der Watt P, Wirtz KW, et al. Photolon (TM), a chlorin e6 derivative, triggers ROS production and light-dependent cell death via necrosis INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY Volume: 40 Issue: 2 Pages: 227-235 Published: 2008
- 2008, Kim EH, Yoon NJ, Kim SU, et al. Arsenic trioxide sensitizes human glioma cells, but not normal astrocytes, to TRAIL-induced apoptosis via CCAAT/enhancer-binding protein homologous protein-dependent DR5 up-regulation CANCER RESEARCH Volume: 68 Issue: 1 Pages: 266-275 Published: JAN 1 2008
- 2008, Dressler M Religio-secular metamorphoses: The re-making of Turkish Alevism JOURNAL OF THE AMERICAN ACADEMY OF RELIGION 76 2 280-311 JUN 2008
- 2008, Kalmbach RD, Choumenkovitch SE, Troen AP, et al. A 19-Base Pair Deletion Polymorphism in Dihydrofolate Reductase Is Associated with Increased Unmetabolized Folic Acid in Plasma and Decreased Red Blood Cell Folate JOURNAL OF NUTRITION 138 12 2323-2327 DEC 2008
- 2008, Mellor HR, Callaghan R. Resistance to chemotherapy in cancer: A complex and integrated cellular response PHARMACOLOGY Volume: 81 Issue: 4 Pages: 275-300 Published: 2008
- 2008, Dulucq S, St-Onge G, Gagne V, et al. DNA variants in the dihydrofolate reductase gene and outcome in childhood ALL BLOOD Volume: 111 Issue: 7 Pages: 3692-3700 Published: APR 1 2008
- 2008, Gorlick RG, Abramson DH, Sowers R, et al. Impairments in antifolate transport are common in retinoblastoma tumor samples PEDIATRIC BLOOD & CANCER 50 3 573-576 MAR 2008
- 2008, Fotoohi AK, Albertioni F Mechanisms of antifolate resistance and methotrexate efficacy in leukemia cells LEUKEMIA & LYMPHOMA 49 3 410-426 2008
- 2008, Zakrzewski R. Application of the iodine-azide postcolumn reaction in RP-HPLC for the determination of thioguanine in urine JOURNAL OF SEPARATION SCIENCE Volume: 31 Issue: 12 Pages: 2199-2205 Published: JUL 2008
- 2007, Dilda PJ, Hogg PJ. Arsenical-based cancer drugs. CANCER TREATMENT REVIEWS 33(6) Pages: 542-564 OCT 2007
- 2007, Zalatnai A. Novel therapeutic approaches in the treatment of advanced pancreatic carcinoma . CANCER TREATMENT REVIEWS 33(3) Pages: 289-298 MAY 2007
- 2007, Mutch DG, Orlando M, Goss T, et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer JOURNAL OF CLINICAL ONCOLOGY 25 (19) 2811-2818 JUL 1 2007
- 2007, Hwang JJ. Role of chemotherapy in the treatment of gastroesophageal cancers . ONCOLOGY-NEW YORK 21(5) Pages: 579-586 APR 2007
- 2007, Rosati G, Cordio S, Caputo G, et al. Phase II trial of a biweekly regimen of fluorouracil and leucovorin plus irinotecan in patients with previously untreated advanced gastric cancer . JOURNAL OF CHEMOTHERAPY 19 (5) Pages: 570-576 OCT 2007
- 2007, Kelsen DP, Winter KA, Gunderson LL, et al. Long-term results of RTOG trial 8911 (USA intergroup 113): A random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. JOURNAL OF CLINICAL ONCOLOGY 25 (24) Pages: 3719-3725 AUG 20 2007
- 2007, Di Lauro L, Nunziata C, Arena MG, et al. Irinotecan, docetaxel and oxaliplatin combination in metastatic gastric or gastroesophageal junction adenocarcinoma. BRITISH JOURNAL OF CANCER 97 (5) Pages: 593-597 AUG 28 2007
- 2007, Foukakis T, Lundell L, Gubanski M, et al. Advances in the treatment of patients with gastric adenocarcinoma . ACTA ONCOLOGICA 46(3) Pages: 277-285 2007
- 2007, Lenz HJ, Lee FC, Haller DG, et al. Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study . CANCER 109(1) Pages: 33-40 JAN 1 2007
- 2007, Hassan G, Khalaf H, Mourad W Dermatologic complications after liver transplantation: A single-center experience TRANSPLANTATION PROCEEDINGS 39 4 1190-1194 MAY 2007
- 2007, Cicin I, Karagol H, Uzunoglu S, et al. Extrapulmonary small-cell carcinoma compared with small-cell lung carcinoma - A retrospective single-center study. CANCER 110(5): 1068-1076 SEP 1 2007
- 2007, Banerji U, Kuciejewska A, Ashley S, et al. Factors determining outcome after third line chemotherapy for metastatic breast cancer BREAST 16 4 359-366 AUG 2007
- 2007, Hayes DF, Thor AD, Dressler LG, et al. HER2 and response to paclitaxel in node-positive breast cancer. NEW ENGLAND JOURNAL OF MEDICINE 357(15) 1496-1506 OCT 11 2007
- 2007, Privette LM, Gonzalez ME, Ding L, et al. Altered expression of the early mitotic checkpoint protein, CHFR, in breast cancers: Implications for tumor suppression. CANCER RESEARCH 67(13): 6064-6074 JUL 1 2007
- 2007, Merritt WM, Sood AK. Markers of angiogenesis in ovarian cancer. DISEASE MARKERS 23(5-6): 419-431 2007
- 2007, Wei YS, Lan Y, Tanga RG, et al.Single nucleotide polymorphism and haplotype association of the interleukin-8 gene with nasopharyngeal carcinoma. CLINICAL IMMUNOLOGY 125(3): 309-317 DEC 2007
- 2007, Chechlinska A, Kaminska J, Markowska J, et al. Peritoneal fluid cytokines and the differential diagnosis of benign and malignant ovarian tumors and residual/recurrent disease examination. INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS 22(3): 172-180 JUL-SEP 2007
- 2007, Derin D, Soydinc HO, Guney N, et al. Serum IL-8 and IL-12 levels in breast cancer. MEDICAL ONCOLOGY 24(2): 163-168 2007
- 2007, Karadeniz H, Alparslan L, Erdem A, et al. Electrochemical investigation of interaction between mitomycin C and DNA in a novel drug-delivery system. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS 45(2): 322-326 OCT 18 2007
- 2007, Jiang MC, Luo SF, Li LT, et al. Synergic CSE1L/CAS, TNFR-1, and p53 apoptotic pathways in combined interferon-gamma/adriamycin-induced apoptosis of Hep G2 hepatoma cells JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH 26 1 91-99 MAR 2007
- 2007, Yu ZY, Liang YG, Xiao H, et al. Melissoidesin G, a diterpenoid purified from Isodon melissoides, induces leukemic-cell apoptosis through induction of redox imbalance and exhibits synergy with other anticancer agents INTERNATIONAL JOURNAL OF CANCER Volume: 121 Issue: 9 Pages: 2084-2094 Published: NOV 1 2007
- 2007, Dilda PJ, Hogg PJ. Arsenical-based cancer drugs CANCER TREATMENT REVIEWS Volume: 33 Issue: 6 Pages: 542-564 Published: OCT 2007
- 2007, Diaz Z, Laurenzana A, Mann KK, et al. Trolox enhances the anti-lymphoma effects of arsenic trioxide, while protecting against liver toxicity LEUKEMIA Volume: 21 Issue: 10 Pages: 2117-2127 Published: OCT 2007
- 2007, Yu J, Qian HL, Li YF, et al. Arsenic trioxide (As2O3) reduces the invasive and metastatic properties of cervical cancer cells in vitro and in vivo GYNECOLOGIC ONCOLOGY Volume: 106 Issue: 2 Pages: 400-406 Published: AUG 2007
- 2007, Kalkner KM, Ullen A, Wersall P, et al. Temporary effect of arsenic trioxide treatment of refractory extragonadal germ cell cancer ACTA ONCOLOGICA Volume: 46 Issue: 6 Pages: 862-863 Published: 2007
- 2007, Tachiwada T, Chen ZS, Che XF, et al. Isolation and characterization of arsenite-resistant human epidermoid carcinoma KB cells ONCOLOGY REPORTS Volume: 18 Issue: 3 Pages: 721-727 Published: SEP 2007
- 2007, Ai ZL, Lu WQ, Ton SX, et al. Arsenic trioxide-mediated growth inhibition in gallbladder carcinoma cells via down-regulation of Cyclin D1 transcription mediated by Sp1 transcription factor BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS Volume: 360 Issue: 3 Pages: 684-689 Published: AUG 31 2007
- 2007, Karasulu HY, Karabulut B, Goker E, et al. Controlled release of methotrexate from W/O microemulsion and its in vitro antitumor activity DRUG DELIVERY Volume: 14 Issue: 4 Pages: 225-233 Published: 2007
- 2007, Zhou CX, Boggess JF, Bae-Jump V, et al. Induction of apoptosis and inhibition of telomerase activity by arsenic trioxide (AS(2)O(3)) in endometrial carcinoma cells GYNECOLOGIC ONCOLOGY Volume: 105 Issue: 1 Pages: 218-222 Published: APR 2007
- 2007, Park MT, Kang YH, Park IC, et al. Combination treatment with arsenic trioxide and phytosphingosine enhances apoptotic cell death in arsenic trioxide-resistant cancer cells MOLECULAR CANCER THERAPEUTICS Volume: 6 Issue: 1 Pages: 82-92 Published: JAN 2007
- 2007, Yin JQ, Shen JN, Su WW, et al. Bufalin induces apoptosis in human osteosarcoma U-2OS and U-2OS methotrexate300-resistant cell lines ACTA PHARMACOLOGICA SINICA Volume: 28 Issue: 5 Pages: 712-720 Published: MAY 2007
- 2007, Garcia K, Duncan T, Su TT. Analysis of the cell division cycle in Drosophila METHODS Volume: 41 Issue: 2 Pages: 198-205 Published: FEB 2007
- 2007, Gellekink H, Blom HJ, van der Linden IJM, et al. Molecular genetic analysis of the human dihydrofolate reductase gene: relation with plasma total homocysteine, serum and red blood cell folate levels EUROPEAN JOURNAL OF HUMAN GENETICS Volume: 15 Issue: 1 Pages: 103-109 Published: JAN 2007
- 2007, Matheson EC, Hogarth LA, Case MC, et al. DHFR and MSH3 co-amplification in childhood acute lymphoblastic leukaemia, in vitro and in vivo CARCINOGENESIS Volume: 28 Issue: 6 Pages: 1341-1346 Published: JUN 2007
- 2007, Myllykangas S, Bohling T, Knuutila S. Specificity, selection and significance of gene amplifications in cancer SEMINARS IN CANCER BIOLOGY Volume: 17 Issue: 1 Pages: 42-55 Published: FEB 2007
- 2006, Taylor BF, McNeely SC, Miller HL, et al. p53 suppression of arsenite-induced mitotic catastrophe is mediated by p21(CIP1/WAF1. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 318 (1): 142-151 JUL 2006.
- 2006, Beer TM, Tangen CM, Nichols CR, et al. Southwest oncology group Phase II trioxide in patients with refractory malignancies. CANCER 106 (12): 2624-2629 JUN 15 2006.
- 2006, Schrader S, Kneuer C, Said HM, et al. Alternative transcripts of rat slc19a1: Defective sorting and inefficient expression of alternative splicing products - an addendum DNA SEQUENCE 17 (1): 83-86 FEB 2006
- 2006, Kim HR, Kim EJ, Yang SH, et al. Combination treatment with arsenic trioxide and sulindac augments their apoptotic potential in lung cancer cells through activation of caspase cascade and mitochondrial dysfunction INTERNATIONAL JOURNAL OF ONCOLOGY 28 (6): 1401-1408 JUN 2006
- 2006, Bergstralh DT, Ting JPY Microtubule stabilizing agents: Their molecular signaling consequences and the potential for enhancement by drug combination CANCER TREATMENT REVIEWS 32 (3): 166-179 MAY 2006
- 2006, Ohtsu A, Yoshida S, Saijo N Disparities in gastric cancer chemotherapy between the East and West JOURNAL OF CLINICAL ONCOLOGY 24 (14): 2188-2196 MAY 10 2006
- 2006, Baek JH, Kim JG, Jeon SB, et al. Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer BRITISH JOURNAL OF CANCER 94 (10): 1407-1411 MAY 22 2006
- 2006, Terek MC, Karabulut B, Selvi N, et al. Arsenic trioxide-loaded, microemulsion-enhanced cytotoxicity on MDAH 2774 ovarian carcinoma cell line INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER 16 (2): 532-537 MAR-APR 2006
- 2006, Ho SY, Huang PC, Guo HR, et al. Mechanisms of apoptosis induction and cell cycle regulation in irradiated leukemia U937 cells and enhancement by arsenic trioxide RADIATION RESEARCH 165 (4): 390-399 APR 2006
- 2006, Luo LQ, Qiao HQ, Meng FQ, et al. Arsenic trioxide synergizes with B7H3-mediated immunotherapy to eradicate hepatocellular carcinomas INTERNATIONAL JOURNAL OF CANCER 118 (7): 1823-1830 APR 1 2006
- 2006, Cheok MH, Lugthart S, Evans WE Pharmacogenomics of acute leukemia ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY 46: 317-353 2006
- 2006, Ajani JA, Lec FC, Singh DA, et al. Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma JOURNAL OF CLINICAL ONCOLOGY 24 (4): 663-667 FEB 1 2006
- 2006, Gomez HL, Santillana SL, Vallejos CS, et al. A phase II trial of pemetrexed in advanced breast cancer: Clinical response and association with molecular target expression CLINICAL CANCER RESEARCH 12 (3): 832-838 Part 1 FEB 1 2006
- 2006, Myllykangas S, Knuutila S Manifestation, mechanisms and mysteries of gene amplifications CANCER LETTERS 232 (1): 79-89 JAN 28 2006
- 2006, Walling J From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates INVESTIGATIONAL NEW DRUGS 24 (1): 37-77 JAN 2006
- 2006, Liu MJ, Ge YB, Payton SG, et al. Transcriptional regulation of the human reduced folate carrier in childhood acute lymphoblastic leukemia cells CLINICAL CANCER RESEARCH 12 (2): 608-616 JAN 15 2006
- 2006, van Trommel NE, Massuger LF, Schijf CP, et al. Early identification of resistance to first-line single-agent methotrexate in patients with persistent trophoblastic disease JOURNAL OF CLINICAL ONCOLOGY 24 (1): 52-58 JAN 1 2006
- 2006, Hooijberg JH, de Vries NA, Kaspers GJL, et al. Multidrug resistance proteins and folate supplementation: therapeutic implications for antifolates and other classes of drugs in cancer treatment CANCER CHEMOTHERAPY AND PHARMACOLOGY 58 (1): 1-12 JUL 2006
- 2006, Ai, Z., Lu, W., Qin, X. Arsenic trioxide induces gallbladder carcinoma cell apoptosis via downregulation of Bcl-2. Biochemical and Biophysical Research Communications, 348 (3) pp. 1075-1081, 2006.
- 2006, Albertson DG. Gene amplification in cancer TRENDS IN GENETICS 22 (8): 447-455 AUG 2006
- 2006, Bhojwani D, Kang HN, Moskowitz NP, et al. Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a Children's Oncology Group study. BLOOD 108 (2): 711-717 JUL 15 2006
- 2006, Wagner AD, Grothe W, Haerting J, et al.Chemotherapy in advanced gastric cancer: A systematic review and meta-analysis based on aggregate data. JOURNAL OF CLINICAL ONCOLOGY 24 (18): 2903-2909 JUN 20 2006
- 2006, Conroy T, Marchal F, Blazeby JM. Quality of life in patients with oesophageal and gastric cancer: An overview . ONCOLOGY 70(6) Pages: 391-402 2006
- 2006, Krishnan S, Rana V, Janjan NA, et al. Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation . CANCER 107(11) Pages: 2589-2596 DEC 1 2006
- 2006, Shah MA, Ramanathan RK, Ilson DH, et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinorna. JOURNAL OF CLINICAL ONCOLOGY 24(33) Pages: 5201-5206 NOV 20 2006
- 2006, Van Cutsem E. Novel cytotoxic regimens in gastric cancer . EJC SUPPLEMENTS 4(10) Pages: 14-18 SEP 2006
- 2006, Ichikawa W, Sasaki Y. Correlation between tumor response to first-line chemotherapy and prognosis in advanced gastric cancer patients . ANNALS OF ONCOLOGY 17(11) Pages: 1665-1672 NOV 2006
- 2006, Hazard L, O'Connor J, Scaife C. Role of radiation therapy in gastric adenocarcinoma . WORLD JOURNAL OF GASTROENTEROLOGY 12(10) Pages: 1511-1520 MAR 14 2006
- 2006, Ajani JA. Chemotherapy for advanced gastric or gastroesophageal cancer: defining the contributions of docetaxel . EXPERT OPINION ON PHARMACOTHERAPY 7(12) Pages: 1627-1631 AUG 2006
- 2006, Wagner AD, Grothe W, Haerting J, et al. Chemotherapy in advanced gastric cancer: A systematic review and meta-analysis based on aggregate data . JOURNAL OF CLINICAL ONCOLOGY 24(18) Pages: 2903-2909 JUN 20 2006
- 2006, Ohtsu A, Yoshida S, Saijo N. Disparities in gastric cancer chemotherapy between the East and West. JOURNAL OF CLINICAL ONCOLOGY 24(14) Pages: 2188-2196 MAY 10 2006
- 2006, Baek JH, Kim JG, Jeon SB, et al. Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer . BRITISH JOURNAL OF CANCER 94(10) Pages: 1407-1411 MAY 22 2006
- 2006, Ajani JA, Lec FC, Singh DA, et al. Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma . JOURNAL OF CLINICAL ONCOLOGY 24(4) Pages: 663-667 FEB 1 2006
- 2006, Bergstralh DT, Ting JPY. Microtubule stabilizing agents: Their molecular signaling consequences and the potential for enhancement by drug combination. CANCER TREATMENT REVIEWS 32(3): 166-179 MAY 2006
- 2006, Kushida S, Ohmae H, Kamma H, et al. Artificial cytokine storm combined with hyperthermia induces significant anti-tumor effect in mice inoculated with Lewis lung carcinoma and B16 melanoma cells INTERNATIONAL JOURNAL OF HYPERTHERMIA 22 8 699-712 DEC 2006
- 2006, Zhang JJ, Wang B. Arsenic trioxide (As2O3) inhibits peritoneal invasion of ovarian carcinoma cells in vitro and in vivo GYNECOLOGIC ONCOLOGY Volume: 103 Issue: 1 Pages: 199-206 Published: OCT 2006
- 2006, McNeely SC, Xu XG, Taylor BF, et al. Exit from arsenite-induced mitotic arrest is p53 dependent ENVIRONMENTAL HEALTH PERSPECTIVES Volume: 114 Issue: 9 Pages: 1401-1406 Published: SEP 2006
- 2006, Ai ZL, Lu WQ, Qin XY. Arsenic trioxide induces gallbladder carcinoma cell apoptosis via downregulation of Bcl-2 BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS Volume: 348 Issue: 3 Pages: 1075-1081 Published: SEP 29 2006
- 2006, Taylor BF, McNeely SC, Miller HL, et al. p53 suppression of arsenite-induced mitotic catastrophe is mediated by p21(CIP1/WAF1) JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Volume: 318 Issue: 1 Pages: 142-151 Published: JUL 2006
- 2006, Beer TM, Tangen CM, Nichols CR, et al.Southwest oncology group Phase II trioxide in patients with refractory malignancies CANCER Volume: 106 Issue: 12 Pages: 2624-2629 Published: JUN 15 2006
- 2006, Kim HR, Kim EJ, Yang SH, et al. Combination treatment with arsenic trioxide and sulindac augments their apoptotic potential in lung cancer cells through activation of caspase cascade and mitochondrial dysfunction INTERNATIONAL JOURNAL OF ONCOLOGY Volume: 28 Issue: 6 Pages: 1401-1408 Published: JUN 2006
- 2006, Terek MC, Karabulut B, Selvi N, et al.Arsenic trioxide-loaded, microemulsion-enhanced cytotoxicity on MDAH 2774 ovarian carcinoma cell line INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER Volume: 16 Issue: 2 Pages: 532-537 Published: MAR-APR 2006
- 2006, Ho SY, Huang PC, Guo HR, et al. Mechanisms of apoptosis induction and cell cycle regulation in irradiated leukemia U937 cells and enhancement by arsenic trioxide RADIATION RESEARCH Volume: 165 Issue: 4 Pages: 390-399 Published: APR 2006
- 2006, Luo LQ, Qiao HQ, Meng FQ, et al. Arsenic trioxide synergizes with B7H3-mediated immunotherapy to eradicate hepatocellular carcinomas INTERNATIONAL JOURNAL OF CANCER Volume: 118 Issue: 7 Pages: 1823-1830 Published: APR 1 2006
- 2006, Divisi D, Gizzonio D, Crisci R Multimodal treatment of osteosarcoma lung metastases THORACIC AND CARDIOVASCULAR SURGEON 54 5 328-331 AUG 2006
- 2006, Walling J. From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates INVESTIGATIONAL NEW DRUGS Volume: 24 Issue: 1 Pages: 37-77 Published: JAN 2006
- 2006, Myllykangas S, Himberg J, Bohling T, et al. DNA copy number amplification profiling of human neoplasms ONCOGENE Volume: 25 Issue: 55 Pages: 7324-7332 Published: NOV 2006
- 2006, Myllykangas S, Knuutila S. Manifestation, mechanisms and mysteries of gene amplifications CANCER LETTERS Volume: 232 Issue: 1 Pages: 79-89 Published: JAN 28 2006
- 2006, Walling J. From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates INVESTIGATIONAL NEW DRUGS Volume: 24 Issue: 1 Pages: 37-77 Published: JAN 2006
- 2005, Ajani JA Evolving chemotherapy for advanced gastric cancer ONCOLOGIST 10: 49-58 Suppl. 3 2005
- 2005, Bornstein J, Sagi S, Haj A, et al. Arsenic Trioxide inhibits the growth of human ovarian carcinoma cell line GYNECOLOGIC ONCOLOGY 99 (3): 726-729 DEC 2005
- 2005, Marshall LA, Rhee MS, Hofmann L, et al. Increased lysosomal uptake of methotrexate-polyglutamates in two methotrexate-resistant cell lines with distinct mechanisms of resistance BIOCHEMICAL PHARMACOLOGY 71 (1-2): 203-213 DEC 19 2005
- 2005, Haga N, Fujita N, Tsuruo T Involvement of mitochondrial aggregation in arsenic trioxide (As2O3)-induced apoptosis in human glioblastoma cells CANCER SCIENCE 96 (11): 825-833 NOV 2005
- 2005, Das P, Ajani JA Gastric and gastro-oesophageal cancer therapy EXPERT OPINION ON PHARMACOTHERAPY 6 (16): 2805-2812 DEC 2005
- 2005, Payton SG, Liu MJ, Ge YB, et al. Transcriptional regulation of the human reduced folate carrier A1/A2 promoter: Identification of critical roles for the USF and GATA families of transcription factors BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION 1731 (2): 115-124 NOV 10 2005
- 2005, Cheng Q, Evans WE Cancer pharmacogenomics may require both qualitative and quantitative approaches CELL CYCLE 4 (11): 1506-1509 NOV 2005
- 2005, Cole PD, Drachtman RA, Smith AK, et al. Phase II trial of oral aminopterin for adults and children with refractory acute leukemia CLINICAL CANCER RESEARCH 11 (22): 8089-8096 NOV 15 2005
- 2005, Beesley AH, Cummings AJ, Freitas JR, et al. The gene expression signature of relapse in paediatric acute lymphoblastic leukaemia: implications for mechanisms of therapy failure BRITISH JOURNAL OF HAEMATOLOGY 131 (4): 447-456 NOV 2005
- 2005, Rollins KD, Lindley C Pemetrexed: A multitargeted antifolate CLINICAL THERAPEUTICS 27 (9): 1343-1382 SEP 2005
- 2005, Morales C, Ribas M, Aiza G, et al. Genetic determinants of methotrexate responsiveness and resistance in colon cancer cells ONCOGENE 24 (45): 6842-6847 OCT 13 2005
- 2005, Ilson D Just when you thought the fluorouracil debate was over: S-1 and gastric cancer JOURNAL OF CLINICAL ONCOLOGY 23 (28): 6826-6828 OCT 1 2005
- 2005, Dai HQ, Chen Y, Elmquist WF Distribution of the novel antifolate pemetrexed to the brain JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 315 (1): 222-229 OCT 2005
- 2005, Bomgaars L, McLeod HL Pharmacogenetics and pediatric cancer CANCER JOURNAL 11 (4): 314-323 JUL-AUG 2005
- 2005, Kong B, Huang S, Wang W, et al. Arsenic trioxide induces apoptosis in cisplatin-sensitive and -resistant ovarian cancer cell lines INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER 15 (5): 872-877 SEP-OCT 2005
- 2005, Ferreri AJM, Reni M Prognostic factors in primary central nervous system lymphomas HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA 19 (4): 629+ AUG 2005
- 2005, Jain A, Tindell CA, Laux I, et al. Epithelial membrane protein-1 is a biomarker of gefitinib resistance PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 102 (33): 11858-11863 AUG 16 2005
- 2005, Rothem L, Berman B, Stark M, et al. The reduced folate carrier gene is a novel selectable marker for recombinant protein overexpression MOLECULAR PHARMACOLOGY 68 (3): 616-624 SEP 2005
- 2005, Huang CC, Hsu PC, Hung YC, et al. Ornithine decarboxylase prevents methotrexate-induced apoptosis by reducing intracellular reactive oxygen species production APOPTOSIS 10 (4): 895-907 AUG 2005
- 2005, Nakaya H, Shimizu T, Isobe K, et al. Microbubble-enhanced ultrasound exposure promotes uptake of methotrexate into synovial cells and enhanced antiinflammatory effects in the knees of rabbits with antigen-induced arthritis ARTHRITIS AND RHEUMATISM 52 (8): 2559-2566 AUG 2005
- 2005, Park MJ, Lee JY, Kwak HJ, et al. Arsenic trioxide (As2O3) inhibits invasion of HT1080 human fibrosarcoma cells: Role of nuclear factor-kappa B and reactive oxygen species JOURNAL OF CELLULAR BIOCHEMISTRY 95 (5): 955-969 AUG 1 2005
- 2005, Gazitt Y, Akay C Arsenic trioxide: An anti cancer missile with multiple warheads HEMATOLOGY 10 (3): 205-213 JUN 2005
- 2005, Rao VK, Wangsa D, Robey RW, et al. Characterization of ABCG2 gene amplification manifesting as extrachromosomal DNA in mitoxantrone-selected SF295 human glioblastoma cells CANCER GENETICS AND CYTOGENETICS 160 (2): 126-133 JUL 15 2005
- 2005, Peters GJ, Hooijberg JH, Kaspers GJL, et al. Folates and antifolates in the treatment of cancer: role of folic acid supplementation on efficacy of folate and non-folate drugs TRENDS IN FOOD SCIENCE & TECHNOLOGY 16 (6-7): 289-297 2005
- 2005, Thomas TP, Majoros IJ, Kotlyar A, et al. Targeting and inhibition of cell growth by an engineered dendritic nanodevice JOURNAL OF MEDICINAL CHEMISTRY 48 (11): 3729-3735 JUN 2 2005
- 2005, Kneuer C, Schrader S, Honscha W Alternative transcripts of rat slc19a1: Cloning, genomic organisation, tissue specific promoters and alternative splicing DNA SEQUENCE 16 (1): 1-6 FEB 2005
- 2005, Dervieux T, Meshkin B, Neri B Pharmacogenetic testing: proofs of principle and pharmacoeconomic implications MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS 573 (1-2): 180-194 JUN 3 2005
- 2005, Douer D, Tallman MS Arsenic trioxide: New clinical experience with an old medication in hematologic malignancies JOURNAL OF CLINICAL ONCOLOGY 23 (10): 2396-2410 APR 1 2005
- 2005, Wolf J, Stranzl T, Filipits M, et al. Expression of resistance markers to methotrexate predicts clinical improvement in patients with rheumatoid arthritis ANNALS OF THE RHEUMATIC DISEASES 64 (4): 564-568 APR 2005
- 2005, Spees WM, Gade TPF, Yang GL, et al. An F-19 magnetic resonance-based in vivo assay of solid tumor methotrexate resistance: Proof of principle CLINICAL CANCER RESEARCH 11 (4): 1454-1461 FEB 15 2005
- 2005, Wozniak A, Drewa G, Wozniak B, et al. The effect of antitumor drugs on oxidative stress in B16 and S91 melanoma cells in vitro MEDICAL SCIENCE MONITOR 11 (1): BR22-BR29 JAN 2005
- 2005, Kager L, Cheok ML, Yang WJ, et al. Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics JOURNAL OF CLINICAL INVESTIGATION 115 (1): 110-117 JAN 2005
- 2005, Payton SG, Whetstine JR, Ge YB, et al. Transcriptional regulation of the human reduced folate carrier promoter C: synergistic transactivation by Sp1 and C/EBP beta and identification of a downstream repressor BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION 1727 (1): 45-57 JAN 21 2005
- 2005, Cody V, Luft JR, Pangborn W Understanding the role of Leu22 variants in methotrexate resistance: comparison of wild-type and Leu22Arg variant mouse and human dihydrofolate reductase ternary crystal complexes with methotrexate and NADPH ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY 61: 147-155 Part 2 FEB 2005
- 2005, Castex U, Lalanne C, Mouchet P, et al. Regioselective synthesis of peptidic derivatives and glycolamidic esters of methotrexate TETRAHEDRON 61 (4): 803-812 JAN 24 2005
- 2005, Chabner BA, Roberts TG Timeline - Chemotherapy and the war on cancer NATURE REVIEWS CANCER 5 (1): 65-72 JAN 2005
- 2005, Das P, Ajani JA. Gastric and gastro-oesophageal cancer therapy. EXPERT OPINION ON PHARMACOTHERAPY 6(16) Pages: 2805-2812 DEC 2005
- 2005, Ilson D. Just when you thought the fluorouracil debate was over: S-1 and gastric cancer JOURNAL OF CLINICAL ONCOLOGY 23(28) : 6826-6828 OCT 1 2005
- 2005, Bornstein J, Sagi S, Haj A, et al. Arsenic Trioxide inhibits the growth of human ovarian carcinoma cell line GYNECOLOGIC ONCOLOGY Volume: 99 Issue: 3 Pages: 726-729 Published: DEC 2005
- 2005, Haga N, Fujita N, Tsuruo T. Involvement of mitochondrial aggregation in arsenic trioxide (As2O3)-induced apoptosis in human glioblastoma cells CANCER SCIENCE Volume: 96 Issue: 11 Pages: 825-833 Published: NOV 2005
- 2005, Kong B, Huang S, Wang W, et al. Arsenic trioxide induces apoptosis in cisplatin-sensitive and -resistant ovarian cancer cell lines INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER Volume: 15 Issue: 5 Pages: 872-877 Published: SEP-OCT 2005
- 2005, Park MJ, Lee JY, Kwak HJ, et al. Arsenic trioxide (As2O3) inhibits invasion of HT1080 human fibrosarcoma cells: Role of nuclear factor-kappa B and reactive oxygen species JOURNAL OF CELLULAR BIOCHEMISTRY Volume: 95 Issue: 5 Pages: 955-969 Published: AUG 1 2005
- 2005, Gazitt Y, Akay C. Arsenic trioxide: An anti cancer missile with multiple warheads HEMATOLOGY Volume: 10 Issue: 3 Pages: 205-213 Published: JUN 2005
- 2005, Douer D, Tallman MS. Arsenic trioxide: New clinical experience with an old medication in hematologic malignancies JOURNAL OF CLINICAL ONCOLOGY Volume: 23 Issue: 10 Pages: 2396-2410 Published: APR 1 2005
- 2005, Wozniak A, Drewa G, Wozniak B, et al. The effect of antitumor drugs on oxidative stress in B16 and S91 melanoma cells in vitro MEDICAL SCIENCE MONITOR Volume: 11 Issue: 1 Pages: BR22-BR29 Published: JAN 2005
- 2005, Erdemir A. Tradition and modernity: Alevis' ambiguous terms and Turkey's ambivalent subjects MIDDLE EASTERN STUDIES Volume: 41 Issue: 6 Pages: 937-951 Published: NOV 2005
- 2005, Poyraz B. The Turkish state and Alevis: Changing parameters of an uneasy relationship MIDDLE EASTERN STUDIES Volume: 41 Issue: 4 Pages: 503-516 Published: JUL 2005
- 2005, Smith TW. Civic nationalism and ethnocultural justice in Turkey HUMAN RIGHTS QUARTERLY Volume: 27 Issue: 2 Pages: 436-470 Published: MAY 2005
- 2005, Nakaya H, Shimizu T, Isobe K, et al. Microbubble-enhanced ultrasound exposure promotes uptake of methotrexate into synovial cells and enhanced antiinflammatory effects in the knees of rabbits with antigen-induced arthritis ARTHRITIS AND RHEUMATISM Volume: 52 Issue: 8 Pages: 2559-2566 Published: AUG 2005
- 2005, Castex U, Lalanne C, Mouchet P, et al. Regioselective synthesis of peptidic derivatives and glycolamidic esters of methotrexate TETRAHEDRON Volume: 61 Issue: 4 Pages: 803-812 Published: JAN 24 2005
- 2005, Dai HQ, Chen Y, Elmquist WF. Distribution of the novel antifolate pemetrexed to the brain JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Volume: 315 Issue: 1 Pages: 222-229 Published: OCT 2005
- 2005, Cody V, Luft JR, Pangborn W. Understanding the role of Leu22 variants in methotrexate resistance: comparison of wild-type and Leu22Arg variant mouse and human dihydrofolate reductase ternary crystal complexes with methotrexate and NADPH ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY Volume: 61 Pages: 147-155 Part: Part 2 Published: FEB 2005
- 2005, Beesley AH, Cummings AJ, Freitas JR, et al. The gene expression signature of relapse in paediatric acute lymphoblastic leukaemia: implications for mechanisms of therapy failure BRITISH JOURNAL OF HAEMATOLOGY Volume: 131 Issue: 4 Pages: 447-456 Published: NOV 2005
- 2005, Jain A, Tindell CA, Laux I, et al. Epithelial membrane protein-1 is a biomarker of gefitinib resistance PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA Volume: 102 Issue: 33 Pages: 11858-11863 Published: AUG 16 2005
- 2005, Rao VK, Wangsa D, Robey RW, et al. Characterization of ABCG2 gene amplification manifesting as extrachromosomal DNA in mitoxantrone-selected SF295 human glioblastoma cells CANCER GENETICS AND CYTOGENETICS Volume: 160 Issue: 2 Pages: 126-133 Published: JUL 15 2005
- 2004, Groninger E, Proost JH, de Graaf SSN Pharmacokinetic studies in children with cancer CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY 52 (3): 173-197 DEC 2004
- 2004, Kang YH, Yi MJ, Kim MJ, et al. Caspase-independent cell death by arsenic trioxide in human cervical cancer cells: Reactive oxygen species-mediated poly(ADP-ribose) polymerise-1 activation signals apoptosis-inducing factor release from mitochondria CANCER RESEARCH 64 (24): 8960-8967 DEC 15 2004
- 2004, Rojewski MT, Korper S, Schrezenmeier H Arsenic trioxide therapy in acute promyelocytic leukemia and beyond: from bench to bedside LEUKEMIA & LYMPHOMA 45 (12): 2387-2401 DEC 2004
- 2004, Yang J, Li H, Chen YY, et al. Anthraquinones sensitize tumor cells to arsenic cytotoxicity in vitro and in vivo via reactive oxygen species-mediated dual regulation of apoptosis FREE RADICAL BIOLOGY AND MEDICINE 37 (12): 2027-2041 DEC 15 2004
- 2004, Dervieux T, Kremer J, Lein DO, et al. Contribution of common polymorphisms in reduced folate carrier and gamma-glutamylhydrolase to methotrexate polyglutamate levels in patients with rheumatoid arthritis PHARMACOGENETICS 14 (11): 733-739 NOV 2004
- 2004, Karasulu HY, Karabulut B, Kantarci G, et al. Preparation of arsenic trioxide-loaded microemulsion and its enhanced cytotoxicity on MCF-7 breast carcinoma cell line DRUG DELIVERY 11 (6): 345-350 NOV-DEC 2004
- 2004, Mehta PA, Davies SM Pharmacogenetics of acute lymphoblastic leukemia CURRENT OPINION IN HEMATOLOGY 11 (6): 434-438 NOV 2004
- 2004, Woo SH, Park IC, Park MJ, et al. Arsenic trioxide sensitizes CD95/Fas-induced apoptosis through ROS-mediated upregulation of CD95/Fas by NF-kappa B activation INTERNATIONAL JOURNAL OF CANCER 112 (4): 596-606 NOV 20 2004
- 2004, Baumgartner M, Sturlan S, Roth E, et al. Enhancement of arsenic trioxide-mediated apoptosis using docosahexaenoic acid in arsenic trioxide-resistant solid tumor cells INTERNATIONAL JOURNAL OF CANCER 112 (4): 707-712 NOV 20 2004
- 2004, Liu MJ, Whetstine JR, Payton SG, et al. Roles of USF, ikaros and Sp proteins in the transcriptional regulation of the human reduced folate carrier B promoter BIOCHEMICAL JOURNAL 383: 249-257 Part 2 OCT 15 2004
- 2004, Lee CH, Macgregor PF Using microarrays to predict resistance to chemotherapy in cancer patients PHARMACOGENOMICS 5 (6): 611-625 SEP 2004
- 2004, Krajinovic M, Moghrabi A Pharmacogenetics of methotrexate PHARMACOGENOMICS 5 (7): 819-834 OCT 2004
- 2004, Li XQ, Ding XZ, Adrian TE Arsenic trioxide causes redistribution of cell cycle, caspase activation, and GADD expression in human colonic, breast, and pancreatic cancer cells CANCER INVESTIGATION 22 (3): 389-400 2004
- 2004, Hour TC, Huang CY, Lin CC, et al. Characterization of molecular events in a series of bladder urothelial carcinoma cell lines with progressive resistance to arsenic trioxide ANTI-CANCER DRUGS 15 (8): 779-785 SEP 2004
- 2004, Ning SC, Knox SJ Increased cure rate of glioblastoma using concurrent therapy with radiotherapy and arsenic trioxide INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS 60 (1): 197-203 SEP 1 2004
- 2004, Moon Y, Park G, Kim Y, et al. Arsenic trioxide (As2O3) sensitivity of carcinoma cell lines and cancer cells from patients with carcinomatosis peritonei ANNALS OF CLINICAL AND LABORATORY SCIENCE 34 (3): 271-276 SUM 2004
- 2004, Ferreri AJM, Dell'Oro S, Capello D, et al. Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas BRITISH JOURNAL OF HAEMATOLOGY 126 (5): 657-664 SEP 2004
- 2004, Cheng Q, Wu BN, Kager L, et al. A substrate specific functional polymorphism of human gamma-glutamyl hydrolase alters catalytic activity and methotrexate polyglutamate accumulation in acute lymphoblastic leukaemia cells PHARMACOGENETICS 14 (8): 557-567 AUG 2004
- 2004, Flatley RM, Payton SG, Taub JW, et al. Primary acute lymphoblastic leukemia cells use a novel promoter and 5 ' noncoding exon for the human reduced folate carrier that encodes a modified carrier translated from an upstream translational start CLINICAL CANCER RESEARCH 10 (15): 5111-5122 AUG 1 2004
- 2004, Evens AM, Tallman MS, Gartenhaus RB The potential of arsenic trioxide in the treatment of malignant disease: past, present, and future LEUKEMIA RESEARCH 28 (9): 891-900 SEP 2004
- 2004, Jansen G, van der Heijden J, Oerlemans R, et al. Sulfasalazine is a potent inhibitor of the reduced folate carrier - Implications for combination therapies with methotrexate in rheumatoid arthritis ARTHRITIS AND RHEUMATISM 50 (7): 2130-2139 JUL 2004
- 2004, Winick NJ, Carroll WL, Hunger SP Childhood leukemia - New advances and challenges NEW ENGLAND JOURNAL OF MEDICINE 351 (6): 601-603 AUG 5 2004
- 2004, Abbing A, Blaschke UK, Grein S, et al. Efficient intracellular delivery of a protein and a low molecular weight substance via recombinant polyomavirus-like particles JOURNAL OF BIOLOGICAL CHEMISTRY 279 (26): 27410-27421 JUN 25 2004
- 2004, Bassan R, Gatta G, Tondini C, et al. Adult acute lymphoblastic leukaemia CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY 50 (3): 223-261 JUN 2004
- 2004, Kneuer C, Honscha W The H+-dependent reduced folate carrier 1 of humans and the sodium-dependent methotrexate carrier-1 of the rat are orthologs FEBS LETTERS 566 (1-3): 83-86 MAY 21 2004
- 2004, Liem NLM, Papa RA, Milross CG, et al. Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies BLOOD 103 (10): 3905-3914 MAY 15 2004
- 2004, Wu XX, Ogawa O, Kakehi Y Enhancement of arsenic trioxide-induced apoptosis in renal cell carcinoma cells by L-buthionine sulfoximine INTERNATIONAL JOURNAL OF ONCOLOGY 24 (6): 1489-1497 JUN 2004
- 2004, Norgaard JM, Olesen LH, Hokland P Changing picture of cellular drug resistance in human leukemia CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY 50 (1): 39-49 APR 2004
- 2004, Cao W, Matherly LH Analysis of the membrane topology for transmembrane domains 7-12 of the human reduced folate carrier by scanning cysteine accessibility methods BIOCHEMICAL JOURNAL 378: 201-206 Part 1 FEB 15 2004
- 2004, Plasschaert SLA, Kamps WA, Vellenga E, et al. Prognosis in childhood and adult acute lymphoblastic leukaemia: a question of maturation? CANCER TREATMENT REVIEWS 30 (1): 37-51 FEB 2004
- 2004, Litzow MR The therapy of relapsed acute leukaemia in adults BLOOD REVIEWS 18 (1): 39-63 MAR 2004
- 2004, Kaufman Y, Drori S, Cole PD, et al. Reduced folate carrier mutations are not the mechanism underlying methotrexate resistance in childhood acute lymphoblastic leukemia CANCER 100 (4): 773-782 FEB 15 2004
- 2004, Sorensen JB Endobronchial metastases from extrapulmonary solid tumors ACTA ONCOLOGICA 43 (1): 73-79 JAN 2004
- 2004, Sumitomo M, Asano T, Asakuma J, et al. Chemosensitization of androgen-independent prostate cancer with neutral endopeptidase CLINICAL CANCER RESEARCH 10 (1): 260-266 Part 1 JAN 1 2004
- 2004, Serra M, Reverter-Branchat G, Maurici D, et al. Analysis of dihydrofolate reductase and reduced folate carrier gene status in relation to methotrexate resistance in osteosarcoma cells ANNALS OF ONCOLOGY 15 (1): 151-160 JAN 2004
- 2004, Rothem L, Stark M, Kaufman Y, et al. Reduced folate carrier gene silencing in multiple antifolate-resistant tumor cell lines is due to a simultaneous loss of function of multiple transcription factors but not promoter methylation JOURNAL OF BIOLOGICAL CHEMISTRY 279 (1): 374-384 JAN 2 2004
- 2004, Kang YH, Yi MJ, Kim MJ, et al. Caspase-independent cell death by arsenic trioxide in human cervical cancer cells: Reactive oxygen species-mediated poly(ADP-ribose) polymerise-1 activation signals apoptosis-inducing factor release from mitochondria CANCER RESEARCH Volume: 64 Issue: 24 Pages: 8960-8967 Published: DEC 15 2004
- 2004, Rojewski MT, Korper S, Schrezenmeier H. Arsenic trioxide therapy in acute promyelocytic leukemia and beyond: from bench to bedside LEUKEMIA & LYMPHOMA Volume: 45 Issue: 12 Pages: 2387-2401 Published: DEC 2004
- 2004, Yang J, Li H, Chen YY, et al. Anthraquinones sensitize tumor cells to arsenic cytotoxicity in vitro and in vivo via reactive oxygen species-mediated dual regulation of apoptosis FREE RADICAL BIOLOGY AND MEDICINE Volume: 37 Issue: 12 Pages: 2027-2041 Published: DEC 15 2004
- 2004, Karasulu HY, Karabulut B, Kantarci G, et al. Preparation of arsenic trioxide-loaded microemulsion and its enhanced cytotoxicity on MCF-7 breast carcinoma cell line DRUG DELIVERY Volume: 11 Issue: 6 Pages: 345-350 Published: NOV-DEC 2004
- 2004, Woo SH, Park IC, Park MJ, et al. Arsenic trioxide sensitizes CD95/Fas-induced apoptosis through ROS-mediated upregulation of CD95/Fas by NF-kappa B activation INTERNATIONAL JOURNAL OF CANCER Volume: 112 Issue: 4 Pages: 596-606 Published: NOV 20 2004
- 2004, Baumgartner M, Sturlan S, Roth E, et al. Enhancement of arsenic trioxide-mediated apoptosis using docosahexaenoic acid in arsenic trioxide-resistant solid tumor cells INTERNATIONAL JOURNAL OF CANCER Volume: 112 Issue: 4 Pages: 707-712 Published: NOV 20 2004
- 2004, Li XQ, Ding XZ, Adrian TE. Arsenic trioxide causes redistribution of cell cycle, caspase activation, and GADD expression in human colonic, breast, and pancreatic cancer cells CANCER INVESTIGATION Volume: 22 Issue: 3 Pages: 389-400 Published: 2004
- 2004, Hour TC, Huang CY, Lin CC, et al.Characterization of molecular events in a series of bladder urothelial carcinoma cell lines with progressive resistance to arsenic trioxide ANTI-CANCER DRUGS Volume: 15 Issue: 8 Pages: 779-785 Published: SEP 2004
- 2004, Ning SC, Knox SJ. Increased cure rate of glioblastoma using concurrent therapy with radiotherapy and arsenic trioxide INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS Volume: 60 Issue: 1 Pages: 197-203 Published: SEP 1 2004
- 2004, Moon Y, Park G, Kim Y, et al. Arsenic trioxide (As2O3) sensitivity of carcinoma cell lines and cancer cells from patients with carcinomatosis peritonei ANNALS OF CLINICAL AND LABORATORY SCIENCE Volume: 34 Issue: 3 Pages: 271-276 Published: SUM 2004
- 2004, Evens AM, Tallman MS, Gartenhaus RB. The potential of arsenic trioxide in the treatment of malignant disease: past, present, and future LEUKEMIA RESEARCH Volume: 28 Issue: 9 Pages: 891-900 Published: SEP 2004
- 2004, Wu XX, Ogawa O, Kakehi Y. Enhancement of arsenic trioxide-induced apoptosis in renal cell carcinoma cells by L-buthionine sulfoximine INTERNATIONAL JOURNAL OF ONCOLOGY Volume: 24 Issue: 6 Pages: 1489-1497 Published: JUN 2004
- 2004, Sumitomo M, Asano T, Asakuma J, et al.Chemosensitization of androgen-independent prostate cancer with neutral endopeptidase CLINICAL CANCER RESEARCH Volume: 10 Issue: 1 Pages: 260-266 Part: Part 1 Published: JAN 1 2004
- 2004, Sorensen JB. Endobronchial metastases from extrapulmonary solid tumors ACTA ONCOLOGICA Volume: 43 Issue: 1 Pages: 73-79 Published: JAN 2004
- 2004, Abbing A, Blaschke UK, Grein S, et al. Efficient intracellular delivery of a protein and a low molecular weight substance via recombinant polyomavirus-like particles JOURNAL OF BIOLOGICAL CHEMISTRY Volume: 279 Issue: 26 Pages: 27410-27421 Published: JUN 25 2004
- 2004, Serra M, Reverter-Branchat G, Maurici D, et al. Analysis of dihydrofolate reductase and reduced folate carrier gene status in relation to methotrexate resistance in osteosarcoma cells ANNALS OF ONCOLOGY Volume: 15 Issue: 1 Pages: 151-160 Published: JAN 2004
- 2004, Krajinovic M, Moghrabi A. Pharmacogenetics of methotrexate PHARMACOGENOMICS Volume: 5 Issue: 7 Pages: 819-834 Published: OCT 2004
- 2004, Bassan R, Gatta G, Tondini C, et al. Adult acute lymphoblastic leukaemia CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY Volume: 50 Issue: 3 Pages: 223-261 Published: JUN 2004
- 2004, Bassan R, Gatta G, Tondini C, et al. Adult acute lymphoblastic leukaemia CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY 50 3 223-261 JUN 2004
- 2004, Liem NLM, Papa RA, Milross CG, et al. Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies BLOOD Volume: 103 Issue: 10 Pages: 3905-3914 Published: MAY 15 2004
- 2004, Kim J, Kaplan R Physical and psychological factors in sense of community - New urbanist Kentlands and nearby orchard village ENVIRONMENT AND BEHAVIOR 36 3 313-340 MAY 2004
- 2004, Litzow MR The therapy of relapsed acute leukaemia in adults BLOOD REVIEWS 18 1 39-63 MAR 2004
- 2004, Groninger E, Proost JH, de Graaf SSN. Pharmacokinetic studies in children with cancer. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY Volume: 52 Issue: 3 Pages: 173-197 Published: DEC 2004
- 2003, Jansen G, Scheper RJ, Dijkmans BAC Multidrug resistance proteins in rheumatoid arthritis, role in disease-modifying antirheumatic drug efficacy and inflammatory processes: an overview SCANDINAVIAN JOURNAL OF RHEUMATOLOGY 32 (6): 325-339 NOV 2003
- 2003, DeAngelis LM Primary central nervous system lymphoma: A curable brain tumor JOURNAL OF CLINICAL ONCOLOGY 21 (24): 4471-4473 DEC 15 2003
- 2003, Pieters R, den Boer ML Molecular pharmacodynamics in childhood leukemia INTERNATIONAL JOURNAL OF HEMATOLOGY 78 (5): 402-413 DEC 2003
- 2003, Wei HL, Su HX, Bai DC, et al. Arsenic trioxide inhibits p-glycoprotein expression in multidrug-resistant human leukemia cells that overexpress the MDR1 gene CHINESE MEDICAL JOURNAL 116 (11): 1644-1648 NOV 2003
- 2003, Jeha S Who should be treating adolescents and young adults with acute lymphoblastic leukaemia? EUROPEAN JOURNAL OF CANCER 39 (18): 2579-2583 DEC 2003
- 2003, Nano R, Invernizzi R, Facoetti A, et al. Quantification of the DHFR gene in blast cells of leukaemia patients by fluorescence in situ hybridisation ANTICANCER RESEARCH 23 (5A): 3883-3887 SEP-OCT 2003
- 2003, McGuire JJ Anticancer antifolates: Current status and future directions. CURRENT PHARMACEUTICAL DESIGN 9 (31): 2593-2613 2003
- 2003, Hattinger CM, Reverter-Branchat G, Remondini D, et al. Genomic imbalances associated with methotrexate resistance in human osteosarcoma cell lines detected by comparative genomic hybridization-based techniques EUROPEAN JOURNAL OF CELL BIOLOGY 82 (9): 483-493 SEP 2003
- 2003, Ifergan I, Meller I, Issakov J, et al. Reduced folate carrier protein expression in osteosarcoma - Implications for the prediction of tumor chemosensitivity CANCER 98 (9): 1958-1966 NOV 1 2003
- 2003, Zhao RB, Goldman ID Resistance to antifolates ONCOGENE 22 (47): 7431-7457 OCT 20 2003
- 2003, Spees WM, Yang GL, Veach D, et al. A fluorine-labeled methotrexate as a probe for monitoring tumor antifolate pharmacokinetics: Synthesis, in vitro cytotoxicity, and pilot in vivo F-19 magnetic resonance spectra MOLECULAR CANCER THERAPEUTICS 2 (10): 933-939 OCT 2003
- 2003, Crispini A, Pucci D, Sessa S, et al. Synthesis and characterization of new transition metal complexes containing DNA intercalators of the acridine family NEW JOURNAL OF CHEMISTRY 27 (10): 1497-1503 2003
- 2003, Kuo CY, Wu HL, Kou HS, et al. Simultaneous determination of methotrexate and its eight metabolites in human whole blood by capillary zone electrophoresis JOURNAL OF CHROMATOGRAPHY A 1014 (1-2): 93-101 OCT 3 2003
- 2003, Costea I, Moghrabi A, Krajinovic M The influence of cyclin D1 (CCND1) 870A > G polymorphism and CCND1-thymidylate synthase (TS) gene - gene interaction on the outcome of childhood acute lymphoblastic leukaemia PHARMACOGENETICS 13 (9): 577-580 SEP 2003
- 2003, Levy AS, Sather HN, Steinherz PG, et al. Reduced folate carrier and dihydrofolate reductase expression in acute lymphocytic leukemia may predict outcome: A Children's Cancer Group study JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY 25 (9): 688-695 SEP 2003
- 2003, Matherly LH, Goldman D Membrane transport of folates VITAMINS AND HORMONES-ADVANCES IN RESEARCH AND APPLICATIONS 66: 403-456 2003
- 2003, Litle VR, Christie NA, Fernando HC, et al. Photodynamic therapy for endobronchial metastases from nonbronchogenic primaries ANNALS OF THORACIC SURGERY 76 (2): 370-375 AUG 2003
- 2003, Mathas S, Lietz A, Janz M, et al. Inhibition of NF-kappa B essentially contributes to arsenic-induced apoptosis BLOOD 102 (3): 1028-1034 AUG 1 2003
- 2003, Bosson G Reduced folate carrier: biochemistry and molecular biology of the normal and methotrexate-resistant cell BRITISH JOURNAL OF BIOMEDICAL SCIENCE 60 (2): 117-129 2003
- 2003, Sowers R, Toguchida J, Qin J, et al. mRNA expression levels of E2F transcription factors correlate with dihydrofolate reductase, reduced folate carrier, and thymidylate synthase mRNA expression in osteosarcoma MOLECULAR CANCER THERAPEUTICS 2 (6): 535-541 JUN 2003
- 2003, Sturlan S, Baumgartner M, Roth E, et al. Docosahexaenoic acid enhances arsenic trioxide-mediated apoptosis in arsenic trioxide-resistant HL-60 cells BLOOD 101 (12): 4990-4997 JUN 15 2003
- 2003, Dervieux T, Hancock ML, Pui CH, et al. Antagonism by methotrexate on mercaptopurine disposition in lymphoblasts during up-front treatment of acute lymphoblastic leukemia CLINICAL PHARMACOLOGY & THERAPEUTICS 73 (6): 506-516 JUN 2003
- 2003, Saldana HB, Garza SM, Lopez RO Molecular diagnosis of cancer REVISTA DE INVESTIGACION CLINICA 55 (2): 128-137 MAR-APR 2003
- 2003, Ozsoz M, Erdem A, Kara P, et al. Electrochemical biosensor for the detection of interaction between arsenic trioxide and DNA based on guanine signal ELECTROANALYSIS 15 (7): 613-619 MAY 2003
- 2003, Wright JE, Yurasek GK, Chen YN, et al. Further studies on the interaction of nonpolyglutamatable aminopterin analogs with dihydrofolate reductase and the reduced folate carrier as determinants of in vitro antitumor activity BIOCHEMICAL PHARMACOLOGY 65 (9): 1427-1433 MAY 1 2003
- 2003, Kanzawa T, Kondo Y, Ito H, et al. Induction of autophagic cell death in malignant glioma cells by arsenic trioxide CANCER RESEARCH 63 (9): 2103-2108 MAY 1 2003
- 2003, Cheok MH, Yang WL, Pui CH, et al. Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells NATURE GENETICS 34 (1): 85-90 MAY 2003
- 2003, Lazo G, Kantarjian H, Estey E, et al. Use of arsenic trioxide (AS(2)O(3)) in the treatment of patients with acute promyelocytic leukemia - The M. D. Anderson experience CANCER 97 (9): 2218-2224 MAY 1 2003
- 2003, Asai S, Miyachi H, Kobayashi H, et al. Large diversity in transport-mediated methotrexate resistance in human leukemia cell line CCRF-CEM established in a high concentration of leucovorin CANCER SCIENCE 94 (2): 210-214 FEB 2003
- 2003, Wang YH, Zhao RB, Goldman ID Decreased expression of the reduced folate carrier and folypolyglutamate synthetase is the basis for acquired resistance to the pemetrexed antifolate (LY231514) in an L1210 murine leukemia cell line BIOCHEMICAL PHARMACOLOGY 65 (7): 1163-1170 APR 1 2003
- 2003, Wang ES, O'Connor O, She YH, et al. Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression LEUKEMIA & LYMPHOMA 44 (6): 1027-1035 2003
- 2003, Yu D, Wang ZH, Zhu LY, et al. Nuclear matrix associated protein PML: an arsenic trioxide apoptosis therapeutic target protein in HepG2 cells CHINESE MEDICAL JOURNAL 116 (1): 93-98 JAN 2003
- 2003, Duyndam MCA, Hulscher STM, van der Wall E, et al. Evidence for a role of p38 kinase in hypoxia-inducible factor 1-independent induction of vascular endothelial growth factor expression by sodium arsenite JOURNAL OF BIOLOGICAL CHEMISTRY 278 (9): 6885-6895 FEB 28 2003
- 2003, Stranzl T, Wolf J, Leeb BF, et al. Expression of folylpolyglutamyl synthetase predicts poor response to methotrexate therapy in patients with rheumatoid arthritis CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 21 (1): 27-32 JAN-FEB 2003
- 2003, Yang R, Sowers R, Mazza B, et al. Sequence alterations in the reduced folate carrier are observed in osteosarcoma tumor samples CLINICAL CANCER RESEARCH 9 (2): 837-844 FEB 2003
- 2003, Wei HL, Su HX, Bai DC, et al. Arsenic trioxide inhibits p-glycoprotein expression in multidrug-resistant human leukemia cells that overexpress the MDR1 gene. CHINESE MEDICAL JOURNAL Volume: 116 Issue: 11 Pages: 1644-1648 Published: NOV 2003
- 2003, Crispini A, Pucci D, Sessa S, et al. Synthesis and characterization of new transition metal complexes containing DNA intercalators of the acridine family. NEW JOURNAL OF CHEMISTRY Volume: 27 Issue: 10 Pages: 1497-1503 Published: 2003
- 2003, Mathas S, Lietz A, Janz M, et al. Inhibition of NF-kappa B essentially contributes to arsenic-induced apoptosis. BLOOD Volume: 102 Issue: 3 Pages: 1028-1034 Published: AUG 1 2003
- 2003, Sturlan S, Baumgartner M, Roth E, et al. Docosahexaenoic acid enhances arsenic trioxide-mediated apoptosis in arsenic trioxide-resistant HL-60 cells. BLOOD Volume: 101 Issue: 12 Pages: 4990-4997 Published: JUN 15 2003
- 2003, Ozsoz M, Erdem A, Kara P, et al. Electrochemical biosensor for the detection of interaction between arsenic trioxide and DNA based on guanine signal. ELECTROANALYSIS Volume: 15 Issue: 7 Pages: 613-619 Published: MAY 2003
- 2003, Kanzawa T, Kondo Y, Ito H, et al. Induction of autophagic cell death in malignant glioma cells by arsenic trioxide. CANCER RESEARCH Volume: 63 Issue: 9 Pages: 2103-2108 Published: MAY 1 2003
- 2003, Lazo G, Kantarjian H, Estey E, et al. Use of arsenic trioxide (AS(2)O(3)) in the treatment of patients with acute promyelocytic leukemia - The M. D. Anderson experience. CANCER Volume: 97 Issue: 9 Pages: 2218-2224 Published: MAY 1 2003
- 2003, Yu D, Wang ZH, Zhu LY, et al. Nuclear matrix associated protein PML: an arsenic trioxide apoptosis therapeutic target protein in HepG2 cells. CHINESE MEDICAL JOURNAL Volume: 116 Issue: 1 Pages: 93-98 Published: JAN 2003
- 2003, Duyndam MCA, Hulscher STM, van der Wall E, et al. Evidence for a role of p38 kinase in hypoxia-inducible factor 1-independent induction of vascular endothelial growth factor expression by sodium arsenite. JOURNAL OF BIOLOGICAL CHEMISTRY Volume: 278 Issue: 9 Pages: 6885-6895 Published: FEB 28 2003
- 2003, Litle VR, Christie NA, Fernando HC, et al. Photodynamic therapy for endobronchial metastases from nonbronchogenic primaries ANNALS OF THORACIC SURGERY Volume: 76 Issue: 2 Pages: 370-375 Published: AUG 2003
- 2003, Hattinger CM, Reverter-Branchat G, Remondini D, et al. Genomic imbalances associated with methotrexate resistance in human osteosarcoma cell lines detected by comparative genomic hybridization-based techniques EUROPEAN JOURNAL OF CELL BIOLOGY Volume: 82 Issue: 9 Pages: 483-493 Published: SEP 2003
- 2003, Saldana HB, Garza SM, Lopez RO. Molecular diagnosis of cancer REVISTA DE INVESTIGACION CLINICA Volume: 55 Issue: 2 Pages: 128-137 Published: MAR-APR 2003
- 2003, Pieters R, den Boer ML. Molecular pharmacodynamics in childhood leukemia INTERNATIONAL JOURNAL OF HEMATOLOGY Volume: 78 Issue: 5 Pages: 402-413 Published: DEC 2003
- 2003, Nano R, Invernizzi R, Facoetti A, et al. Quantification of the DHFR gene in blast cells of leukaemia patients by fluorescence in situ hybridisation ANTICANCER RESEARCH Volume: 23 Issue: 5A Pages: 3883-3887 Published: SEP-OCT 2003
- 2003, Ifergan I, Meller I, Issakov J, et al. Reduced folate carrier protein expression in osteosarcoma - Implications for the prediction of tumor chemosensitivity CANCER Volume: 98 Issue: 9 Pages: 1958-1966 Published: NOV 1 2003
- 2003, Levy AS, Sather HN, Steinherz PG, et al. Reduced folate carrier and dihydrofolate reductase expression in acute lymphocytic leukemia may predict outcome: A Children's Cancer Group study JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY Volume: 25 Issue: 9 Pages: 688-695 Published: SEP 2003
- 2003, Stranzl T, Wolf J, Leeb BF, et al. Expression of folylpolyglutamyl synthetase predicts poor response to methotrexate therapy in patients with rheumatoid arthritis CLINICAL AND EXPERIMENTAL RHEUMATOLOGY Volume: 21 Issue: 1 Pages: 27-32 Published: JAN-FEB 2003
- 2003, McGuire JJ. Anticancer antifolates: Current status and future directions CURRENT PHARMACEUTICAL DESIGN Volume: 9 Issue: 31 Pages: 2593-2613 Published: 2003
- 2003, Pieters R, den Boer ML Molecular pharmacodynamics in childhood leukemia INTERNATIONAL JOURNAL OF HEMATOLOGY 78 5 402-413 DEC 2003
- 2003, Dervieux T, Hancock ML, Pui CH, et al. Antagonism by methotrexate on mercaptopurine disposition in lymphoblasts during up-front treatment of acute lymphoblastic leukemia CLINICAL PHARMACOLOGY & THERAPEUTICS Volume: 73 Issue: 6 Pages: 506-516 Published: JUN 2003
- 2002, Pui CH, Relling MV, Evans WE Role of pharmacogenomics and pharmacodynamics in the treatment of acute lymphoblastic leukaemia BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY 15 (4): 741-756 DEC 2002
- 2002, Goldman ID, Zhao RB Molecular, biochemical, and cellular pharmacology of pemetrexed SEMINARS IN ONCOLOGY 29 (6): 3-17 Suppl. 18 DEC 2002
- 2002, Witt TL, Matherly LH Identification of lysine-411 in the human reduced folate carrier as an important determinant of substrate selectivity and carrier function by systematic site-directed mutagenesis BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES 1567 (1-2): 56-62 DEC 23 2002
- 2002, Gifford AJ, Haber M, Witt TL, et al. Role of the E45K-reduced folate carrier gene mutation in methotrexate resistance in human leukemia cells LEUKEMIA 16 (12): 2379-2387 DEC 2002
- 2002, Panetta JC, Yanishevski Y, Pui CH, et al. A mathematical model of in vivo methotrexate accumulation in acute lymphoblastic leukemia CANCER CHEMOTHERAPY AND PHARMACOLOGY 50 (5): 419-428 NOV 2002
- 2002, Laverdiere C, Chiasson S, Costea I, et al. Polymorphism G(80)A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia BLOOD 100 (10): 3832-3834 NOV 15 2002
- 2002, Sadlish H, Williams FMR, Flintoff WF Functional role of arginine 373 in substrate translocation by the reduced folate carrier JOURNAL OF BIOLOGICAL CHEMISTRY 277 (44): 42105-42112 NOV 1 2002
- 2002, Whetstine JR, Flatley RM, Matherly LH The human reduced folate carrier gene is ubiquitously and differentially expressed in normal human tissues: identification of seven non-coding exons and characterization of a novel promoter BIOCHEMICAL JOURNAL 367: 629-640 Part 3 NOV 1 2002
- 2002, Mellinghoff IK, Sawyers CL The emergence of resistance to targeted cancer therapeutics PHARMACOGENOMICS 3 (5): 603-623 SEP 2002
- 2002, Iadarola P, Annovazzi L, Lupi A, et al. Capillary electrophoresis as a modern tool for determining proteolytic activities in purified specimens and in real samples JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES 25 (13-15): 1919-1945 2002
- 2002, Kabanov AV, Batrakova EV, Alakhov VY Pluronic((R)) block copolymers for overcoming drug resistance in cancer ADVANCED DRUG DELIVERY REVIEWS 54 (5): 759-779 SEP 13 2002
- 2002, Nathrath M, Kremer M, Letzel H, et al. Expression of genes of potential importance in the response to chemotherapy in osteosarcoma patients KLINISCHE PADIATRIE 214 (4): 230-235 JUL-AUG 2002
- 2002, Pu YS, Hour TC, Chen J, et al. Cytotoxicity of arsenic trioxide to transitional carcinoma cells UROLOGY 60 (2): 346-350 AUG 2002
- 2002, Li XQ, Ding XZ, Adrian TE Arsenic trioxide inhibits proliferation and induces apoptosis in pancreatic cancer cells ANTICANCER RESEARCH 22 (4): 2205-2213 JUL-AUG 2002
- 2002, Miller WH, Schipper HM, Lee JS, et al. Mechanisms of action of arsenic trioxide CANCER RESEARCH 62 (14): 3893-3903 JUL 15 2002
- 2002, Panetta JC, Wall A, Pui CH, et al. Methotrexate intracellular disposition in acute lymphoblastic leukemia: A mathematical model of gamma-glutamyl hydrolase activity CLINICAL CANCER RESEARCH 8 (7): 2423-2429 JUL 2002
- 2002, Banerjee D, Mayer-Kuckuk P, Capiaux G, et al. Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE 1587 (2-3): 164-173 Sp. Iss. SI JUL 18 2002
- 2002, Carre M, Carles G, Andre N, et al. Involvement of microtubules and mitochondria in the antagonism of arsenic trioxide on paclitaxel-induced apoptosis BIOCHEMICAL PHARMACOLOGY 63 (10): 1831-1842 MAY 15 2002
- 2002, Sadlish H, Williams FMR, Flintoff WF Cytoplasmic domains of the reduced folate carrier are essential for trafficking, but not function BIOCHEMICAL JOURNAL 364: 777-786 Part 3 JUN 15 2002
- 2002, Sarris AH, Phan A, Duvic M, et al. Trimetrexate in relapsed T-cell lymphoma with skin involvement JOURNAL OF CLINICAL ONCOLOGY 20 (12): 2876-2880 JUN 15 2002
- 2002, Woo SH, Park IC, Park MJ, et al. Arsenic trioxide induces apoptosis through a reactive oxygen species-dependent pathway and loss of mitochondrial membrane potential in HeLa cells INTERNATIONAL JOURNAL OF ONCOLOGY 21 (1): 57-63 JUL 2002
- 2002, Sharina IG, Zhao RB, Wang YH, et al. Role of the C-terminus and the long cytoplasmic loop in reduced folate carrier expression and function BIOCHEMICAL PHARMACOLOGY 63 (9): 1717-1724 MAY 1 2002
- 2002, Styczynski J, Wysocki M In vitro drug resistance profiles of adult acute lymphoblastic leukemia: Possible explanation for difference in outcome to similar therapeutic regimens LEUKEMIA & LYMPHOMA 43 (2): 301-307 FEB 2002
- 2002, Calvert H, Bunn PA Future directions in the development of pemetrexed SEMINARS IN ONCOLOGY 29 (2): 54-61 Suppl. 5 APR 2002
- 2002, Chun YJ, Park IC, Park MJ, et al. Enhancement of radiation response in human cervical cancer cells in vitro and in vivo by arsenic trioxide (As2O3) FEBS LETTERS 519 (1-3): 195-200 MAY 22 2002
- 2002, Ramakers-van Woerden NL, Pieters R, Rots MG, et al. Infants with acute lymphoblastic leukemia: no evidence for high methotrexate resistance LEUKEMIA 16 (5): 949-951 MAY 2002
- 2002, Baj G, Arnulfo A, Deaglio S, et al. Arsenic trioxide and breast cancer: Analysis of the apoptotic, differentiative and immunomodulatory effects BREAST CANCER RESEARCH AND TREATMENT 73 (1): 61-73 MAY 2002
- 2002, Pu YS, Hour TC, Chen J, et al. Arsenic trioxide as a novel anticancer agent against human transitional carcinoma - characterizing its apoptotic pathway ANTI-CANCER DRUGS 13 (3): 293-300 MAR 2002
- 2002, Efferth T, Miyachi H, Drexler HG, et al. Methylthioadenosine phosphorylase as target for chemoselective treatment of T-cell acute lymphoblastic leukemic cells BLOOD CELLS MOLECULES AND DISEASES 28 (1): 47-56 JAN-FEB 2002
- 2002, Amado RG, Rosen LS, Hecht JR, et al. Low-dose trimetrexate glucuronate and protracted 5-fluorouracil infusion in previously untreated patients with advanced pancreatic cancer ANNALS OF ONCOLOGY 13 (4): 582-588 APR 2002
- 2002, Ouellette M, Drummelsmith J, El Fadili A, et al. Pterin transport and metabolism in Leishmania and related trypanosomatid parasites INTERNATIONAL JOURNAL FOR PARASITOLOGY 32 (4): 385-398 APR 2002
- 2002, Mauritz R, Peters GJ, Priest DG, et al. Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis BIOCHEMICAL PHARMACOLOGY 63 (2): 105-115 JAN 15 2002
- 2002, Damiani D, Michelutti A, Michieli M, et al. P-glycoprotein, lung resistance-related protein and multidrug resistance-associated protein in de novo adult acute lymphoblastic leukaemia BRITISH JOURNAL OF HAEMATOLOGY 116 (3): 519-527 MAR 2002
- 2002, Rojewski MT, Baldus C, Knauf W, et al. Dual effects of arsenic trioxide (AS(2)O(3)) on non-acute promyelocytic leukaemia myeloid cell lines: induction of apoptosis and inhibition of proliferation BRITISH JOURNAL OF HAEMATOLOGY 116 (3): 555-563 MAR 2002
- 2002, Bertino JR Modulation of 5-fluorouracil/leucovorin by trimetrexate - did it work? ANNALS OF ONCOLOGY 13 (1): 10-11 JAN 2002
- 2002, Punt CJA, Keizer HJ, Douma J, et al. Trimetrexate as biochemical modulator of 5-fluorouracil/leucovorin in advanced colorectal cancer: final results of a randomised European study ANNALS OF ONCOLOGY 13 (1): 81-86 JAN 2002
- 2002, Blanke CD, Shultz J, Cox J, et al. A double-blind placebo-controlled randomized phase III trial of 5-fluorouracil and leucovorin, plus or minus trimetrexate, in previously untreated patients with advanced colorectal cancer ANNALS OF ONCOLOGY 13 (1): 87-91 JAN 2002
- 2002, Goldman ID Membrane transport of chemotherapeutics and drug resistance: Beyond the ABC family of exporters to the role of carrier-mediated processes CLINICAL CANCER RESEARCH 8 (1): 4-6 JAN 2002
- 2002, Smith HO, Blessing JA, Vaccarello L Trimetrexate in the treatment of recurrent or advanced leiomyosarcoma of the uterus: A phase II study of the gynecologic oncology group GYNECOLOGIC ONCOLOGY 84 (1): 140-144 JAN 2002
- 2002, Thomas DA, Cortes J, Kantarjian HM New agents in the treatment of acute lymphocytic leukaemia BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY 15 (4): 771-790 DEC 2002
- 2002, Pu YS, Hour TC, Chen J, et al. Cytotoxicity of arsenic trioxide to transitional carcinoma cells. UROLOGY Volume: 60 Issue: 2 Pages: 346-350 Published: AUG 2002
- 2002, Li XQ, Ding XZ, Adrian TE. Arsenic trioxide inhibits proliferation and induces apoptosis in pancreatic cancer cells. ANTICANCER RESEARCH Volume: 22 Issue: 4 Pages: 2205-2213 Published: JUL-AUG 2002
- 2002, Miller WH, Schipper HM, Lee JS, et al. Mechanisms of action of arsenic trioxide. CANCER RESEARCH Volume: 62 Issue: 14 Pages: 3893-3903 Published: JUL 15 2002
- 2002, Carre M, Carles G, Andre N, et al. Involvement of microtubules and mitochondria in the antagonism of arsenic trioxide on paclitaxel-induced apoptosis. BIOCHEMICAL PHARMACOLOGY Volume: 63 Issue: 10 Pages: 1831-1842 Published: MAY 15 2002
- 2002, Woo SH, Park IC, Park MJ, et al. Arsenic trioxide induces apoptosis through a reactive oxygen species-dependent pathway and loss of mitochondrial membrane potential in HeLa cells. INTERNATIONAL JOURNAL OF ONCOLOGY Volume: 21 Issue: 1 Pages: 57-63 Published: JUL 2002
- 2002, Chun YJ, Park IC, Park MJ, et al. Enhancement of radiation response in human cervical cancer cells in vitro and in vivo by arsenic trioxide (As2O3). FEBS LETTERS Volume: 519 Issue: 1-3 Pages: 195-200 Published: MAY 22 2002
- 2002, Baj G, Arnulfo A, Deaglio S, et al. Arsenic trioxide and breast cancer: Analysis of the apoptotic, differentiative and immunomodulatory effects. BREAST CANCER RESEARCH AND TREATMENT Volume: 73 Issue: 1 Pages: 61-73 Published: MAY 2002
- 2002, Pu YS, Hour TC, Chen J, et al. Arsenic trioxide as a novel anticancer agent against human transitional carcinoma - characterizing its apoptotic pathway. ANTI-CANCER DRUGS Volume: 13 Issue: 3 Pages: 293-300 Published: MAR 2002
- 2002, Rojewski MT, Baldus C, Knauf W, et al. Dual effects of arsenic trioxide (AS(2)O(3)) on non-acute promyelocytic leukaemia myeloid cell lines: induction of apoptosis and inhibition of proliferation. BRITISH JOURNAL OF HAEMATOLOGY Volume: 116 Issue: 3 Pages: 555-563 Published: MAR 2002
- 2002, Kabanov AV, Batrakova EV, Alakhov VY. Pluronic((R)) block copolymers for overcoming drug resistance in cancer ADVANCED DRUG DELIVERY REVIEWS Volume: 54 Issue: 5 Pages: 759-779 Published: SEP 13 2002
- 2002, Nathrath M, Kremer M, Letzel H, et al. Expression of genes of potential importance in the response to chemotherapy in osteosarcoma patients KLINISCHE PADIATRIE Volume: 214 Issue: 4 Pages: 230-235 Published: JUL-AUG 2002
- 2002, Efferth T, Miyachi H, Drexler HG, et al. Methylthioadenosine phosphorylase as target for chemoselective treatment of T-cell acute lymphoblastic leukemic cells BLOOD CELLS MOLECULES AND DISEASES Volume: 28 Issue: 1 Pages: 47-56 Published: JAN-FEB 2002
- 2002, Pui CH, Relling MV, Evans WE. Role of pharmacogenomics and pharmacodynamics in the treatment of acute lymphoblastic leukaemia BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY Volume: 15 Issue: 4 Pages: 741-756 Published: DEC 2002
- 2002, Mellinghoff IK, Sawyers CL. The emergence of resistance to targeted cancer therapeutics PHARMACOGENOMICS Volume: 3 Issue: 5 Pages: 603-623 Published: SEP 2002
- 2002, Banerjee D, Mayer-Kuckuk P, Capiaux G, et al. Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE Volume: 1587 Issue: 2-3 Special Issue: Sp. Iss. SI Pages: 164-173 Published: JUL 18 2002
- 2002, Styczynski J, Wysocki M. In vitro drug resistance profiles of adult acute lymphoblastic leukemia: Possible explanation for difference in outcome to similar therapeutic regimens LEUKEMIA & LYMPHOMA Volume: 43 Issue: 2 Pages: 301-307 Published: FEB 2002
- 2002, Smith HO, Blessing JA, Vaccarello L. Trimetrexate in the treatment of recurrent or advanced leiomyosarcoma of the uterus: A phase II study of the gynecologic oncology group GYNECOLOGIC ONCOLOGY Volume: 84 Issue: 1 Pages: 140-144 Published: JAN 2002
- 2002, Thomas DA, Cortes J, Kantarjian HM New agents in the treatment of acute lymphocytic leukaemia BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY 15 4 771-790 DEC 2002
- 2001, Relling MV, Dervieux T Pharmacogenetics and cancer therapy NATURE REVIEWS CANCER 1 (2): 99-108 NOV 2001
- 2001, Weigand M, Hartung G, Roboz J, et al. Mode of action of methotrexate-albumin in a human T-cell leukemia line and activity against an MTX-resistant clone ANTI-CANCER DRUG DESIGN 16 (4-5): 227-237 AUG 2001
- 2001, Estlin EJ Continuing therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of methotrexate, 6-mercaptopurine and 6-thioguanine CANCER TREATMENT REVIEWS 27 (6): 351-363 DEC 2001
- 2001, Goldie JH Drug resistance in cancer: A perspective CANCER AND METASTASIS REVIEWS 20 (1-2): 63-68 Sp. Iss. SI 2001
- 2001, Duyndam MCA, Hulscher TM, Fontijn D, et al. Induction of vascular endothelial growth factor expression and hypoxia-inducible factor 1 alpha protein by the oxidative stressor arsenite JOURNAL OF BIOLOGICAL CHEMISTRY 276 (51): 48066-48076 DEC 21 2001
- 2001, Deng Y, Xu HB, Huang KX, et al. Size effects of realgar particles on apoptosis in a human umbilical vein endothelial cell line: ECV-304 PHARMACOLOGICAL RESEARCH 44 (6): 513-518 DEC 2001
- 2001, Schimmer AD, Hedley DW, Penn LZ, et al. Receptor- and mitochondrial-mediated apoptosis in acute leukemia: a translational view BLOOD 98 (13): 3541-3553 DEC 15 2001
- 2001, Tallman MS Arsenic trioxide: its role in acute promyelocytic leukemia and potential in other hematologic malignancies BLOOD REVIEWS 15 (3): 133-142 SEP 2001
- 2001, Zhang TD, Chen GQ, Wang ZG, et al. Arsenic trioxide, a therapeutic agent for APL ONCOGENE 20 (49): 7146-7153 OCT 29 2001
- 2001, Worm J, Kirkin AF, Dzhandzhugazyan KN, et al. Methylation-dependent silencing of the reduced folate carrier gene in inherently methotrexate-resistant human breast cancer cells JOURNAL OF BIOLOGICAL CHEMISTRY 276 (43): 39990-40000 OCT 26 2001
- 2001, Costi MP, Ferrari S Update on antifolate drugs targets CURRENT DRUG TARGETS 2 (2): 135-166 JUN 2001
- 2001, Gump J, McGavran L, Wei Q, et al. Analysis of TP53 mutations in relapsed childhood acute lymphoblastic leukemia JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY 23 (7): 416-419 OCT 2001
- 2001, DeAngelis LM Commentary on "High-dose methotrexate for isolated central nervous system relapse in patients with testicular non-Hodgkin's lymphoma" CLINICAL LYMPHOMA 2 (2): 120-120 SEP 2001
- 2001, Zeng H, Chen ZS, Belinsky MG, et al. Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: Effect of polyglutamylation on MTX transport CANCER RESEARCH 61 (19): 7225-7232 OCT 1 2001
- 2001, Matherly LH Molecular and cellular biology of the human reduced folate carrier PROGRESS IN NUCLEIC ACID RESEARCH AND MOLECULAR BIOLOGY 67: 131-162 2001
- 2001, Durand R, Savel J Dihydrofolate reductase inhibitors: new developments in antiparasitic chemotherapy EXPERT OPINION ON THERAPEUTIC PATENTS 11 (8): 1285-1290 AUG 2001
- 2001, Pepponi R, Graziani G, Falcinelli S, et al. hMSH3 overexpression and cellular response to cytotoxic anticancer agents CARCINOGENESIS 22 (8): 1131-1137 AUG 2001
- 2001, Jang KA, Ahn SJ, Choi JH, et al. Polymerase chain reaction (PCR) for human herpesvirus 8 and heteroduplex PCR for clonality assessment in angiolymphoid hyperplasia with eosinophilia and Kimura's disease JOURNAL OF CUTANEOUS PATHOLOGY 28 (7): 363-367 AUG 2001
- 2001, Wang YH, Zhao RB, Russell RG, et al. Localization of the murine reduced folate carrier as assessed by immunohistochemical analysis BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES 1513 (1): 49-54 JUL 2 2001
- 2001, Donnelly JG Folic acid CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES 38 (3): 183-223 2001
- 2001, Shah SJ, Taub JW, Witt TL, et al. Relationship of p15 and p16 gene alterations to elevated dihydrofolate reductase in childhood acute lymphoblastic leukaemia BRITISH JOURNAL OF HAEMATOLOGY 113 (3): 746-756 JUN 2001
- 2001, Mitsiades CS, Koutsilieris M Molecular biology and cellular physiology of refractoriness to androgen ablation therapy in advanced prostate cancer EXPERT OPINION ON INVESTIGATIONAL DRUGS 10 (6): 1099-1115 JUN 2001
- 2001, Cole PD, Kamen BA, Gorlick R, et al. Effects of overexpression of gamma-glutamyl hydrolase on methotrexate metabolism and resistance CANCER RESEARCH 61 (11): 4599-4604 JUN 1 2001
- 2001, Cataland SR, Daugherty CK, Weseman EC, et al. Preliminary experience with a new chemotherapy regimen for adults with acute lymphoblastic leukemia LEUKEMIA & LYMPHOMA 41 (3-4): 297-307 APR 2001
- 2001, Ding BC, Witt TL, Hukku B, et al. Association of deletions and translocation of the reduced folate carrier gene with profound loss of gene expression in methotrexate-resistant K562 human erythroleukemia cells BIOCHEMICAL PHARMACOLOGY 61 (6): 665-675 MAR 15 2001
- 2001, Rots MG, Pieters R, Jansen G, et al. A possible role for methotrexate in the treatment of childhood acute myeloid leukaemia, in particular for acute monocytic leukaemia EUROPEAN JOURNAL OF CANCER 37 (4): 492-498 MAR 2001
- 2001, Garcia-Manero G, Thomas DA Salvage therapy for refractory or relapsed acute lymphocytic leukemia HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA 15 (1): 163+ FEB 2001
- 2001, Trippett TM, Garcia S, Manova K, et al. Localization of a human reduced folate carrier protein in the mitochondrial as well as the cell membrane of leukemia cells CANCER RESEARCH 61 (5): 1941-1947 MAR 1 2001
- 2001, Whetstine JR, Matherly LH The basal promoters for the human reduced folate carrier gene are regulated by a GC box and a cAMP-response element/AP-1-like element - Basis for tissue-specific gene expression JOURNAL OF BIOLOGICAL CHEMISTRY 276 (9): 6350-6358 MAR 2 2001
- 2001, Belur LR, Boelk-Galvan D, Diers MD, et al. Methotrexate accumulates to similar levels in animals transplanted with normal versus drug-resistant transgenic marrow CANCER RESEARCH 61 (4): 1522-1526 FEB 15 2001
- 2001, Nishikawa M, Yamamoto M, Watanabe Y, et al. Clinical significance of low protein phosphatase-1 activity of blasts in acute myelogenous leukemia with high white cell counts INTERNATIONAL JOURNAL OF ONCOLOGY 18 (3): 559-565 MAR 2001
- 2001, Longo-Sorbello GSA, Bertino JR Current understanding of methotrexate pharmacology and efficacy in acute leukemias. Use of newer antifolates in clinical trials HAEMATOLOGICA 86 (2): 121-127 FEB 2001
- 2001, Petersdorf SH, Kopecky KJ, Head DR, et al. Comparison of the L10M consolidation regimen to an alternative regimen including escalating methotrexate/L-asparaginase for adult acute lymphoblastic leukemia: a Southwest Oncology Group Study LEUKEMIA 15 (2): 208-216 FEB 2001
- 2001, Estlin EJ, Pinkerton CR, Lewis IJ, et al. A phase I study of nolatrexed dihydrochloride in children with advanced cancer. A United Kingdom Children's Cancer Study Group Investigation BRITISH JOURNAL OF CANCER 84 (1): 11-18 JAN 5 2001
- 2001, Bacich DJ, Pinto JT, Tong WP, et al. Cloning, expression, genomic localization, and enzymatic activities of the mouse homolog of prostate-specific membrane antigen/NAALADase/folate hydrolase MAMMALIAN GENOME 12 (2): 117-123 FEB 2001
- 2001, Duyndam MCA, Hulscher TM, Fontijn D, et al. Induction of vascular endothelial growth factor expression and hypoxia-inducible factor 1 alpha protein by the oxidative stressor arsenite. JOURNAL OF BIOLOGICAL CHEMISTRY Volume: 276 Issue: 51 Pages: 48066-48076 Published: DEC 21 2001
- 2001, Deng Y, Xu HB, Huang KX, et al. Size effects of realgar particles on apoptosis in a human umbilical vein endothelial cell line: ECV-304 PHARMACOLOGICAL RESEARCH Volume: 44 Issue: 6 Pages: 513-518 Published: DEC 2001
- 2001, Tallman MS. Arsenic trioxide: its role in acute promyelocytic leukemia and potential in other hematologic malignancies BLOOD REVIEWS Volume: 15 Issue: 3 Pages: 133-142 Published: SEP 2001
- 2001, Zhang TD, Chen GQ, Wang ZG, et al. Arsenic trioxide, a therapeutic agent for APL ONCOGENE Volume: 20 Issue: 49 Pages: 7146-7153 Published: OCT 29 2001
- 2001, Weigand M, Hartung G, Roboz J, et al. Mode of action of methotrexate-albumin in a human T-cell leukemia line and activity against an MTX-resistant clone ANTI-CANCER DRUG DESIGN Volume: 16 Issue: 4-5 Pages: 227-237 Published: AUG 2001
- 2001, Mitsiades CS, Koutsilieris M. Molecular biology and cellular physiology of refractoriness to androgen ablation therapy in advanced prostate cancer EXPERT OPINION ON INVESTIGATIONAL DRUGS Volume: 10 Issue: 6 Pages: 1099-1115 Published: JUN 2001
- 2001, Costi MP, Ferrari S. Update on antifolate drugs targets CURRENT DRUG TARGETS Volume: 2 Issue: 2 Pages: 135-166 Published: JUN 2001
- 2001, DeAngelis LM. Commentary on 'High-dose methotrexate for isolated central nervous system relapse in patients with testicular non-Hodgkin's lymphoma' CLINICAL LYMPHOMA Volume: 2 Issue: 2 Pages: 120-120 Published: SEP 2001
- 2001, Schimmer AD, Hedley DW, Penn LZ, et al. Receptor- and mitochondrial-mediated apoptosis in acute leukemia: a translational view BLOOD Volume: 98 Issue: 13 Pages: 3541-3553 Published: DEC 15 2001
- 2001, Gump J, McGavran L, Wei Q, et al. Analysis of TP53 mutations in relapsed childhood acute lymphoblastic leukemia JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY Volume: 23 Issue: 7 Pages: 416-419 Published: OCT 2001
- 2001, Shah SJ, Taub JW, Witt TL, et al. Relationship of p15 and p16 gene alterations to elevated dihydrofolate reductase in childhood acute lymphoblastic leukaemia BRITISH JOURNAL OF HAEMATOLOGY Volume: 113 Issue: 3 Pages: 746-756 Published: JUN 2001
- 2001, Belur LR, Boelk-Galvan D, Diers MD, et al. Methotrexate accumulates to similar levels in animals transplanted with normal versus drug-resistant transgenic marrow CANCER RESEARCH Volume: 61 Issue: 4 Pages: 1522-1526 Published: FEB 15 2001
- 2001, Longo-Sorbello GSA, Bertino JR. Current understanding of methotrexate pharmacology and efficacy in acute leukemias. Use of newer antifolates in clinical trials HAEMATOLOGICA Volume: 86 Issue: 2 Pages: 121-127 Published: FEB 2001
- 2001, Donnelly JG. Folic acid CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES Volume: 38 Issue: 3 Pages: 183-223 Published: 2001
- 2001, Rots MG, Pieters R, Jansen G, et al. A possible role for methotrexate in the treatment of childhood acute myeloid leukaemia, in particular for acute monocytic leukaemia EUROPEAN JOURNAL OF CANCER Volume: 37 Issue: 4 Pages: 492-498 Published: MAR 2001
- 2001, Garcia-Manero G, Thomas DA. Salvage therapy for refractory or relapsed acute lymphocytic leukemia HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA Volume: 15 Issue: 1 Pages: 163-+ Published: FEB 2001
- 2000, Muller-Ladner U, Nishioka K p53 in rheumatoid arthritis: friend or foe? ARTHRITIS RESEARCH 2 (3): 175-178 2000
- 2000, Royce ME, Medgyesy D, Zukowski TH, et al. Colorectal cancer: Chemotherapy treatment overview ONCOLOGY-NEW YORK 14 (12): 40-46 Suppl. 14 DEC 2000
- 2000, Ma DQ, Huang H, Moscow JA Down-regulation of reduced folate carrier gene (RFC1) expression after exposure to methotrexate in ZR-75-1 breast cancer cells BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 279 (3): 891-897 DEC 29 2000
- 2000, Rots MG, Willey JC, Jansen G, et al. mRNA expression levels of methotrexate resistance-related proteins in childhood leukemia as determined by a standardized competitive template-based RT-PCR method LEUKEMIA 14 (12): 2166-2175 DEC 2000
- 2000, van den Berg H, van der Lelie J Acute lymphoblastic leukaemia in puberty and adolescence ANNALS OF ONCOLOGY 11 (11): 1375-1379 NOV 2000
- 2000, Ladanyi M, Gorlick R Molecular pathology and molecular pharmacology of osteosarcoma PEDIATRIC PATHOLOGY & MOLECULAR MEDICINE 19 (5): 391-413 SEP 2000
- 2000, Fuskevag OM, Kristiansen C, Olsen R, et al. Microvascular perturbations in rats receiving the maximum tolerated dose of methotrexate or its major metabolite 7-hydroxymethotrexate ULTRASTRUCTURAL PATHOLOGY 24 (5): 325-332 SEP-OCT 2000
- 2000, Punt CJA Trimetrexate as a biochemical modulator of 5-fluorouracil and leucovorin in colorectal cancer SEMINARS IN ONCOLOGY 27 (5): 88-90 Suppl. 10 OCT 2000
- 2000, Gambacorti-Passerini C, Barni R, le Coutre P, et al. Role of alpha 1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the Abl inhibitor STI571 JOURNAL OF THE NATIONAL CANCER INSTITUTE 92 (20): 1641-1650 OCT 18 2000
- 2000, Rots MG, Pieters R, Kaspers GJL, et al. Classification of ex vivo methotrexate resistance in acute lymphoblastic and myeloid leukaemia BRITISH JOURNAL OF HAEMATOLOGY 110 (4): 791-800 SEP 2000
- 2000, Styczynski J, Pieters R, Huismans DR, et al. In vitro drug resistance profiles of adult versus childhood acute lymphoblastic leukaemia BRITISH JOURNAL OF HAEMATOLOGY 110 (4): 813-818 SEP 2000
- 2000, Peters GJ, van der Wilt CL, van Moorsel CJA, et al. Basis for effective combination cancer chemotherapy with antimetabolites PHARMACOLOGY & THERAPEUTICS 87 (2-3): 227-253 AUG-SEP 2000
- 2000, Royce ME, Hoff PM, Pazdur R Progress in colorectal cancer chemotherapy - How far have we come, how far to go? DRUGS & AGING 17 (3): 201-216 SEP 2000
- 2000, Renner S, Kuci Z, d'Cruze H, et al. Isotachophoretic analysis of the dihydrofolate reductase reaction in the presence of methotrexate and ascorbic acid ELECTROPHORESIS 21 (14): 2828-2833 AUG 2000
- 2000, Zhao RB, Babani S, Gao F, et al. The mechanism of transport of the multitargeted antifolate (MTA) and its cross-resistance pattern in cells with markedly impaired transport of methotrexate CLINICAL CANCER RESEARCH 6 (9): 3687-3695 SEP 2000
- 2000, Zhao RB, Titus S, Gao F, et al. Molecular analysis of murine leukemia cell lines resistant to 5,10-dideazatetrahydrofolate identifies several amino acids critical to the function of folylpolyglutamate synthetase JOURNAL OF BIOLOGICAL CHEMISTRY 275 (34): 26599-26606 AUG 25 2000
- 2000, Takemura Y, Kobayashi H, Miyachi H Raltitrexed, a novel folate-based thymidylate synthase inhibitor, for the treatment of acute leukemia: Is this drug active against acute myelogenous leukemia? INTERNATIONAL JOURNAL OF HEMATOLOGY 72 (1): 112-114 JUL 2000
- 2000, Backus HHJ, Pinedo HM, Wouters D, et al. Folate depletion increases sensitivity of solid tumor cell lines to 5-fluorouracil and antifolates INTERNATIONAL JOURNAL OF CANCER 87 (6): 771-778 SEP 15 2000
- 2000, Zhao R, Gao F, Babani S, et al. Sensitivity to 5,10-dideazatetrahydrofolate is fully conserved in a murine leukemia cell line highly resistant to methotrexate due to impaired transport mediated by the reduced folate carrier CLINICAL CANCER RESEARCH 6 (8): 3304-3311 AUG 2000
- 2000, Estlin EJ, Lowis SP, Hall AG Optimizing antimetabolite-based chemotherapy for the treatment of childhood acute lymphoblastic leukaemia BRITISH JOURNAL OF HAEMATOLOGY 110 (1): 29-40 JUL 2000
- 2000, Weigand M, Frei E, Graf N, et al. Comparative analysis of methotrexate polyglutamates in lymphoblast preparations from bone marrow and blood, and the contribution of residual red blood cells JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY 126 (7): 407-411 JUL 2000
- 2000, Rots MG, Pieters R, Peters GJ, et al. Methotrexate resistance in relapsed childhood acute lymphoblastic leukaemia BRITISH JOURNAL OF HAEMATOLOGY 109 (3): 629-634 JUN 2000
- 2000, Takebe N, Nakahara S, Zhao SC, et al. Comparison of methotrexate resistance conferred by a mutated dihydrofolate reductase (DHFR) cDNA in two different retroviral vectors CANCER GENE THERAPY 7 (6): 910-919 JUN 2000
- 2000, Morganti M, Coronnello M, Caciagli B, et al. Modulation of dihydrofolate reductase gene expression in methotrexate-resistant human leukemia CCRF-CEM/E cells by antisense oligonucleotides ANTI-CANCER DRUGS 11 (4): 285-294 APR 2000
- 2000, Zhao RB, Gao F, Liu LB, et al. The reduced folate carrier in L1210 murine leukemia cells is a 58-kDa protein BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES 1466 (1-2): 7-10 JUN 1 2000
- 2000, Szelenyi H, Hohenberger P, Lochs H, et al. Sequential trimetrexate, 5-fluorouracil and folinic acid are effective and well tolerated in metastatic colorectal carcinoma ONCOLOGY 58 (4): 273-279 2000
- 2000, Rosowsky A, Wright JE, Vaidya CM, et al. The effect of side-chain, para-aminobenzoyl region, and B-ring modifications on dihydrofolate reductase binding, influx via the reduced folate carrier, and cytotoxicity of the potent nonpolyglutamatable antifolate N-alpha-(4-amino-4-deoxypteroyl)-N-delta-hemiphthaloyl-L-ornithine PHARMACOLOGY & THERAPEUTICS 85 (3): 191-205 MAR 2000
- 2000, Mahoney DH, Shuster JJ, Nitschke R, et al. Intensification with intermediate-dose intravenous methotrexate is effective therapy for children with lower-risk B-precursor acute lymphoblastic leukemia: A pediatric oncology group study JOURNAL OF CLINICAL ONCOLOGY 18 (6): 1285-1294 MAR 2000
- 2000, Sadlish H, Murray RC, Williams FMR, et al. Mutations in the reduced-folate carrier affect protein localization and stability BIOCHEMICAL JOURNAL 346: 509-518 Part 2 MAR 1 2000
- 2000, Jarvinen TAH, Tanner M, Rantanen V, et al. Amplification and deletion of topoisomerase II alpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer AMERICAN JOURNAL OF PATHOLOGY 156 (3): 839-847 MAR 2000
- 2000, le Coutre P, Tassi E, Varella-Garcia M, et al. Induction of resistance to the Abelson inhibitor ST1571 in human leukemic cells through gene amplification BLOOD 95 (5): 1758-1766 MAR 1 2000
- 2000, Wall AM, Gajjar A, Link A, et al. Individualized methotrexate dosing in children with relapsed acute lymphoblastic leukemia LEUKEMIA 14 (2): 221-225 FEB 2000
- 2000, Katzir I, Shani J, Wolf W, et al. Enhancement of 5-fluorouracil anabolism by methotrexate and trimetrexate in two rat solid tumor models, Walker 256 carcinosarcoma and Novikoff hepatoma, as evaluated by F-19-magnetic resonance spectroscopy CANCER INVESTIGATION 18 (1): 20-27 2000
- 2000, Leoni LM, Hamel E, Genini D, et al. Indanocine, a microtubule-binding indanone and a selective inducer of apoptosis in multidrug-resistant cancer cells JOURNAL OF THE NATIONAL CANCER INSTITUTE 92 (3): 217-224 FEB 2 2000
- 2000, Barnes MJ, Taylor GA, Newell DR Development of a whole cell assay to measure methotrexate-induced inhibition of thymidylate synthase and de novo purine synthesis in leukaemia cells BIOCHEMICAL PHARMACOLOGY 59 (4): 321-328 FEB 15 2000
- 2000, Weigand M, Frei E, Graf N, et al. Comparative analysis of methotrexate polyglutamates in lymphoblast preparations from bone marrow and blood, and the contribution of residual red blood cells JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY Volume: 126 Issue: 7 Pages: 407-411 Published: JUL 2000
- 2000, Fuskevag OM, Kristiansen C, Olsen R, et al. Microvascular perturbations in rats receiving the maximum tolerated dose of methotrexate or its major metabolite 7-hydroxymethotrexate ULTRASTRUCTURAL PATHOLOGY Volume: 24 Issue: 5 Pages: 325-332 Published: SEP-OCT 2000
- 2000, Muller-Ladner U, Nishioka K. p53 in rheumatoid arthritis: friend or foe? ARTHRITIS RESEARCH Volume: 2 Issue: 3 Pages: 175-178 Published: 2000
- 2000, Gambacorti-Passerini C, Barni R, le Coutre P, et al. Role of alpha 1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the Abl inhibitor STI571 JOURNAL OF THE NATIONAL CANCER INSTITUTE Volume: 92 Issue: 20 Pages: 1641-1650 Published: OCT 18 2000
- 2000, Rots MG, Pieters R, Kaspers GJL, et al. Classification of ex vivo methotrexate resistance in acute lymphoblastic and myeloid leukaemia BRITISH JOURNAL OF HAEMATOLOGY Volume: 110 Issue: 4 Pages: 791-800 Published: SEP 2000
- 2000, Takemura Y, Kobayashi H, Miyachi H. Raltitrexed, a novel folate-based thymidylate synthase inhibitor, for the treatment of acute leukemia: Is this drug active against acute myelogenous leukemia? INTERNATIONAL JOURNAL OF HEMATOLOGY Volume: 72 Issue: 1 Pages: 112-114 Published: JUL 2000
- 2000, Rots MG, Pieters R, Peters GJ, et al. Methotrexate resistance in relapsed childhood acute lymphoblastic leukaemia BRITISH JOURNAL OF HAEMATOLOGY Volume: 109 Issue: 3 Pages: 629-634 Published: JUN 2000
- 2000, Takebe N, Nakahara S, Zhao SC, et al. Comparison of methotrexate resistance conferred by a mutated dihydrofolate reductase (DHFR) cDNA in two different retroviral vectors CANCER GENE THERAPY Volume: 7 Issue: 6 Pages: 910-919 Published: JUN 2000
- 2000, Morganti M, Coronnello M, Caciagli B, et al. Modulation of dihydrofolate reductase gene expression in methotrexate-resistant human leukemia CCRF-CEM/E cells by antisense oligonucleotides ANTI-CANCER DRUGS Volume: 11 Issue: 4 Pages: 285-294 Published: APR 2000
- 2000, Mahoney DH, Shuster JJ, Nitschke R, et al. Intensification with intermediate-dose intravenous methotrexate is effective therapy for children with lower-risk B-precursor acute lymphoblastic leukemia: A pediatric oncology group study JOURNAL OF CLINICAL ONCOLOGY Volume: 18 Issue: 6 Pages: 1285-1294 Published: MAR 2000
- 2000, Jarvinen TAH, Tanner M, Rantanen V, et al. Amplification and deletion of topoisomerase II alpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer AMERICAN JOURNAL OF PATHOLOGY Volume: 156 Issue: 3 Pages: 839-847 Published: MAR 2000
- 2000, le Coutre P, Tassi E, Varella-Garcia M, et al. Induction of resistance to the Abelson inhibitor ST1571 in human leukemic cells through gene amplification BLOOD Volume: 95 Issue: 5 Pages: 1758-1766 Published: MAR 1 2000
- 2000, Leoni LM, Hamel E, Genini D, et al. Indanocine, a microtubule-binding indanone and a selective inducer of apoptosis in multidrug-resistant cancer cells JOURNAL OF THE NATIONAL CANCER INSTITUTE Volume: 92 Issue: 3 Pages: 217-224 Published: FEB 2 2000
- 2000, Barnes MJ, Taylor GA, Newell DR. Development of a whole cell assay to measure methotrexate-induced inhibition of thymidylate synthase and de novo purine synthesis in leukaemia cells BIOCHEMICAL PHARMACOLOGY Volume: 59 Issue: 4 Pages: 321-328 Published: FEB 15 2000
- 2000, Katzir I, Shani J, Wolf W, et al. Enhancement of 5-fluorouracil anabolism by methotrexate and trimetrexate in two rat solid tumor models, Walker 256 carcinosarcoma and Novikoff hepatoma, as evaluated by F-19-magnetic resonance spectroscopy CANCER INVESTIGATION Volume: 18 Issue: 1 Pages: 20-27 Published: 2000
- 2000, Renner S, Kuci Z, d'Cruze H, et al. Isotachophoretic analysis of the dihydrofolate reductase reaction in the presence of methotrexate and ascorbic acid ELECTROPHORESIS Volume: 21 Issue: 14 Pages: 2828-2833 Published: AUG 2000
- 2000, Weigand M, Frei E, Graf N, et al. Comparative analysis of methotrexate polyglutamates in lymphoblast preparations from bone marrow and blood, and the contribution of residual red blood cells JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY Volume: 126 Issue: 7 Pages: 407-411 Published: JUL 2000
- 2000, Rosowsky A, Wright JE, Vaidya CM, et al. The effect of side-chain, para-aminobenzoyl region, and B-ring modifications on dihydrofolate reductase binding, influx via the reduced folate carrier, and cytotoxicity of the potent nonpolyglutamatable antifolate N-alpha-(4-amino-4-deoxypteroyl)-N-delta-hemiphthaloyl-L-ornithine PHARMACOLOGY & THERAPEUTICS Volume: 85 Issue: 3 Pages: 191-205 Published: MAR 2000
- 1999, Comella P, Lorusso V, Casaretti R, et al. Concurrent modulation of 5-fluorouracil with methotrexate and L-leucovorin: An effective and moderately toxic regimen for the treatment of advanced colorectal carcinoma - A multicenter phase II study of the Southern Italy Cooperative Oncology Group TUMORI 85 (6): 465-472 NOV-DEC 1999
- 1999, Leamon CP, DePrince RB, Hendren RW Folate-mediated drug delivery: Effect of alternative conjugation chemistry JOURNAL OF DRUG TARGETING 7 (3): 157-169 1999
- 1999, Schmoll HJ, Buchele T, Grothey A, et al. Where do we stand with 5-fluorouracil? SEMINARS IN ONCOLOGY 26 (6): 589-605 DEC 1999
- 1999, Gorlick R, Bertino JR Drug resistance in colon cancer SEMINARS IN ONCOLOGY 26 (6): 606-611 DEC 1999
- 1999, Neuman MG, Cameron RG, Haber JA, et al. Inducers of cytochrome P450 2E1 enhance methotrexate-induced hepatocytotoxicity CLINICAL BIOCHEMISTRY 32 (7): 519-536 OCT 1999
- 1999, Klein HO, Demir G "Multi-enzyme-targeted" immunochemotherapy: A salvage therapy protocol ANTICANCER RESEARCH 19 (4C): 3451-3458 JUL-AUG 1999
- 1999, Rots MG, Pieters R, Peters GJ, et al. Circumvention of methotrexate resistance in childhood leukemia subtypes by rationally designed antifolates BLOOD 94 (9): 3121-3128 NOV 1 1999
- 1999, Lansiaux A, Degardin M, Bailly C A multitargeted antifolate (MTA) BULLETIN DU CANCER 86 (9): 727-731 SEP 1999
- 1999, Zhao RB, Gao F, Goldman ID Discrimination among reduced folates and methotrexate as transport substrates by a phenylalanine substitution for serine within the predicted eighth transmembrane domain of the reduced folate carrier BIOCHEMICAL PHARMACOLOGY 58 (10): 1615-1624 NOV 15 1999
- 1999, Royce ME, McGarry W, Bready B, et al. Sequential biochemical modulation of fluorouracil with folinic acid, N-phosphonacetyl-L-aspartic acid, and interferon alfa-2a in advanced colorectal cancer JOURNAL OF CLINICAL ONCOLOGY 17 (10): 3276-3282 OCT 1999
- 1999, Matherly LH, Taub JW Molecular and cellular correlates of methotrexate response in childhood acute lymphoblastic leukemia LEUKEMIA & LYMPHOMA 35 (1-2): 1-20 SEP 1999
- 1999, Kim R, Ohi Y, Inoue H, et al. Activation and the interaction of proapoptotic genes in modulating sensitivity to anticancer drugs in gastric cancer cells INTERNATIONAL JOURNAL OF ONCOLOGY 15 (4): 751-756 OCT 1999
- 1999, Bonavida B, Ng CP, Jazirehi A, et al. Selectivity of TRAIL-mediated apoptosis of cancer cells and synergy with drugs: The trail to non-toxic cancer therapeutics (Review) INTERNATIONAL JOURNAL OF ONCOLOGY 15 (4): 793-802 OCT 1999
- 1999, Evans WE, Pui CH, Relling MV Defining the optimal dosage of methotrexate for childhood acute lymphoblastic leukemia - New insights from the lab and clinic ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 457: 537-541 1999
- 1999, Gorlick R, Cole G, Banerjee D, et al. Mechanisms of methotrexate resistance in acute leukemia - Decreased transport and polyglutamylation ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 457: 543-550 1999
- 1999, Aguayo A, Cortes J, Thomas D, et al. Combination therapy with methotrexate, vincristine, polyethylene-glycol conjugated-asparaginase, and prednisone in the treatment of patients with refractory or recurrent acute lymphoblastic leukemia CANCER 86 (7): 1203-1209 OCT 1 1999
- 1999, Barnes MJ, Estlin EJ, Taylor GA, et al. Impact of polyglutamation on sensitivity to raltitrexed and methotrexate in relation to drug-induced inhibition of de novo thymidylate and purine biosynthesis in CCRF-CEM cell lines CLINICAL CANCER RESEARCH 5 (9): 2548-2558 SEP 1999
- 1999, Takemura Y, Kobayashi H, Miyachi H Variable expression of the folylpolyglutamate synthetase gene at the level of mRNA transcription in human leukemia cell lines sensitive, or made resistant, to various antifolate drugs ANTI-CANCER DRUGS 10 (7): 677-683 AUG 1999
- 1999, Weigand M, Frei E, Graf N, et al. Mechanisms of resistance to methotrexate in childhood acute lymphoblastic leukemia: circumvention of thymidylate synthase inhibition JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY 125 (8-9): 513-519 AUG-SEP 1999
- 1999, Drummond JT Genomic amplification of the human DHFR/MSH3 locus remodels mismatch recognition and repair activities ADVANCES IN ENZYME REGULATION 39: 129-141 1999
- 1999, Brito RA, Medgyesy D, Zukowski TH, et al. Fluoropyrimidines: A critical evaluation ONCOLOGY 57: 2-8 Suppl. 1 1999
- 1999, Ramanathan RK, Lipsitz S, Asbury RF, et al. Phase II trial of trimetrexate for patients with advanced gastric carcinoma - An Eastern Cooperative Oncology Group Study (E1287) CANCER 86 (4): 572-576 AUG 15 1999
- 1999, Zhao RB, Sharina IG, Goldman ID Pattern of mutations that results in loss of reduced folate carrier function under antifolate selective pressure augmented by chemical mutagenesis MOLECULAR PHARMACOLOGY 56 (1): 68-76 JUL 1999
- 1999, Gong MK, Cowan KH, Gudas J, et al. Isolation and characterization of genomic sequences involved in the regulation of the human reduced folate carrier gene (RFC1) GENE 233 (1-2): 21-31 JUN 11 1999
- 1999, Xu Y Capillary electrophoresis ANALYTICAL CHEMISTRY 71 (12): 309R-313R JUN 15 1999
- 1999, Hooijberg JH, Broxterman HJ, Kool M, et al. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2 CANCER RESEARCH 59 (11): 2532-2535 JUN 1 1999
- 1999, Kundig C, Haimeur A, Legare D, et al. Increased transport of pteridines compensates for mutations in the high affinity folate transporter and contributes to methotrexate resistance in the protozoan parasite Leishmania tarentolae EMBO JOURNAL 18 (9): 2342-2351 MAY 4 1999
- 1999, Trippett TM, Bertino JR Therapeutic strategies targeting proteins that regulate folate and reduced folate transport JOURNAL OF CHEMOTHERAPY 11 (1): 3-10 FEB 1999
- 1999, Garcia-Sanz R, Lopez-Perez R, Langerak AW, et al. Heteroduplex PCR analysis of rearranged immunoglobulin genes for clonality assessment in multiple myeloma HAEMATOLOGICA 84 (4): 328-335 APR 1999
- 1999, Carlson KM, Gruber A, Liliemark E, et al. Characterization of drug-resistant cell lines by comparative genomic hybridization CANCER GENETICS AND CYTOGENETICS 111 (1): 32-36 MAY 1999
- 1999, Wong SC, Zhang L, Witt TL, et al. Impaired membrane transport in methotrexate-resistant CCRF-CEM cells involves early translation termination and increased turnover of a mutant reduced folate carrier JOURNAL OF BIOLOGICAL CHEMISTRY 274 (15): 10388-10394 APR 9 1999
- 1999, Burke GAA, Estlin EJ, Lowis SP The role of pharmacokinetic and pharmacodynamic studies in the planning of protocols for the treatment of childhood cancer CANCER TREATMENT REVIEWS 25 (1): 13-27 FEB 1999
- 1999, Silvis NG, Levine N Pulse dosing of thioguanine in recalcitrant psoriasis ARCHIVES OF DERMATOLOGY 135 (4): 433-437 APR 1999
- 1999, Pangalos MN, Neefs JM, Somers M, et al. Isolation and expression of novel human glutamate carboxypeptidases with N-acetylated alpha-linked acidic dipeptidase and dipeptidyl peptidase IV activity JOURNAL OF BIOLOGICAL CHEMISTRY 274 (13): 8470-8483 MAR 26 1999
- 1999, Guo W, Healey JH, Meyers PA, et al. Mechanisms of methotrexate resistance in osteosarcoma CLINICAL CANCER RESEARCH 5 (3): 621-627 MAR 1999
- 1999, Wahid F, Monneret C, Dauzonne D Synthesis and biological evaluation of 5-arylfuro[2,3-d]pyrimidines as novel dihydrofolate reductase inhibitors CHEMICAL & PHARMACEUTICAL BULLETIN 47 (2): 156-164 FEB 1999
- 1999, Sun XL, Jayaram HN, Gharehbaghi K, et al. Modulation of the cytotoxicity of 3 '-azido-3 '-deoxythymidine and methotrexate after transduction of folate receptor cDNA into human cervical carcinoma: Identification of a correlation between folate receptor expression and thymidine kinase activity CANCER RESEARCH 59 (4): 940-946 FEB 15 1999
- 1999, Belkov VM, Krynetski EY, Schuetz JD, et al. Reduced folate carrier expression in acute lymphoblastic leukemia: A mechanism for ploidy but not lineage differences in methotrexate accumulation BLOOD 93 (5): 1643-1650 MAR 1 1999
- 1999, Rots MG, Pieters R, Peters GJ, et al. Role of folylpolyglutamate synthetase and folylpolyglutamate hydrolase in methotrexate accumulation and polyglutamylation in childhood leukemia BLOOD 93 (5): 1677-1683 MAR 1 1999
- 1999, Bodey B, Bodey B, Siegel SE Tumor suppressor genes in childhood malignancies: A review INTERNATIONAL JOURNAL OF PEDIATRIC HEMATOLOGY/ONCOLOGY 6 (1): 47+ 1999
- 1999, Rots MG, Pieters R, Kaspers GJL, et al. Differential methotrexate resistance in childhood T- versus common/PreB-acute lymphoblastic leukemia can be measured by an in situ thymidylate synthase inhibition assay, but not by the MTT assay BLOOD 93 (3): 1067-1074 FEB 1 1999
- 1999, Koivisto PA, Rantala I Amplification of the androgen receptor gene is associated with p53 mutation in hormone-refractory recurrent prostate cancer JOURNAL OF PATHOLOGY 187 (2): 237-241 JAN 1999
- 1999, Weigand M, Frei E, Graf N, et al. Mechanisms of resistance to methotrexate in childhood acute lymphoblastic leukemia: circumvention of thymidylate synthase inhibition OURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY Volume: 125 Issue: 8-9 Pages: 513-519 Published: AUG-SEP 1999
- 1999, Leamon CP, DePrince RB, Hendren RW. Folate-mediated drug delivery: Effect of alternative conjugation chemistry JOURNAL OF DRUG TARGETING Volume: 7 Issue: 3 Pages: 157-169 Published: 1999
- 1999, Klein HO, Demir G. 'Multi-enzyme-targeted' immunochemotherapy: A salvage therapy protocol ANTICANCER RESEARCH Volume: 19 Issue: 4C Pages: 3451-3458 Published: JUL-AUG 1999
- 1999, Carlson KM, Gruber A, Liliemark E, et al. Characterization of drug-resistant cell lines by comparative genomic hybridization CANCER GENETICS AND CYTOGENETICS Volume: 111 Issue: 1 Pages: 32-36 Published: MAY 1999
- 1999, Pangalos MN, Neefs JM, Somers M, et al. Isolation and expression of novel human glutamate carboxypeptidases with N-acetylated alpha-linked acidic dipeptidase and dipeptidyl peptidase IV activity JOURNAL OF BIOLOGICAL CHEMISTRY Volume: 274 Issue: 13 Pages: 8470-8483 Published: MAR 26 1999
- 1999, Bodey B, Bodey B, Siegel SE. Tumor suppressor genes in childhood malignancies: A review INTERNATIONAL JOURNAL OF PEDIATRIC HEMATOLOGY/ONCOLOGY Volume: 6 Issue: 1 Pages: 47-+ Published: 1999
- 1999, Gorlick R, Bertino JR. Drug resistance in colon cancer SEMINARS IN ONCOLOGY Volume: 26 Issue: 6 Pages: 606-611 Published: DEC 1999
- 1999, Rots MG, Pieters R, Peters GJ, et al. Circumvention of methotrexate resistance in childhood leukemia subtypes by rationally designed antifolates BLOOD Volume: 94 Issue: 9 Pages: 3121-3128 Published: NOV 1 1999
- 1999, Matherly LH, Taub JW. Molecular and cellular correlates of methotrexate response in childhood acute lymphoblastic leukemia LEUKEMIA & LYMPHOMA Volume: 35 Issue: 1-2 Pages: 1-20 Published: SEP 1999
- 1999, Kim R, Ohi Y, Inoue H, et al. Activation and the interaction of proapoptotic genes in modulating sensitivity to anticancer drugs in gastric cancer cells INTERNATIONAL JOURNAL OF ONCOLOGY Volume: 15 Issue: 4 Pages: 751-756 Published: OCT 1999
- 1999, Gorlick R, Cole G, Banerjee D, et al. Mechanisms of methotrexate resistance in acute leukemia - Decreased transport and polyglutamylation DRUG RESISTANCE IN LEUKEMIA AND LYMPHOMA III Book Series: ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY Volume: 457 Pages: 543-550 Published: 1999
- 1999, Drummond JT. Genomic amplification of the human DHFR/MSH3 locus remodels mismatch recognition and repair activities ADVANCES IN ENZYME REGULATION, VOL 39 Book Series: ADVANCES IN ENZYME REGULATION Volume: 39 Pages: 129-141 Published: 1999
- 1999, Guo W, Healey JH, Meyers PA, et al. Mechanisms of methotrexate resistance in osteosarcoma CLINICAL CANCER RESEARCH Volume: 5 Issue: 3 Pages: 621-627 Published: MAR 1999
- 1999, Koivisto PA, Rantala I. Amplification of the androgen receptor gene is associated with p53 mutation in hormone-refractory recurrent prostate cancer JOURNAL OF PATHOLOGY Volume: 187 Issue: 2 Pages: 237-241 Published: JAN 1999
- 1999, Trippett TM, Bertino JR. Therapeutic strategies targeting proteins that regulate folate and reduced folate transport JOURNAL OF CHEMOTHERAPY Volume: 11 Issue: 1 Pages: 3-10 Published: FEB 1999
- 1999, Rots MG, Pieters R, Peters GJ, et al. : Role of folylpolyglutamate synthetase and folylpolyglutamate hydrolase in methotrexate accumulation and polyglutamylation in childhood leukemia BLOOD Volume: 93 Issue: 5 Pages: 1677-1683 Published: MAR 1 1999
- 1999, Silvis NG, Levine N. Pulse dosing of thioguanine in recalcitrant psoriasis ARCHIVES OF DERMATOLOGY Volume: 135 Issue: 4 Pages: 433-437 Published: APR 1999
- 1998, Ouellette M, Leblanc E, Kundig C, et al. Antifolate resistance mechanisms from bacteria to cancer cells with emphasis on parasites ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 456: 99-113 1998
- 1998, Williams FMR, Flintoff WF Structural organization of the human reduced folate carrier gene: Evidence for 5 ' heterogeneity in lymphoblast mRNA SOMATIC CELL AND MOLECULAR GENETICS 24 (3): 143-156 MAY 1998
- 1998, Vladimirskaya EB, Kislyak NS, Rumyantsev AG Drug resistance in leukemia and lymphomas in children: causes and correction. GEMATOLOGIYA I TRANSFUZIOLOGIYA 43 (6): 3-7 NOV-DEC 1998
- 1998, Scotto KW, Egan DA Transcriptional regulation of MDR genes CYTOTECHNOLOGY 27 (1-3): 257-269 1998
- 1998, Sprecher E, Bergman R, Sprecher H, et al. Reduced folate carrier (RFC-1) gene expression in normal and psoriatic skin ARCHIVES OF DERMATOLOGICAL RESEARCH 290 (12): 656-660 DEC 1998
- 1998, Hum M, Holcenberg JS, Tkaczewski I, et al. High-dose trimetrexate and minimal-dose leucovorin: A case for selective protection CLINICAL CANCER RESEARCH 4 (12): 2981-2984 DEC 1998
- 1998, Eres N, Bellmunt J Regulatory proteins of the cell cycle: Alterations in the cyclin C1 route as a paradigm. Findings in breast cancer MEDICINA CLINICA 111 (15): 592-596 NOV 7 1998
- 1998, Jansen G, Mauritz R, Drori S, et al. A structurally altered human reduced folate carrier with increased folic acid transport mediates a novel mechanism of antifolate resistance JOURNAL OF BIOLOGICAL CHEMISTRY 273 (46): 30189-30198 NOV 13 1998
- 1998, Ferraccioli GF, Bartoli E Xenobiotics or biological response modifiers? Methotrexate remains the anchor drug for rheumatoid arthritis CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 16 (6): 662-666 NOV-DEC 1998
- 1998, Henderson CA Therapeutic options for the treatment of colorectal cancer following 5-fluorouracil failure SEMINARS IN ONCOLOGY 25 (5): 29-38 Suppl. 11 OCT 1998
- 1998, Wong SC, Zhang L, Proefke SA, et al. Effects of the loss of capacity for N-glycosylation on the transport activity and cellular localization of the human reduced folate carrier BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES 1375 (1-2): 6-12 OCT 15 1998
- 1998, Jansen G, Pieters R The role of impaired transport in (pre)clinical resistance to methotrexate: insights on new antifolates DRUG RESISTANCE UPDATES 1 (3): 211-218 1998
- 1998, Papadopoulou B, Kundig C, Singh A, et al. Drug resistance in Leishmania: similarities and differences to other organisms DRUG RESISTANCE UPDATES 1 (4): 266-278 1998
- 1998, Mauritz R, Bekkenk MW, Rots MG, et al. Ex vivo activity of methotrexate versus novel antifolate inhibitors of dihydrofolate reductase and thymidylate synthase against childhood leukemia cells CLINICAL CANCER RESEARCH 4 (10): 2399-2410 OCT 1998
- 1998, Gifford AJ, Kavallaris M, Madafiglio J, et al. P-Glycoprotein-mediated methotrexate resistance in CCRF-CEM sublines deficient in methotrexate accumulation due to a point mutation in the reduced folate carrier gene INTERNATIONAL JOURNAL OF CANCER 78 (2): 176-181 OCT 5 1998
- 1998, Thibodeau PA, Bissonnette N, Bedard SK, et al. Induction by estrogens of methotrexate resistance in MCF-7 breast cancer cells CARCINOGENESIS 19 (9): 1545-1552 SEP 1998
- 1998, Zhang L, Taub JW, Williamson M, et al. Reduced folate carrier gene expression in childhood acute lymphoblastic leukemia: Relationship to immunophenotype and ploidy CLINICAL CANCER RESEARCH 4 (9): 2169-2177 SEP 1998
- 1998, Sprecher E, Bergman R, Sprecher H, et al. The reduced folate carrier (RFC-1) gene is expressed in the murine epidermis ARCHIVES OF DERMATOLOGICAL RESEARCH 290 (7): 394-396 JUL 1998
- 1998, Kaye SB New antimetabolites in cancer chemotherapy and their clinical impact BRITISH JOURNAL OF CANCER 78: 1-7 Suppl. 3 1998
- 1998, Calvert AH, Walling JM Clinical studies with MTA BRITISH JOURNAL OF CANCER 78: 35-40 Suppl. 3 1998
- 1998, Moscow JA Methotrexate transport and resistance LEUKEMIA & LYMPHOMA 30 (3-4): 215-224 JUL 1998
- 1998, Punt CJA New drugs in the treatment of colorectal carcinoma CANCER 83 (4): 679-689 AUG 15 1998
- 1998, Marra G, Iaccarino I, Lettieri T, et al. Mismatch repair deficiency associated with overexpression of the MSH3 gene PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 95 (15): 8568-8573 JUL 21 1998
- 1998, Zhao R, Assaraf YG, Goldman ID A mutated murine reduced folate carrier (RFC1) with increased affinity for folic acid, decreased affinity for methotrexate, and an obligatory anion requirement for transport function JOURNAL OF BIOLOGICAL CHEMISTRY 273 (30): 19065-19071 JUL 24 1998
- 1998, Farrugia DC, Norman AR, Cunningham D Single agent infusional 5-fluorouracil is not effective second-line therapy after raltitrexed (Tomudex (R)) in advanced colorectal cancer EUROPEAN JOURNAL OF CANCER 34 (7): 987-991 JUN 1998
- 1998, Zhang L, Wong SC, Matherly LH Transcript heterogeneity of the human reduced folate carrier results from the use of multiple promoters and variable splicing of alternative upstream exons BIOCHEMICAL JOURNAL 332: 773-780 Part 3 JUN 15 1998
- 1998, Prokocimer M, Unger R, Rennert HS, et al. Pooled analysis of p53 mutations in hematological malignancies HUMAN MUTATION 12 (1): 4-18 1998
- 1998, Tang JL, Tien HF, Lin MT, et al. Frequent p53 mutation in relapsed acute lymphoblastic leukemia with cytogenetic instability: A longitudinal analysis ANTICANCER RESEARCH 18 (2B): 1273-1278 MAR-APR 1998
- 1998, Kamm YJL, Wagener DJT, Rietjens IMCM, et al. 5-fluorouracil in colorectal cancer: rationale and clinical results of frequently used schedules ANTI-CANCER DRUGS 9 (5): 371-380 JUN 1998
- 1998, Navaratnam S, Williams GJ, Rubinger M, et al. Expression of P53 predicts treatment failure in aggressive non-Hodgkin's lymphomas LEUKEMIA & LYMPHOMA 29 (1-2): 139-144 MAR 1998
- 1998, Chessells JM, Hall E, Prentice HG, et al. The impact of age on outcome in lymphoblastic leukaemia: MRC UKALL X and XA compared: a report from the MRC Paediatric and Adult Working Parties LEUKEMIA 12 (4): 463-473 APR 1998
- 1998, Bassan R Randomized clinical trials in adult acute lymphoblastic leukemia: which is the question? HAEMATOLOGICA 83 (3): 193-196 MAR 1998
- 1998, Ribera JM, Ortega UJ, Oriol A, et al. Late intensification chemotherapy has not improved the results of intensive chemotherapy in adult acute lymphoblastic leukemia. Results of a prospective multicenter randomized trial (PETHEMA ALL-89) HAEMATOLOGICA 83 (3): 222-230 MAR 1998
- 1998, Ardalan B, Luis R, Jaime M, et al. Biomodulation of fluorouracil in colorectal cancer CANCER INVESTIGATION 16 (4): 237-251 1998
- 1998, Ek O, Reaman GH, Crankshaw DL, et al. Combined therapeutic efficacy of the thymidylate synthase inhibitor ZD1694 (TOMUDEX) and the immunotoxin B43(anti-CD19)-PAP in a SCID mouse model of human B-lineage acute lymphoblastic leukemia LEUKEMIA & LYMPHOMA 28 (5-6): 509-514 FEB 1998
- 1998, Gorlick R, Metzger R, Danenberg KD, et al. Higher levels of thymidylate synthase gene expression are observed in pulmonary as compared with hepatic metastases of colorectal adenocarcinoma JOURNAL OF CLINICAL ONCOLOGY 16 (4): 1465-1469 APR 1998
- 1998, Zhao RB, Assaraf YG, Goldman ID A reduced folate carrier mutation produces substrate-dependent alterations in carrier mobility in murine leukemia cells and methotrexate resistance with conservation of growth in 5-formyltetrahydrofolate JOURNAL OF BIOLOGICAL CHEMISTRY 273 (14): 7873-7879 APR 3 1998
- 1998, Kinsella AR, Smith D Tumor resistance to antimetabolites GENERAL PHARMACOLOGY-THE VASCULAR SYSTEM 30 (5): 623-626 MAY 1998
- 1998, Grude P, Conti F, Molinier N, et al. Mechanisms of resistance to anticancer drugs in digestive cancers. GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE 22 (2): 132-143 FEB 1998
- 1998, Blakley RL, Sorrentino BP In vitro mutations in dihydrofolate reductase that confer resistance to methotrexate: Potential for clinical application HUMAN MUTATION 11 (4): 259-263 1998
- 1998, Wallace CA The use of methotrexate in childhood rheumatic diseases ARTHRITIS AND RHEUMATISM 41 (3): 381-391 MAR 1998
- 1998, Sauerbrey A, Stammler G, Zintl F, et al. Expression of the retinoblastoma tumor suppressor gene (RB-1) in acute leukemia LEUKEMIA & LYMPHOMA 28 (3-4): 275-+ JAN 1998
- 1998, Longo GSA, Izzo J, Chang YM, et al. Pretreatment of colon carcinoma cells with tomudex enhances 5-fluorouracil cytotoxicity CLINICAL CANCER RESEARCH 4 (2): 469-473 FEB 1998
- 1998, Uckun FM, Sensel MG, Sun L, et al. Biology and treatment of childhood T-lineage acute lymphoblastic leukemia BLOOD 91 (3): 735-746 FEB 1 1998
- 1998, Shen DW, Pastan I, Gottesman MM Cross-resistance to methotrexate and metals in human cisplatin-resistant cell lines results from a pleiotropic defect in accumulation of these compounds associated with reduced plasma membrane binding proteins CANCER RESEARCH 58 (2): 268-275 JAN 15 1998
- 1998, Aherne GW, Ward E, Lawrence N, et al. Comparison of plasma and tissue levels of ZD1694 (Tomudex), a highly polyglutamatable quinazoline thymidylate synthase inhibitor, in preclinical models BRITISH JOURNAL OF CANCER 77 (2): 221-226 JAN 1998
- 1998, Chang AY, Kim K, Boucher H, et al. A randomized phase II trial of echinomycin, trimetrexate, and cisplatin plus etoposide in patients with metastatic nonsmall cell lung carcinoma - An Eastern Cooperative Oncology Group Study (E1587) CANCER 82 (2): 292-300 JAN 15 1998
- 1998, Koivisto P, Kolmer M, Visakorpi T, et al. Androgen receptor gene and hormonal therapy failure of prostate cancer AMERICAN JOURNAL OF PATHOLOGY 152 (1): 1-9 JAN 1998
- 1998, Ek O, Reaman GH, Crankshaw DL, et al. Combined therapeutic efficacy of the thymidylate synthase inhibitor ZD1694 (TOMUDEX) and the immunotoxin B43(anti-CD19)-PAP in a SCID mouse model of human B-lineage acute lymphoblastic leukemia LEUKEMIA & LYMPHOMA Volume: 28 Issue: 5-6 Pages: 509-514 Published: FEB 1998
- 1998, Scotto KW, Egan DA. Transcriptional regulation of MDR genes CYTOTECHNOLOGY Volume: 27 Issue: 1-3 Pages: 257-269 Published: 1998
- 1998, Ouellette M, Leblanc E, Kundig C, et al. Antifolate resistance mechanisms from bacteria to cancer cells with emphasis on parasites RESOLVING THE ANTIBIOTIC PARADOX - PROGRESS IN UNDERSTANDING DRUG RESISTANCE AND DEVELOPMENT OF NEW ANTIBIOTICS Book Series: ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY Volume: 456 Pages: 99-113 Published: 1998
- 1998, Mauritz R, Bekkenk MW, Rots MG, et al. Ex vivo activity of methotrexate versus novel antifolate inhibitors of dihydrofolate reductase and thymidylate synthase against childhood leukemia cells CLINICAL CANCER RESEARCH Volume: 4 Issue: 10 Pages: 2399-2410 Published: OCT 1998
- 1998, Thibodeau PA, Bissonnette N, Bedard SK, et al. Induction by estrogens of methotrexate resistance in MCF-7 breast cancer cells CARCINOGENESIS Volume: 19 Issue: 9 Pages: 1545-1552 Published: SEP 1998
- 1998, Prokocimer M, Unger R, Rennert HS, et al. Pooled analysis of p53 mutations in hematological malignancies HUMAN MUTATION Volume: 12 Issue: 1 Pages: 4-18 Published: 1998
- 1998, Tang JL, Tien HF, Lin MT, et al. Frequent p53 mutation in relapsed acute lymphoblastic leukemia with cytogenetic instability: A longitudinal analysis ANTICANCER RESEARCH Volume: 18 Issue: 2B Pages: 1273-1278 Published: MAR-APR 1998
- 1998, Navaratnam S, Williams GJ, Rubinger M, et al. Expression of P53 predicts treatment failure in aggressive non-Hodgkin's lymphomas LEUKEMIA & LYMPHOMA Volume: 29 Issue: 1-2 Pages: 139-144 Published: MAR 1998
- 1998, Gorlick R, Metzger R, Danenberg KD, et al. Higher levels of thymidylate synthase gene expression are observed in pulmonary as compared with hepatic metastases of colorectal adenocarcinoma JOURNAL OF CLINICAL ONCOLOGY Volume: 16 Issue: 4 Pages: 1465-1469 Published: APR 1998
- 1998, Kinsella AR, Smith D. Tumor resistance to antimetabolites GENERAL PHARMACOLOGY-THE VASCULAR SYSTEM Volume: 30 Issue: 5 Pages: 623-626 Published: MAY 1998
- 1998, Koivisto P, Kolmer M, Visakorpi T, et al. Androgen receptor gene and hormonal therapy failure of prostate cancer AMERICAN JOURNAL OF PATHOLOGY Volume: 152 Issue: 1 Pages: 1-9 Published: JAN 1998
- 1998, Hum M, Holcenberg JS, Tkaczewski I, et al. High-dose trimetrexate and minimal-dose leucovorin: A case for selective protection CLINICAL CANCER RESEARCH Volume: 4 Issue: 12 Pages: 2981-2984 Published: DEC 1998
- 1997, Hall MJ, Lawrence DA, Lansiedel JC, et al. Long-term exposure to methotrexate induces immunophenotypic changes, decreased methotrexate uptake and increased dihydrofolate gene copy number in jurkat T cells INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY 19 (11-12): 709-720 NOV-DEC 1997
- 1997, Whitehead VM Sensitivity and resistance to methotrexate in childhood B-progenitor cell acute lymphoblastic leukemia INTERNATIONAL JOURNAL OF PEDIATRIC HEMATOLOGY/ONCOLOGY 4 (6): 543-552 1997
- 1997, Langerak AW, Szczepanski T, van der Burg M, et al. Heteroduplex PCR analysis of rearranged T cell receptor genes for clonality assessment in suspect T cell proliferations LEUKEMIA 11 (12): 2192-2199 DEC 1997
- 1997, Takemura Y, Kobayashi H, Miyachi H Cellular and molecular mechanisms of resistance to antifolate drugs: new analogues and approaches to overcome the resistance INTERNATIONAL JOURNAL OF HEMATOLOGY 66 (4): 459-477 DEC 1997
- 1997, Kamen B Folate and antifolate pharmacology SEMINARS IN ONCOLOGY 24 (5): 30-39 Suppl. 18 OCT 1997
- 1997, Bertino JR Biomodulation of 5-fluorouracil with antifolates SEMINARS IN ONCOLOGY 24 (5): 52-56 Suppl. 18 OCT 1997
- 1997, Blanke CD, Messenger M, Taplin SC Trimetrexate: Review and current clinical experience in advanced colorectal cancer SEMINARS IN ONCOLOGY 24 (5): 57-63 Suppl. 18 OCT 1997
- 1997, Cheon J, Ko SC, Gardner TA, et al. Chemogene therapy: Osteocalcin promoter-based suicide gene therapy in combination with methotrexate in a murine osteosarcoma model CANCER GENE THERAPY 4 (6): 359-365 NOV-DEC 1997
- 1997, Chen ZH, Olopade OI, Savarese TM Expression of methylthioadenosine phosphorylase cDNA in p16(-), MTAP(-) malignant cells: Restoration of methylthioadenosine phosphorylase-dependent salvage pathways and alterations of sensitivity to inhibitors of purine de novo synthesis MOLECULAR PHARMACOLOGY 52 (5): 903-911 NOV 1997
- 1997, Pinzani P, Carotti S, Gerli A, et al. Evaluation of methotrexate sensitivity in human leukemia cell lines by an adenosine triphosphate bioluminescence assay ANTI-CANCER DRUGS 8 (8): 767-777 SEP 1997
- 1997, Galipeau J, Benaim E, Spencer HT, et al. A bicistronic retroviral vector for protecting hematopoietic cells against antifolates and P-glycoprotein effluxed drugs HUMAN GENE THERAPY 8 (15): 1773-1783 OCT 10 1997
- 1997, Miyachi H, Takemura Y, Kobayashi H, et al. Cytotoxicity of trimetrexate against antifolate-resistant human T-cell leukemia cell lines developed in oxidized or reduced folate JAPANESE JOURNAL OF CANCER RESEARCH 88 (9): 900-906 SEP 199
- 1997, Savchenko VG, Parovichnikova EN, Isaev VG, et al. Treatment of acute lymphoblastic leukemia in adults TERAPEVTICHESKII ARKHIV 69 (7): 5-11 1997
- 1997, Karp JE Acute leukemia: Mechanisms of cell survival as targets for therapy (Review) INTERNATIONAL JOURNAL OF ONCOLOGY 11 (4): 657-674 OCT 1997
- 1997, Preudhomme C, Fenaux P The clinical significance of mutations of the P53 tumour suppressor gene in haematological malignancies BRITISH JOURNAL OF HAEMATOLOGY 98 (3): 502-511 SEP 1997
- 1997, Longo GSA, Gorlick R, Tong WP, et al. gamma-glutamyl hydrolase and folylpolyglutamate synthetase activities predict polyglutamylation of methotrexate in acute leukemias ONCOLOGY RESEARCH 9 (5): 259-263 1997
- 1997, Brisco MJ, Sykes PJ, Dolman G, et al. Effect of the Philadelphia chromosome on minimal residual disease in acute lymphoblastic leukemia LEUKEMIA 11 (9): 1497-1500 SEP 1997
- 1997, Kakihara T, Fukuda T, Kamishima T, et al. Resistance to apoptosis induced by serum depletion and all-trans retinoic acid in drug-resistant leukemic cell lines LEUKEMIA & LYMPHOMA 26 (3-4): 369-376 JUL 1997
- 1997, Isacoff WH, Borud K Chemotherapy for the treatment of patients with metastatic colorectal cancer: An overview WORLD JOURNAL OF SURGERY 21 (7): 748-762 SEP 1997
- 1997, Matherly LH, Taub JW, Wong SC, et al. Increased frequency of expression of elevated dihydrofolate reductase in T-cell versus B-precursor acute lymphoblastic leukemia in children BLOOD 90 (2): 578-589 JUL 15 1997
- 1997, Punt CJA, Kamm YL, Wagener DJT Weekly chronomodulated 48 h infusion of high-dose 5-fluorouracil modulated by methotrexate and (6S)-leucovorin in advanced colorectal cancer: A phase IB study ANTI-CANCER DRUGS 8 (5): 454-458 JUN 1997
- 1997, Galpin AJ, Schuetz JD, Masson E, et al. Differences in folylpolyglutamate synthetase and dihydrofolate reductase expression in human B-lineage versus T-lineage leukemic lymphoblasts: Mechanisms for lineage differences in methotrexate polyglutamylation and cytotoxicity MOLECULAR PHARMACOLOGY 52 (1): 155-163 JUL 1997
- 1997, Argiris A, Longo GSA, Gorlick R, et al. Increased methotrexate polyglutamylation in acute megakaryocytic leukemia (M7) compared to other subtypes of acute myelocytic leukemia LEUKEMIA 11 (6): 886-889 JUN 1997
- 1997, Thyss A, Suciu S, Bertrand Y, et al. Systemic effect of intrathecal methotrexate during the initial phase of treatment of childhood acute lymphoblastic leukemia JOURNAL OF CLINICAL ONCOLOGY 15 (5): 1824-1830 MAY 1997
- 1997, Waltham MC, Li WW, Gritsman H, et al. gamma-glutamyl hydrolase from human sarcoma HT-1080 cells: Characterization and inhibition by glutamine antagonists MOLECULAR PHARMACOLOGY 51 (5): 825-832 MAY 1997
- 1997, Fan JG, Banerjee D, Stambrook PJ, et al. Modulation of cytotoxicity of chemotherapeutic drugs by activated H-ras BIOCHEMICAL PHARMACOLOGY 53 (8): 1203-1209 APR 25 1997
- 1997, Waltham MC, Lin SL, Li WW, et al. Capillary electrophoresis of methotrexate polyglutamates and its application in evaluation of gamma-glutamyl hydrolase activity JOURNAL OF CHROMATOGRAPHY B 689 (2): 387-392 FEB 21 1997
- 1997, Blanke CD, Kasimis B, Schein P, et al. Phase II study of trimetrexate, fluorouracil, and leucovorin for advanced colorectal cancer JOURNAL OF CLINICAL ONCOLOGY 15 (3): 915-920 MAR 1997
- 1997, Pieters R, Klumper E, Kaspers GJL, et al. Everything you always wanted to know about cellular drug resistance in childhood acute lymphoblastic leukemia CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY 25 (1): 11-26 JAN 1997
- 1997, Thandla S, Aplan PD Molecular biology of acute lymphocytic leukemia SEMINARS IN ONCOLOGY 24 (1): 45-56 FEB 1997
- 1997, Gorlick R, Goker E, Trippett T, et al. Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression BLOOD 89 (3): 1013-1018 FEB 1 1997
- 1997, Burnett AK, Eden OB The treatment of acute leukaemia LANCET 349 (9047): 270-275 JAN 25 1997
- 1997, Koivisto P, Kononen J, Palmberg C, et al. Androgen receptor gene amplification: A possible molecular mechanism for androgen deprivation therapy failure in prostate cancer CANCER RESEARCH 57 (2): 314-319 JAN 15 1997
- 1997, Sobrero AF, Aschele C, Bertino JR Fluorouracil in colorectal cancer a tale of two drugs: Implications for biochemical modulation JOURNAL OF CLINICAL ONCOLOGY 15 (1): 368-381 JAN 1997
- 1997, VanHalteren HK, Wagener DJT, Vreugdenhil G, et al. Advanced colorectal cancer, refractory to infusional fluorouracil treatment: Efficacy of second line fluorouracil in combination with a different biochemical modulation ANTICANCER RESEARCH 17 (4A): 2715-2719 JUL-AUG 1997
- 1997, Longo GSA, Gorlick R, Tong WP, et al. Disparate affinities of antifolates for folylpolyglutamate synthetase from human leukemia cells BLOOD 90 (3): 1241-1245 AUG 1 1997
- 1997, Sadelain M Genetic treatment of the haemogloinopathies: Recombinations and new combinations BRITISH JOURNAL OF HAEMATOLOGY 98 (2): 247-253 AUG 1997
- 1997, Hall MJ, Lawrence DA, Lansiedel JC, et al. Long-term exposure to methotrexate induces immunophenotypic changes, decreased methotrexate uptake and increased dihydrofolate gene copy number in jurkat T cells INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY Volume: 19 Issue: 11-12 Pages: 709-720 Published: NOV-DEC 1997
- 1997, Fan JG, Banerjee D, Stambrook PJ, et al. Modulation of cytotoxicity of chemotherapeutic drugs by activated H-ras BIOCHEMICAL PHARMACOLOGY Volume: 53 Issue: 8 Pages: 1203-1209 Published: APR 25 1997
- 1997, Chen ZH, Olopade OI, Savarese TM. Expression of methylthioadenosine phosphorylase cDNA in p16(-), MTAP(-) malignant cells: Restoration of methylthioadenosine phosphorylase-dependent salvage pathways and alterations of sensitivity to inhibitors of purine de novo synthesis MOLECULAR PHARMACOLOGY Volume: 52 Issue: 5 Pages: 903-911 Published: NOV 1997
- 1997, Pinzani P, Carotti S, Gerli A, et al. Evaluation of methotrexate sensitivity in human leukemia cell lines by an adenosine triphosphate bioluminescence assay ANTI-CANCER DRUGS Volume: 8 Issue: 8 Pages: 767-777 Published: SEP 1997
- 1997, Karp JE. Acute leukemia: Mechanisms of cell survival as targets for therapy (Review) INTERNATIONAL JOURNAL OF ONCOLOGY Volume: 11 Issue: 4 Pages: 657-674 Published: OCT 1997
- 1997, Preudhomme C, Fenaux P. The clinical significance of mutations of the P53 tumour suppressor gene in haematological malignancies BRITISH JOURNAL OF HAEMATOLOGY Volume: 98 Issue: 3 Pages: 502-511 Published: SEP 1997
- 1997, Kakihara T, Fukuda T, Kamishima T, et al. Resistance to apoptosis induced by serum depletion and all-trans retinoic acid in drug-resistant leukemic cell lines LEUKEMIA & LYMPHOMA Volume: 26 Issue: 3-4 Pages: 369-376 Published: JUL 1997
- 1997, Matherly LH, Taub JW, Wong SC, et al.Increased frequency of expression of elevated dihydrofolate reductase in T-cell versus B-precursor acute lymphoblastic leukemia in children BLOOD Volume: 90 Issue: 2 Pages: 578-589 Published: JUL 15 1997
- 1997, Waltham MC, Li WW, Gritsman H, et al. gamma-glutamyl hydrolase from human sarcoma HT-1080 cells: Characterization and inhibition by glutamine antagonists MOLECULAR PHARMACOLOGY Volume: 51 Issue: 5 Pages: 825-832 Published: MAY 1997
- 1997, Waltham MC, Lin SL, Li WW, et al. Capillary electrophoresis of methotrexate polyglutamates and its application in evaluation of gamma-glutamyl hydrolase activity JOURNAL OF CHROMATOGRAPHY B Volume: 689 Issue: 2 Pages: 387-392 Published: FEB 21 1997
- 1997, Pieters R, Klumper E, Kaspers GJL, et al.Everything you always wanted to know about cellular drug resistance in childhood acute lymphoblastic leukemia CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY Volume: 25 Issue: 1 Pages: 11-26 Published: JAN 1997
- 1997, Gorlick R, Goker E, Trippett T, et al. Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression BLOOD Volume: 89 Issue: 3 Pages: 1013-1018 Published: FEB 1 1997
- 1997, Koivisto P, Kononen J, Palmberg C, et al. Androgen receptor gene amplification: A possible molecular mechanism for androgen deprivation therapy failure in prostate cancer CANCER RESEARCH Volume: 57 Issue: 2 Pages: 314-319 Published: JAN 15 1997
- 1997, Takemura Y, Kobayashi H, Miyachi H. Cellular and molecular mechanisms of resistance to antifolate drugs: new analogues and approaches to overcome the resistance INTERNATIONAL JOURNAL OF HEMATOLOGY Volume: 66 Issue: 4 Pages: 459-477 Published: DEC 1997
- 1997, Kamen B. Folate and antifolate pharmacology SEMINARS IN ONCOLOGY Volume: 24 Issue: 5 Pages: 30-39 Supplement: Suppl. 18 Published: OCT 1997
- 1997, Galipeau J, Benaim E, Spencer HT, et al. A bicistronic retroviral vector for protecting hematopoietic cells against antifolates and P-glycoprotein effluxed drugs HUMAN GENE THERAPY Volume: 8 Issue: 15 Pages: 1773-1783 Published: OCT 10 1997
- 1997, Longo GSA, Gorlick R, Tong WP, et al. Disparate affinities of antifolates for folylpolyglutamate synthetase from human leukemia cells BLOOD Volume: 90 Issue: 3 Pages: 1241-1245 Published: AUG 1 1997
- 1997, Argiris A, Longo GSA, Gorlick R, et al. Increased methotrexate polyglutamylation in acute megakaryocytic leukemia (M7) compared to other subtypes of acute myelocytic leukemia LEUKEMIA Volume: 11 Issue: 6 Pages: 886-889 Published: JUN 1997
- 1996, Hilgenfeld RU, Kreuser ED Immunological and biochemical modulation in the treatment of advanced colorectal cancer: Update and future directions CURRENT TOPICS IN MICROBIOLOGY AND IMMUNOLOGY 213: 217-240 Part III 1996
- 1996, Koivisto P, Visakorpi T, Kallioniemi OP Androgen receptor gene amplification: A novel molecular mechanism for endocrine therapy resistance in human prostate cancer SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION 56: 57-63 Suppl. 226 1996
- 1996, Flavell DJ Modelling human leukemia and lymphoma in severe combined immunodeficient (SCID) mice: Practical applications HEMATOLOGICAL ONCOLOGY 14 (2): 67-82 JUN 1996
- 1996, Harris CC Structure and function of the p53 tumor suppressor gene: Clues for rational cancer therapeutic strategies JOURNAL OF THE NATIONAL CANCER INSTITUTE 88 (20): 1442-1455 OCT 16 1996
- 1996, Gorlick R, Goker E, Trippett T, et al. Intrinsic and acquired resistance to methotrexate in acute leukemia NEW ENGLAND JOURNAL OF MEDICINE 335 (14): 1041-1048 OCT 3 1996
- 1996, Comella P, Palmieri G, Lorusso V, et al. Double biochemical modulation of 5-fluorouracil by methotrexate and levo-folinic acid in the treatment of advanced digestive tract malignancies EUROPEAN JOURNAL OF CANCER 32A (10): 1719-1726 SEP 1996
- 1996, Pinto JT, Suffoletto BP, Berzin TM, et al. Prostate-specific membrane antigen: A novel folate hydrolase in human prostatic carcinoma cells CLINICAL CANCER RESEARCH 2 (9): 1445-1451 SEP 1996
- 1996, Hochhauser D, Schnieders B, ErcikanAbali E, et al. Effect of cyclin D1 overexpression on drug sensitivity in a human fibrosarcoma cell line JOURNAL OF THE NATIONAL CANCER INSTITUTE 88 (18): 1269-1275 SEP 18 1996
- 1996, Hum MC, Kamen BA Folate, antifolates, and folate analogs in pediatric oncology INVESTIGATIONAL NEW DRUGS 14 (1): 101-111 1996
- 1996, Spinella MJ, Brigle KE, Freemantle SJ, et al. Comparison of methotrexate polyglutamylation in L1210 leukemia cells when influx is mediated by the reduced folate carrier or the folate receptor - Lack of evidence for influx route-specific effects BIOCHEMICAL PHARMACOLOGY 52 (5): 703-712 SEP 13 1996
- 1996, Ahmad MF, Nasrin N, Akhtar M, et al. Studies of the p(53) gene mutation in Saudi non-Hodgkin's lymphoma CANCER LETTERS 104 (2): 225-231 JUL 12 1996
- 1996, Matherly LH, Taub JW Methotrexate pharmacology and resistance in childhood acute lymphoblastic leukemia LEUKEMIA & LYMPHOMA 21 (5-6): 359-368 MAY 1996
- 1996, Gokbuget N, Hoelzer D High-dose methotrexate in the treatment of adult acute lymphoblastic leukemia ANNALS OF HEMATOLOGY 72 (4): 194-201 APR 1996
- 1996, Spencer HT, Sorrentino BP, Pui CH, et al. Mutations in the gene for human dihydrofolate reductase: An unlikely cause of clinical relapse in pediatric leukemia after therapy with methotrexate LEUKEMIA 10 (3): 439-446 MAR 1996
- 1996, Spencer HT, Sleep SEH, Rehg JE, et al. A gene transfer strategy for making bone marrow cells resistant to trimetrexate BLOOD 87 (6): 2579-2587 MAR 15 1996
- 1996, Synold TW, Willits EM, Barredo JC Role of folylpolygutamate synthetase (FPGS) in antifolate chemotherapy: A biochemical and clinical update LEUKEMIA & LYMPHOMA 21 (1-2): 9-15 MAR 1996
- 1996, Bassan R, Lerede T, Barbui T Strategies for the treatment of recurrent acute lymphoblastic leukemia in adults HAEMATOLOGICA 81 (1): 20-36 JAN-FEB 1996
- 1996, Lacerda JF, Ladanyi M, Jagiello C, et al. Administration of rabbit anti-asialo GM1 antiserum facilitates the development of human Epstein-Barr virus-induced lymphoproliferations in xenografted C.B-17 scid/scid mice TRANSPLANTATION 61 (3): 492-497 FEB 15 1996
- 1996, Bertino JR, Goker E, Gorlick R, et al. Resistance mechanisms to methotrexate in tumors STEM CELLS 14 (1): 5-9 JAN 1996
- 1996, Hoelzer D, Ludwig WD, Thiel E, et al. Improved outcome in adult B-cell acute lymphoblastic leukemia BLOOD 87 (2): 495-508 JAN 15 1996
- 1996, Masson E, Relling MV, Synold TW, et al. Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo - A rationale for high-dose methotrexate JOURNAL OF CLINICAL INVESTIGATION 97 (1): 73-80 JAN 1 1996
- 1996, Pinto JT, Suffoletto BP, Berzin TM, et al. Prostate-specific membrane antigen: A novel folate hydrolase in human prostatic carcinoma cells CLINICAL CANCER RESEARCH Volume: 2 Issue: 9 Pages: 1445-1451 Published: SEP 1996
- 1996, Koivisto P, Visakorpi T, Kallioniemi OP. Androgen receptor gene amplification: A novel molecular mechanism for endocrine therapy resistance in human prostate cancer SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION Volume: 56 Pages: 57-63 Supplement: Suppl. 226 Published: 1996
- 1996, Harris CC. Structure and function of the p53 tumor suppressor gene: Clues for rational cancer therapeutic strategies JOURNAL OF THE NATIONAL CANCER INSTITUTE Volume: 88 Issue: 20 Pages: 1442-1455 Published: OCT 16 1996
- 1996, Gorlick R, Goker E, Trippett T, et al. Intrinsic and acquired resistance to methotrexate in acute leukemia NEW ENGLAND JOURNAL OF MEDICINE Volume: 335 Issue: 14 Pages: 1041-1048 Published: OCT 3 1996
- 1996, Hochhauser D, Schnieders B, ErcikanAbali E, et al. Effect of cyclin D1 overexpression on drug sensitivity in a human fibrosarcoma cell line JOURNAL OF THE NATIONAL CANCER INSTITUTE Volume: 88 Issue: 18 Pages: 1269-1275 Published: SEP 18 1996
- 1996, Ahmad MF, Nasrin N, Akhtar M, et al. Studies of the p(53) gene mutation in Saudi non-Hodgkin's lymphoma CANCER LETTERS Volume: 104 Issue: 2 Pages: 225-231 Published: JUL 12 1996
- 1996, Matherly LH, Taub JW. Methotrexate pharmacology and resistance in childhood acute lymphoblastic leukemia LEUKEMIA & LYMPHOMA Volume: 21 Issue: 5-6 Pages: 359-368 Published: MAY 1996
- 1996, Spencer HT, Sorrentino BP, Pui CH, et al.Mutations in the gene for human dihydrofolate reductase: An unlikely cause of clinical relapse in pediatric leukemia after therapy with methotrexate LEUKEMIA Volume: 10 Issue: 3 Pages: 439-446 Published: MAR 1996
- 1996, Flavell DJ. Modelling human leukemia and lymphoma in severe combined immunodeficient (SCID) mice: Practical applications HEMATOLOGICAL ONCOLOGY Volume: 14 Issue: 2 Pages: 67-82 Published: JUN 1996
- 1996, Hum MC, Kamen BA. Folate, antifolates, and folate analogs in pediatric oncology INVESTIGATIONAL NEW DRUGS Volume: 14 Issue: 1 Pages: 101-111 Published: 1996
- 1996, Gokbuget N, Hoelzer D. High-dose methotrexate in the treatment of adult acute lymphoblastic leukemia ANNALS OF HEMATOLOGY Volume: 72 Issue: 4 Pages: 194-201 Published: APR 1996
- 1996, Spencer HT, Sleep SEH, Rehg JE, et al. A gene transfer strategy for making bone marrow cells resistant to trimetrexate BLOOD Volume: 87 Issue: 6 Pages: 2579-2587 Published: MAR 15 1996
- 1996, Bassan R, Lerede T, Barbui T. Strategies for the treatment of recurrent acute lymphoblastic leukemia in adults HAEMATOLOGICA Volume: 81 Issue: 1 Pages: 20-36 Published: JAN-FEB 1996
- 1996, Lacerda JF, Ladanyi M, Jagiello C, et al. Administration of rabbit anti-asialo GM1 antiserum facilitates the development of human Epstein-Barr virus-induced lymphoproliferations in xenografted C.B-17 scid/scid mice TRANSPLANTATION Volume: 61 Issue: 3 Pages: 492-497 Published: FEB 15 1996
- 1996, Bertino JR, Goker E, Gorlick R, et al. Resistance mechanisms to methotrexate in tumors STEM CELLS Volume: 14 Issue: 1 Pages: 5-9 Published: JAN 1996
- 1995, McGuire JJ, Haile WH, Russell CA, et al. Evolution of drug resistance in CCRF-CEM human leukemia cells selected by intermittent methotrexate exposure ONCOLOGY RESEARCH 7 (10-11): 535-543 1995
- 1995, Banerjee D, ErcikanAbali E, Waltham M, et al. Molecular mechanisms of resistance to antifolates, a review ACTA BIOCHIMICA POLONICA 42 (4): 457-464 1995
- 1995, CLARKSON B, CHABNER BA, WEINBERG RA TARGETS FOR SPECIFIC THERAPIES IN LEUKEMIA CANCER RESEARCH 55 (19): 4488-4498 OCT 1 1995
- 1995, CARON PC, LAI LT, SCHEINBERG DA INTERLEUKIN-2 ENHANCEMENT OF CYTOTOXICITY BY HUMANIZED MONOCLONAL-ANTIBODY M195 (ANTI-CD33) IN MYELOGENOUS LEUKEMIA CLINICAL CANCER RESEARCH 1 (1): 63-70 JAN 1995
- 1995, GOKER E, WALTHAM M, KHERADPOUR A, et al. AMPLIFICATION OF THE DIHYDROFOLATE-REDUCTASE GENE IS A MECHANISM OF ACQUIRED-RESISTANCE TO METHOTREXATE IN PATIENTS WITH ACUTE LYMPHOBLASTIC-LEUKEMIA AND IS CORRELATED WITH P53 GENE-MUTATIONS BLOOD 86 (2): 677-684 JUL 15 1995
- 1995, LACERDA JF, GOKER E, KHERADPOUR A, et al. SELECTIVE TREATMENT OF SCID MICE BEARING METHOTREXATE-TRANSPORT-RESISTANT HUMAN ACUTE LYMPHOBLASTIC-LEUKEMIA TUMORS WITH TRIMETREXATE AND LEUCOVORIN PROTECTION BLOOD 85 (10): 2675-2679 MAY 15 1995
- 1995, SPEARS CP CLINICAL RESISTANCE TO ANTIMETABOLITES HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA 9 (2): 397-413 APR 1995
- 1995, GOKER E, KHERADPOUR A, WALTHAM M, et al. ACUTE MONOCYTIC LEUKEMIA - A MYELOID-LEUKEMIA SUBSET THAT MAY BE SENSITIVE TO METHOTREXATE LEUKEMIA 9 (2): 274-276 FEB 1995
- 1995, COPELAN EA, MCGUIRE EA THE BIOLOGY AND TREATMENT OF ACUTE LYMPHOBLASTIC-LEUKEMIA IN ADULTS BLOOD 85 (5): 1151-1168 MAR 1 1995
- 1995, MATHERLY LH, TAUB JW, RAVINDRANATH Y, et al. ELEVATED DIHYDROFOLATE-REDUCTASE AND IMPAIRED METHOTREXATE TRANSPORT AS ELEMENTS IN METHOTREXATE RESISTANCE IN CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA BLOOD 85 (2): 500-509 JAN 15 1995
- 1995, Banerjee D, ErcikanAbali E, Waltham M, et al.Molecular mechanisms of resistance to antifolates, a review ACTA BIOCHIMICA POLONICA Volume: 42 Issue: 4 Pages: 457-464 Published: 1995
- 1994, MACHOVER D THE PHARMACOLOGICAL MODULATION OF 5-FLUOROURACIL WITH FOLINIC ACID, METHOTREXATE, TRIMETREXATE, AND N-PHOSPHONACETYL-1-ASPARTIC ACID (PALA) - MECHANISMS OF THE INTERACTIONS AND CLINICAL-DATA BULLETIN DU CANCER 81: S74-S77 Suppl. 2 DEC 1994
- 1994, SYNOLD TW, RELLING MV, BOYETT JM, et al. BLAST CELL METHOTREXATE-POLYGLUTAMATE ACCUMULATION IN-VIVO DIFFERS BY LINEAGE, PLOIDY, AND METHOTREXATE DOSE IN ACUTE LYMPHOBLASTIC-LEUKEMIA JOURNAL OF CLINICAL INVESTIGATION 94 (5): 1996-2001 NOV 1994
- 1994, TAN CTC, WOLLNER N, TRIPPETT T, et al. PHARMACOLOGICAL-GUIDED TRIAL OF SEQUENTIAL METHOTREXATE AND THIOGUANINE IN CHILDREN WITH ADVANCED MALIGNANCIES JOURNAL OF CLINICAL ONCOLOGY 12 (9): 1955-1962 SEP 1994
- 1994, BARREDO JC, SYNOLD TW, LAVER J, et al. DIFFERENCES IN CONSTITUTIVE AND POST-METHOTREXATE FOLYLPOLYGLUTAMATE SYNTHETASE-ACTIVITY IN B-LINEAGE AND T-LINEAGE LEUKEMIA BLOOD 84 (2): 564-569 JUL 15 1994
Kitapları (2 adet)- Koch OM, Volkenandt M, Göker E, Buer J, Wienecke R, Banerjee D, Danenberg K, Horikoshi T, Danenberg PV, Lenz H, Bertino JR: Acute Leukemia IV, Prognostic Factors, Buchner et al (Eds), 1994
- Bertino JR, Li WW, Lin J, Trippett T, Goker E, Schweitzer B, and Banerjee D: Natural and acquired resistance of human cancer cells to antimetabolites. In Accomplishments in Cancer Research , Fortner JG and Rhoads JE (eds) pp 218-224,1991

Bilimsel Kuruluş Üyeliklerim (8 adet)- Balkan Onkoloji Derneği
- Balkan Union of Oncology (kurucu üye)
- Ege Meme Hastalıkları Derneği
- EORTC
- European Society of Medical Oncology
- Tıbbi Onkoloji Derneği
- Toraks Derneği
- Ulusal Hematoloji Derneği ve Türk Lösemi Grubu
Kazandığı Ödüller (3 adet)- 1999, Ulusal Kanser Kongresi Sözel Sunu Ödülü 3 adet, Poster Ödülü 1, Özet ödülü 1
- 1998, Roche Tıp Ödülü, Hematoloji Dalı Üçüncülüğü, Ankara
- 1993, ABD Ulusal Hematoloji Kongresi En İyi Poster için Seyahat Ödülü